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 Angiogenesis is associated with metastasis of mammary carcinoma. Angiogenesis 
occurs in response to the stimulation of angiogenic factors secreted by mammary carcinoma 
or stromal cells (Folkman et al., 1971, Folkman, 1992) . Trefoil Factor 3 (TFF3) is a small 
secreted protein and physiologically involved in mucosal repair and restitution (Taupin and 
Podolsky, 2003). Increased TFF3 expression is oncogenic and stimulates invasiveness and 
metastasis of mammary carcinoma cells (Kannan et al., 2010, Pandey et al., 2014). 
 The role of TFF3 in de novo angiogenesis of mammary carcinoma has not been 
determined. Herein, I defined the effect of TFF3 secreted from mammary carcinoma cells on 
human umbilical vein endothelial cells (HUVEC) using an indirect co-culture transwell 
system in which mammary carcinoma cells were plated in the membrane of transwell insert 
co-cultured with HUVEC seeded in the bottom well of companion plate. Forced expression of 
TFF3 in mammary carcinoma cells promoted HUVEC monolayer proliferation, cell cycle 
progression, survival, migration, invasion, and tubule formation in vitro. In xenograft models, 
mammary carcinoma cells with forced expression of TFF3 produced tumors with increased 
IL-8 expression and enhanced microvessel density (CD31 and CD34 positive) as compared to 
tumors formed by control cells. Depletion of TFF3 in mammary carcinoma cells by siRNA 
decreased the angiogenic behaviors of HUVEC. Mechanistically, forced expression of TFF3 
in mammary carcinoma cells stimulated IL-8 promoter activity and subsequently increased 
IL-8 expression. Depletion of IL-8 in mammary carcinoma cells by siRNA or inhibition of 
IL-8 with anti-IL-8 monoclonal antibody abrogated the stability of TFF3 on stimulation of 
HUVEC migration, invasion, and tubule formation in vitro. Blocking of IL-8 receptor namely 
CXCR2 in HUVEC by anti-CXCR2 monoclonal antibody inhibited TFF3-stimulated HUVEC 
tubule formation in vitro mediated by IL-8. TFF3 enhanced STAT3 phosphorylation. 
Depletion of STAT3 in mammary carcinoma cells by siRNA partially abrogated the effect of 
TFF3 on IL-8 promoter activity and subsequently decreased IL-8 expression. Depletion of 
STAT3 in mammary carcinoma cells by siRNA also partially abrogated the stimulatory 
VIII 
 
effects of TFF3 on HUVEC migration, invasion and tubule formation in vitro. Furthermore, 
exogenous rhTFF3 stimulated HUVEC monolayer proliferation, migration, invasion, and 
tubule formation in vitro in a concentration-dependent manner. Exogenous rhTFF3 directly 
acted on HUVEC to promote angiogenic behaviors of HUVEC. Additionally, TFF3 secreted 
from HUVEC increased monolayer cell proliferation, cell cycle progression, survival, 
migration, invasion, and tubule formation in vitro. TFF3 secreted from HUVEC enhanced IL-
8 promoter activity and increased IL-8 expression in endothelial cells, albeit slightly. Hence, 
TFF3 is a promoter of angiogenesis, which may co-coordinate with the growth promoting and 
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 Trefoil factors (TFF) family consists of three members, namely TFF1, TFF2, and 
TFF3. In the normal physiology, all three TFF proteins are expressed in the epithelial cells 
that line the mucous membrane. The biological functions of TFF peptides include protection 
of gastrointestinal (GI) tract from injury and mucosal restitution (Taupin et al., 2000b, Taupin 
and Podolsky, 2003). However, TFF peptides, particularly Trefoil factor 3 (TFF3) have been 
documented to be over-expressed in human malignancies including breast (Poulsom et al., 
1997), gastric (Yamachika et al., 2002, Dhar et al., 2005), prostate (Faith et al., 2004), 
hepatocellular (Okada et al., 2005), and endometrial (Bignotti et al., 2008). Accumulating 
evidence suggests that increased expression of TFF peptides is tightly linked to the 
progression of cancers (May and Westley, 1997a).  This introduction will be divided into five 
sections.  The first section describes hallmarks and the development of cancer.  The second 
sections describes pathogenesis and treatment of human mammary carcinoma. The third 
section describes the biology of TFF3, the signaling pathways of TFF3, and the potential 
oncogenic effects of TFF3 in cancer progression. The fourth section describes the mechanism 
and regulation of angiogenesis, and the angiogenic factors involved in tumor angiogenesis. 
The last section describes the rationales and objectives of this research project. 
 
1.1 Epidemiology of cancer  
 Cancer is a major disease worldwide with an annual incidence of greater than 10 
million (Stewart et al., 2003). In 2012, the newly diagnosed cancer cases and cancer death 
were approximately 14.1 million and 8.2 million respectively (Ferlay et al., 2012). Cancer is 
the second commonest of death that accounts with nearly 25% of all deaths. In 2014, the 
number of newly diagnosed cancer cases is expected to be approximately 1.7 million with 
cancer deaths of 585,720 in the United States (American Cancer Society, 2014). Current 
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statistics indicate that 50% of men and 30% of women will develop cancer during their 
lifetime (Howlader et al., 2014). According to the American Cancer Society, the leading 
cancer death for men (28%) and women (26%) is lung cancer, followed by prostate (10%) in 
men and breast (15%) in women (American Cancer Society, 2014). The mortality rate showed 
only a slight decline, despite advances in early diagnosis and introduction of new therapeutic 
modalities tailored to target cancer cells. The statistics underlie the importance of 
understanding the biology of cancer and its signaling pathway. 
 
1.1.1 Heterogeneity of cancer 
 Cancer is a neoplastic disease characterized by alterations of the genome that results 
in deregulation of normal cell processes including cell division and cell differentiation. 
Consequently, the normal balance between the cell replication and cell death is disturbed, 
thereby, resulting in uncontrolled cell proliferation (Vogelstein and Kinzler, 2004, Ruddon, 
2007). Under normal physiological conditions, normal cells divide in response to growth 
factor signals cease dividing in response to anti-growth signals (Vogelstein and Kinzler, 2004, 
Ruddon, 2007). The signaling molecules that moderate cell division are released by 
neighboring cells. In response to genetic or environmental insults, normal cells undergo 
programmed cell death or apoptosis. Cancer is a genetic disease that originates from a single 
ancestral cell and is clonal in nature. Tumors starts when a single cell acquires a series of 
mutations which collectively transforms normal cells into cancerous cells that divide 
uncontrollably and eventually spread throughout the body (Hanahan and Weinberg, 2000). As 
cancer growth progresses, genetic drift such as gene alteration or mutation produces 
heterogeneity in cancer cell population (Futreal et al., 2004). Tumors are classified as either 
benign or malignant. Benign tumors are non-cancerous cells that unable to invade 
neighboring tissues or metastasize, and can only grow locally. Malignant tumors are cancer 
cells that are able to invade, spread to lymph nodes or bloodstream, and metastasize to 
secondary site in the body (Silverstein et al., 2006). In general, malignant tumors cause 
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significant morbidity and are fatal if untreated. The etiology of cancer is complex, and 
partially understood. Current studies indicated that only 5 - 10% of cancer is attributed to 
genetic defects and the remaining is caused by environmental and lifestyle factors (Anand et 
al., 2008, Khan et al., 2010), suggesting that cancer is a preventable disease and could be 
treated if it is detected early with therapeutic treatments. 
 
1.1.2 The hallmarks of cancer 
 Cancer is a complex and multifactorial disease in which there is strong interplay 
between genetic and environmental factors. Perturbations of the normal control mechanism 
drive normal cells to become cancerous cells. Cancer cells acquire a series of genetic 
mutations that lead to uncontrolled cell growth and division, inhibition of cell differentiation, 
and resistance to cell death (Futreal et al., 2004). Tumors secrete angiogenic factors that 
stimulate new blood vessels formation in a process known as angiogenesis to supply cancer 
cells with oxygen and nutrients, a process called angiogenesis (Folkman, 1990). Some 
malignant tumors may remain localized and encapsulated. However, most cancer cells 
eventually invade surrounding tissue and breaking through the basal laminas to spread to 
distant organs in a process called metastasis (Varmus and Weinberg, 1993). The ability of 
cancer cells to override normal control mechanisms is underlined by six "hallmarks of cancer" 
as proposed by Hanahan and Weinberg (2000). The hallmarks of cancer encompass six 
biological features acquired during cancer cells development. The acquired biological 
capabilities are as follows (Figure 1): 
 (i) Self-sufficiency in growth signal.  
 The ability of cancer cells to divide without growth factor stimulation. Deregulation 
of cell surface receptors (i.e. growth factor receptors) that rely on growth-stimulatory signals 
into the cells during tumor pathogenesis and receptors over-expression may also enable the 
cancer cells to become hyper-responsiveness to growth factors (Fedi et al., 2000). Mutation or 
structural alterations in cell surface receptors resulted in ligand independent growth signaling 
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pathways or cross-talking connections with other pathways to trigger multiple biological 
effects. 
(ii) Insensitivity to anti-growth signals.  
 In cancer, cells acquire the ability to divide in the presence of anti-growth signals. On 
the contrary, under normal cellular condition, anti-growth signals can inhibit proliferation by 
forcing actively proliferating cells to enter quiescent (G0) state. Alternatively, cells may be 
induced to enter into postmitotic state resulting in inhibition of their proliferative potential. 
However, cancer cells evade anti-growth signals by avoiding differentiation and promoting 
growth.   
 (iii) Evading apoptosis.  
 Cancer cells acquired capability to escape apoptosis or programmed cell death. The 
growth of tumor cell is influenced by both the rate of cell proliferation as well as the rate of 
apoptosis. Acquiring the capability to resist apoptosis can be through a variety of strategies 
such as mutation in p53 tumor suppressor gene and loss of function of a pro-apoptotic 
regulator, which resulting in production of functional inactivation of p53 protein (Harris, 
1996). An estimated of more than 50% of cancers contained p53 mutations that results in 
promoting survival signaling pathway instead of apoptotic machinery.  
 (iv) Limitless replication potential.  
 Cancer cells acquired capability for unlimited replication and maintenance of 
telomere length despite repeated cell divisions. Normal cells have a limited number of 
doublings to be completed before entering senescence (aging process) (Hayflick, 1997).  
However, cancer cells acquired the capability to multiply without limit and attribute an 
infinite replicative potential, the trait termed as immortalization, i.e. the ability of a cell to 
continue dividing without limit.  Telomeres are eroded with every cell cycle and the erosion 
signals a cell to enter senescence. Hence, maintenance of telomerase is observed in 85 - 90% 
of all type of cancer cells through up-regulation of telomerase enzyme expression or elevating 
telomerase activity (Shay and Bacchetti, 1997).   
5 
 
 (v) Sustained angiogenesis.  
 Angiogenesis is a cellular event whereby new blood vessels are formed to supply 
oxygen and nutrients to tissues.  It is a tightly regulated process, which becomes deregulated 
in cancer, whereby neoplastic lesions stimulate sprouting of pre-existing blood vessels or 
formation of  new vasculatures to facilitate tumor growth and metastasis (Bouck et al., 1996, 
Hanahan and Folkman, 1996). 
 (vi) Tissue invasion and metastasis.  
 As cancer progresses, cells acquire capability that enables invasion into surrounding 
tissues and subsequent dissemination to other parts of the body. The main cause of cancer 
deaths is due to the metastasis where primary tumor spread to the other parts of the body 
(Sporn, 1996).  Metastasis is a complex mechanism involving dissolution of cell-to-cell 
contacts (e.g., down-regulation of adhesion proteins such as E-cadherin), alteration of cell-to-
microenvironment interactions in cancer through changes in integrin expression, and 
activation of extracellular proteases and matrix degrading proteases responsible for degrading 
extracellular matrix (ECM) substrates in cancer cells (Coussens and Werb, 1996, Christofori 
and Semb, 1999). The capability for cancer cells to invade and metastasize enables escape 
from the primary tumor site and colonizes at distant organs with sufficient supply of nutrient 






Figure 1: The hallmarks of cancer. The hallmarks of cancer describe functional 
characteristics, which most cancers acquire during the process of tumor growth and 
progression (Hanahan and Weinberg, 2000). Reproduced with permission. 
 
 The hallmarks of cancer activities are important acquired capabilities that required for 
development and maintenance of cancer. Further, these acquired capabilities restated that 
cancer as a multistep disease mainly initiated through the perturbation of the cellular 
regulatory mechanisms that important for normal cell proliferation as well as homeostasis 
(Hanahan and Weinberg, 2000). In addition to the existing functional characteristics, genome 
instability in cancer cells produces genetic variability that accelerates their acquisition of 
capabilities. Besides, tumor-microenvironment interaction may produce inflammatory 
responses that are advantages to the cancer cells. The high proliferative state and survival of 
cancer cells produce genomic instability associated with DNA mutations or DNA damage 
repair (Charames and Bapat, 2003) and chromosomal abnormalities associated with mutations 
in oncogenes such as TP53. Consequently, the mechanisms controlling cell cycle, telomere 
length, and telomerase activity are deregulated (Negrini et al., 2010). Furthermore, two 
emerging hallmarks have recently been described in the pathogenesis of all if not some 
cancers (Figure 2). Firstly, deregulating cellular energetics such as modification or 
reprogramming of metabolism is necessary for cancer cells proliferation. Secondly, avoiding 
immune destruction provided cancer cells the advantage to escape immunological 
7 
 
surveillance, particularly by lymphocytes and natural killer cells (Hanahan and Weinberg, 
2011). Acquisition of these hallmarks lead to the generation of mutant cells with an increased 




Figure 2: Emerging hallmarks and enabling characteristics. Two additional hallmarks of 
cancer, namely deregulating cellular energetics and avoiding immune destruction, are 
implicated in the pathogenesis of cancers. Genomic instability in cancer cells caused by 
mutations promotes tumor progression. Inflammation initiated by immune cells that function 
to fight against infections and injury can support multiple hallmark capabilities instead 
(Hanahan and Weinberg, 2011). Reproduced with permission. 
 
1.1.3 Tumor microenvironment  
 The highly proliferative cancer cells have been suggested as one of the most crucial 
agents in the tumor mass. Carcinoma arising from epithelium is initiated by mutation. 
However, promotion of tumor progression involved the stroma in the tumor environment 
(Egeblad et al., 2005).  Therefore, the series of mutations in cancer cells do not completely 
elucidate the aggressive or invasive phenotype of tumors (Sager, 1997, Park et al., 2000, 
Ronnov-Jessen and Bissell, 2009). It was lately discovered that the gene expressions of cells 
in the tumor microenvironment (TME) is essential for cancer cells to become malignant  
(Sager, 1997). Emerging evidence indicates that tumorigenesis involve complex 
heterogeneous interactions between tumors and its interstitium (Liotta and Kohn, 2001, 
Dvorak et al., 2011).  The distinct population of cells that constitute solid tumors include 
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cancer mesenchymal cells, cancer stem cells, other cell types such as fibroblasts, endothelial 
cells, stroma cells, and immune inflammatory cells, and the ECM. Together, these 
components create the tumor microenvironment that contributes to the acquisition of hallmark 
traits, thereby promoting tumor progression (Hanahan and Weinberg, 2011, Floor et al., 
2012). 
 The capability of the TME to promote tumor growth and progression results from 
exploiting the ability of its cellular components, particularly cancer-associated fibroblasts, 
macrophages and endothelial cells (Figure 3). In the immune system, immunological cells 
play a role to eliminate foreign cellular components such as tumors. However, in cancer, these 
immunological cells can be paralyzed, which in turn become advantageous for tumor growth 
and metastasis (Leibovici et al., 2011). The stroma supports tumors growth by providing 
growth factors from degradation of the extracellular matrix (ECM) by the matrix 
metalloproteinases (MMPs). Additionally, stroma provides angiogenic factors, which 
promotes vascularization necessary for growth and metastasis (Leibovici et al., 2011). 
Therefore, the TME is involved to promote progression of tumor at different stages through 
the enhancement of invasion, angiogenesis and metastasis (Whiteside, 2008). It has been 
explicitly shown that tumor microenvironment have a critical part in tumor development and 








Figure 3: Microenvironment of tumor. The transition from non-invasive to invasive 
carcinoma required activation of a range of cell types including fibroblasts, immune cells and 
endothelial cells. Interaction between the stromal cells and the premalignant epithelium is 
needed for invasion (Liotta and Kohn, 2001). Reproduced with permission. 
 
1.1.4 Invasion metastasis cascade 
 At advanced stages of primary tumors, cancer cells can gain entry into blood or 
lymphatic vessels, circulate through the intravascular stream, and proliferate at distant site in 
the body in a process known as metastasis. The multistep process of cell-biological events has 
been schematized as sequential and interrelated steps, defined as invasion-metastasis cascade 
(Fidler, 2003, Talmadge and Fidler, 2010). Each step of this cascade is important as failure to 
complete any step effectively impedes the tumor cells success to invade and metastasize  
(Poste and Fidler, 1980). During the process of invasion and metastasis, a series of events 
have to take place (Figure 4), which begin from local invasion through ECM at primary site, 
followed by intravasation into blood vessels, survival in circulation, arrest at secondary site, 
subsequently extravasation into secondary tissues, survival in new microenvironments by 
forming micrometastases, reinitiation of proliferation, and  finally production of macroscopic 





Figure 4: The invasion-metastasis cascade. Invasion-metastasis is a complex series of 
cellular events. During metastatic progression, cancer cells invade locally from the primary 
tumor site, break through the basement membrane, enter into the circulation, arrest at a 
secondary site, and survive in the secondary tissues (Fidler, 2003). Reproduced with 
permission. 
 
 Accumulating evidence have shown that the normal tissue architecture serves as 
barrier against invasion which cancer cells have to break through to metastasize successfully 
(Valastyan and Weinberg). The ECM in tissue architecture provides a support for 
organization of cells into specific tissues. For example, basement membrane of the ECM 
structures served as physical barrier that prevents invasion and metastasis. To initiate the 
invasion-metastasis cascade, cell invasion initially participated in modification of cell 
adhesion, degradation of ECM, and migration of tumor cells. Subsequently, the cancer 
cells could co-opt with epithelial-mesenchymal transition (EMT) program that implicated in 
normal embryonic morphogenesis (Shook and Keller, 2003). Epithelial cells are connected 
with each other by cell-cell junctions to ensure the integrity and the stabilization of the 
epithelium. During the process of EMT, the tumor cells acquire invasion and migration 





Figure 5: EMT in development and disease. In normal conditions, EMT (cells in green) 
occurs during development of embryos, such as during neural crest cell delamination from the 
dorsal neural tube. EMT inducers usually remained quiescent but become highly active in 
invasive carcinomas. The influence of cell state during development or disease is highly 
dependent on epithelial-mesenchymal transitions (Acloque et al., 2009). Reproduced with 
permission. 
 
 EMT inducers are activated in primary tumor which lead to the dissociation of 
adherens or tight junctions, loss of cell polarity, transition of epithelial cell to adopt 
mesenchymal characteristics which include increased cellular invasiveness and 
aggressiveness (Baum et al., 2008, Thiery et al., 2009) (Figure 6). Furthermore, EMT is 
organized by a set of transcription factors, including ZEB1, SLUG, TWIST, SNAIL, and 
ZEB2 that allows carcinoma cells to gain mesenchymal properties by repressing expression of 





Figure 6: Cellular events in EMT. The EMT occurs at the primary tumor site whereby 
normal epithelial cells transform into invasive carcinoma in situ due to the loss of 
tight/adherents junctions as well as cell polarity. As basement membrane becomes degraded, 
tumor cells begin to invade the surrounding stroma to intravasate into blood vessels or lymph 
node, and finally be transported  in circulation until they colonize at a distant organ (Bacac 
and Stamenkovic, 2008). Reproduced with permission. 
 
 EMT is induced by multiple signaling pathways that mediated by growth factors, Src, 
Ras, Integrin, Wnt/beta-catenin and Notch. One of the most important molecular 
characteristic of EMT is the down-regulation of E-cadherin, which is a cell adhesion molecule 
commonly found in normal epithelial cells and plays a role in tumor suppression. However, 
the expression of E-cadherin is found to be down-regulated during cell transformation  (Larue 
and Bellacosa, 2005). Numerous studies have shown that TGF-β to be a multifunctional 
peptide can suppress or promote tumors formation (Muraoka-Cook et al., 2005, Lebrun, 
2012). The TGF-β pathway is found to suppress cell transformation by preventing cell 
division and inducing cell death or senescence. During late tumorigenesis, stimulation of 
TGF-β signaling is associated with cancer-related events such as promoting cell proliferation, 
cell motility, new blood vessels development, invasion and metastasis (Muraoka-Cook et al., 
2005, Lebrun, 2012). Metastatic events are stimulated by EMT through activation of the 
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phosphatidylinositol 3' kinase (PI3K)/Akt signaling pathway that induces Slug- or Snail-
mediated repression of E-cadherin gene, which in turn resulted in alterations of cell 
morphology, tumorigenicity, cell motility and invasiveness (Larue and Bellacosa, 2005). 
TWIST is an EMT transcription factor, which induces EMT and contributes metastatic feature 
of tumors (Yang et al., 2004). Therefore, multiple signaling pathways determine the growth 
and metastatic potential of tumors. 
 
1.2 Human mammary carcinoma 
 Human mammary carcinoma is also known as breast cancer. It is a type of tumor that 
originates from breast tissue i.e. epithelial cell in the inner lining of milk ducts or the lobules 
(Sariego, 2010). Benign breast conditions (non-cancerous) are very commonly found in 
women. Non-invasive or in situ breast cancers are malignant breast tumors that remain inside 
the ducts and have not spread into the surrounding breast tissue (Majure, 2000). This type of 
breast cancer could be cured by early detection and treatment. In contrast, invasive 
(infiltrating) breast cancers spread beyond the membrane lining a duct or lobule, invade the 
neighboring tissue and metastasize to the liver, lung, and brain (Majure, 2000). This type of 
breast cancer can severely affect the mortality or morbidity of women.  
 
1.2.1 Epidemiology of mammary carcinoma 
 Mammary carcinoma is the major cause of death for women worldwide that accounts 
for 29% (232,670) of newly diagnosed cancer cases and 15% (40,000) of total cancer 
mortality in the United States (American Cancer Society, 2014). It is estimated that about 
12.3% women will be diagnosed with breast cancer in their lifetime (Siegel et al., 2014). 
Moreover, World Health Organization (WHO) predicts that up to 70% of the new breast 
cancer cases will occur in the developing countries by 2020 (Ferlay et al., 2012) and that 84 




 In Singapore, cancer is the leading cause of mortality, constituting 18,481 of total 
cancer deaths and 56,316 new cancer cases in 2012. The incidence rates of cancer have 
increased for the period 2006 - 2010 (Teo and Soo, 2013). Breast cancer is the top frequently 
diagnosed cancer (29.4%) with mortality rate of 17.9% in Singapore women (Singapore 
Cancer Registry, 2012). About 1,600 women are diagnosed with breast cancer each year 
(Singapore Cancer Registry, 2012).  GLOBOCAN 2012 revealed a sharp rise of breast cancer 
incidence in women and highlighted to the importance and priority of preventive and control 
measures (Ferlay et al., 2012). There is an urgent demand for eradicating breast cancer, 
encouraging considerable efforts to elucidate the underlying mechanism of this deadly disease.  
 
1.2.2 Development and structure of normal human mammary gland 
 The mammary gland is a highly complex, dynamic, and specialized organ that 
consists of multiple lobes. Each lobes are made up of several lobules that contain multiple 
acini, which eventually drain milk into the nipple via the ducts (Owens et al., 2013). The 
basic functional unit in the human mammary gland is terminal end bud (TEB) consists of a 
lobule and the draining duct supported by a network of adipose tissues and connective tissue 
(Ramsay et al., 2005). Human mammary gland is composed of glandular structures whose 
major function is to produce milk under the influence and control of hormones.  
 Mammary gland development take places at different stages such as embryonic, 
prepubertal, pubertal, pregnancy, lactation, and involution that are related during reproduction 
as well as sexual development (Hennighausen and Robinson, 2001). In the embryogenesis of 
mammary development, both males and females share the same primitive mammary gland at 
birth. In female, mammary gland development is initiated during the onset of puberty and is 
regulated by the elevated secretion of ovarian hormones such as estrogen and progesterone. 
After puberty, the female mammary gland experienced cycles of growth and morphologic 
changes including TEB formation, ductal elongation, lateral branching, and terminal duct 
lobular formation as well as stroma expansion. Additionally, morphologic changes to or 
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regulation of female mammary glands are governed by the menstrual cycle, pregnancy and 
lactation (Ali and Coombes, 2002). Unlike females, the male mammary glands do not 
undergo morphologic changes and remained in quiescent state (Sternlicht, 2006). The female 
mammary gland consist a primitive branching ductal system and the process of duct and acini 
development is known as branching morphogenesis. The duct originates in the fetus and 
terminates at early childhood until puberty when hormones begin to stimulate and trigger 
differentiation. Under hormonal influences, the interaction between epithelium and 
mesenchyme results in differentiation of the prenatal primitive structure to produce a mature 
mammary gland (Javed and Lteif, 2013).
.
  
 Humans have two complex mammary glands that consist of 10 - 20 simple glands in 
each breast.  Two tissue compartments that constitute the mammary gland are the parenchyma, 
which forms the branching duct system from which secretory acini develop. The mammary 
fat pad is made up of adipose stroma or connective tissue which serves a support in which the 
parenchyma develops and functions (Medina, 1996). The parenchyma is composed of the 
alveoli that are made up of milk-secreting epithelial cells that are surrounded by myoepithelial 
cells (Figure 7). The branching ductal system is mainly developed during puberty. In contrasts, 
the lobuloalveolar begins to develop during pregnancy. The ducts branch into smaller 
ductules that terminate in lobules.  
The mammary gland is composed of approximately 15 - 20 lobes. The mammary 
epithelium is mainly composed of two cell types, the basal and the luminal. The basal 
epithelium comprises the myoepithelial and a subpopulation of stem cells. The myoepithelial 
cells possess contractile functions and form the outer layer of the mammary gland. The 
function of the small subpopulation of stem cells is to generate or produce different cell types. 
The luminal epithelium gives rise to the ducts and secretory alveoli. Both myoepithelium and 
luminal epithelium function together to generate a bi-layered, tubular structure that enables 






Figure 7: Anatomy of the human mammary gland. Mammary carcinoma duct is covered 
with a layer of epithelial cells that function in producing milk. The glands are surrounded by 
an outer layer of myoepithelial cells that possess contractile properties. Abnormal cells are 
found in ductal carcinoma. Adapted from http://www.breastcancer.org. 
 
 It has been proposed that the cell lineages that compose the mammary gland are 
derived from a mammary stem cell population (Smalley and Ashworth, 2003). A hierarchy of 
stem cells including unipotent and multipotent cells appear to be present within the mammary 
gland whereby each of them likely to have a distinct function in the morphogenesis and 
mammary epithelium maintenance (Van Keymeulen et al., 2011). These cells are capable of 
differentiating into multiple cell type of the mammary gland depending on different stages 
such as during development, pregnancy or even self-renewal. Self-renewal is essential to 
drive the growth of subsequent pregnancies due to the massive apoptotic events occurring 
during post weaning.  (Tiede and Kang, 2011). It has been postulated that the mammary stem 
cells (MSCs) made up the epithelial compartment of the mammary gland. These MSCs 
possess self-renewal potential and produce epithelial precursor cells, which are further 
differentiated into either basal or luminal epithelial (Figure 8). The presence of stem cells is 






Figure 8: Model of the epithelial differentiation hierarchy in the mammary gland. A 
heterogeneous compartment of stem cells is present in mammary gland, in which the 
multipotent stem cell has greater self-renewal capacity than the unipotent stem cells (Myo‐SC: 
myoepithelial‐stem cell, Lum‐SC: luminal‐stem cell, Preg‐SC: short term pregnancy-stem 
cell). The bipotent progenitors develop into either luminal or myoepithelial progenitor. 
Myoepithelial cells and luminal cells are formed as the ducts grow out postnatally during 
puberty. On initiation of pregnancy, myoepithelial and luminal cells are generated to 
synthesize and secrete milk (Visvader and Lindeman, 2011). Reproduced with permission. 
 
1.2.3 Development and hormonal control of the mammary gland 
 At puberty and pregnancy stages, the mammary gland undergoes tissue remodeling in 
response to hormonal stimuli (Richert et al., 2000, Hovey et al., 2002). During puberty, 
estrogen and growth hormone function together to initiate mammary duct elongation. During 
pregnancy, other hormones such as progesterone (Pg) and prolactin (PRL) work coordinately 
to stimulate alveolar formation for production of milk for the young. Morphologic changes to 
the mammary gland are influenced by the presence and secretion level of hormones through 
paracrine actions and by transcription factors that modulate mammary stem cells activity 
(Asselin-Labat et al., 2006, Joshi et al., 2010). During the post-pregnancy stage, mammary 
epithelial cells express estrogen and progesterone receptors to enable ductal elongation, 
branching and alveolar expansion through regulating cell proliferation and turnover of cells in 
estrous cycles. Both estrogen and progesterone also function in other organs such as the 
uterus, ovaries and the hypothalamus for regulation of sexual development (Hennighausen 
and Robinson, 2001).  
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 Mammary gland development is controlled by a variety of steroid hormones and their 
receptors. Estrogen binds to two distinct estrogen receptors, ERα and ERβ, which functions as 
transcription factors when binding of steroid hormone. ERα plays a role during normal ductal 
outgrowth and elongation during puberty (Bocchinfuso et al., 2000). On the contrary, ERβ 
deletion does not have significant effects on the development of alveolar or duct (Forster et 
al., 2002). Progesterone and its cognate receptors (A and B isoforms) play a crucial function 
during pregnancy stage by inducing mammary ductal side branching essential for 
lobuloalveolar development (Brisken et al., 1998, Atwood et al., 2000). Progesterone receptor 
B (PR-B) primarily mediates progesterone proliferative effects during pregnancy (Bromberg 
and Darnell, 2000). Prolactin (PRL) is a protein hormone produced by the pituitary gland that 
stimulates mammary gland development and milk production (Bole-Feysot et al., 1998). PRL 
has a direct function on the formation of alveolar bud, however it does not have any 
contributions in ductal side branching in adult mammary glands (Ormandy et al., 1997). 
Prolactin (PRL), cooperate with cortisol and insulin to stimulate transcription of the genes 
that encode milk proteins (Ormandy et al., 2003).  
 
1.2.4 Risk factors and etiology of mammary carcinoma 
 The incidence rate of breast cancer is determined by sexual reproduction, lifestyle, 
age, and many other factors (Key et al., 2001). The breast cancer risk is greater amongst 
women with early age at menarche, delayed age at first full term pregnancy, breast feeding 
duration and late age at menopause, all of which are associated with prolonged exposure to 
estrogen (Lester, 2010). Collaborative Group on Hormonal Factors in Breast Cancer (Beral 
and Collaborative Group on Hormonal Factors in Breast, 1997) reported that the use of oral 
contraceptives and postmenopausal hormonal replacement therapy increase the risk of this 
disease as these exogenous estrogen agents increase cancer cells proliferation and induce 
mutagenesis (Persson, 2000). More than 60% of all breast cancers are dependent on hormones 
such as estrogen for their growth (Pasqualini, 2004). One of the definite risk factors of breast 
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cancer is history of atypical hyperplasia, which has a higher prevalence of transforming to 
malignant tumor than non-atypical proliferative breast lesions. Women with high density 
breast tissue, that has higher density of epithelial component compared to fatty and 
connective tissue component, are more likely to develop breast cancer than women with low 
density breast tissue (McCormack and dos Santos Silva, 2006). Other risk factors correlated 
to higher risk of breast cancer include increase height (Green et al., 2011), higher body mass 
index (Reeves et al., 2007), obesity, alcohol consumption and exposure to irradiation (Lester, 
2010). 
 The incidence of breast cancer is also significantly increased in women with family 
history of breast cancer such as women with one first-degree relative with breast cancer have 
higher risk as compared with those without family history of the disease (Pharoah et al., 
1997). Furthermore, hereditary breast cancer accounts for close to 15% of cases and is caused 
by germline mutations in cancer susceptibility genes such as BRCA1, BRCA2 and TP53 
(Thull and Vogel, 2004, Monnerat et al., 2007). BRAC1 and BRCA2 proteins are important 
in maintaining genomic stability for homologous recombination and DNA repair of normal 
cells (Gudmundsdottir and Ashworth, 2006). Genetic mutation in BRCA1 and BRCA2 are 
associated with familial breast cancers. Individuals inherit these gene mutations have a range 
of 50% - 87% lifetime risk of development of breast cancer.  Loss of function of such as 
tumor suppressor genes can result in high grade tumor and breast cancer progression 
(Osborne et al., 2004). The p53 tumor suppressor protein regulates genes involved in cellular 
processes including apoptosis, cell cycle, and senescence (Brosh and Rotter, 2009). It has 
been reported that over-expression of mutated p53 protein in breast cancer patient is 
associated with poor prognosis and a greater incidence of recurrence (Macdonald, 2004). 
Additionally, over-expression of HER2/neu, a transmembrane tyrosine kinase member of the 
epidermal growth factor receptor family, was observed in 30% patients with breast cancer. 
Several studies have concluded that over-expression of this receptor is associated with a poor 
survival outcome of breast cancer patients (Ross and Fletcher, 1998, Nunes and Harris, 2002). 
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Nevertheless, the beneficial factors such as healthy lifestyle, physical exercise, lower age of 
first pregnancy, having more children and prolonged breastfeeding is positively associated 
with a reduced risk of developing breast cancer (Baselga and Norton, 2002). 
 
1.2.5 Development of mammary carcinoma 
 Breast cancer is a complex and heterogeneous disease that is developed during the 
process of lesions from epithelial hyperplasia to invasive carcinoma and eventually metastasis 
(Allred et al., 2001, Polyak, 2007). Breast cancer is initiated from a series of transformation 
events (genetic or epigenetic) in a single cell. The subsequent tumor progression is the 
resultant of accumulation of various genetic alterations such as amplification of oncogenes 
and/or  mutation/loss of tumor suppressor genes (Beckmann et al., 1997). A study by Allred 
et al. (2001) has demonstrated that the development of breast cancer is a multistage 
progression involving series of intermediate hyperplastic lesions such as epithelial 
hyperplasia, atypical ductal hyperplasia (ADH), followed by growth into non-invasive in situ 
carcinoma (ductal carcinoma in situ or  lobular carcinoma in situ), invasive carcinoma, and 
finally metastatic cancer (Allred et al., 2001). Normal breast duct consists of an epithelial 
cells layer and a myoepithelial cells layer that are separated from the stroma by a basement 
membrane. The ducts are surrounded by an interstitium consists of extracellular matrix (ECM) 
and stromal cells (e.g., endothelial cells, fibroblasts and leukocytes) (Man and Sang, 2004, 
Man, 2007). ADH is a premalignant lesion characterized by the presence of abnormal cell 
layers within the duct or lobule. The epithelial cells in ADH are abnormal in number, size, 
shape, appearance, and even excessive growth of cells in the ducts or lobules. ADH triggered 
by perturbed hormonal levels, inflammatory response and neoplasia. ADH increases the 
lifetime risk for developing of breast cancer (Vargo-Gogola and Rosen, 2007). In situ 
carcinomas are composed of lobular carcinoma in situ (LCIS) and ductal carcinoma in situ 
(DCIS). DCIS is a non-invasive cancer in which abnormal outgrowth of cells are confined to 
the lumen of the mammary duct. LCIS is an abnormal outgrowth of cancer cells in the milk-
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producing lobules. The presence of DCIS can greatly increase the risk of developing into 
invasive breast cancer (Khamis et al., 2012) as it is a precursor lesion of invasive growth 
called invasive breast cancer (IBC) (Figure 9). Unlike DCIS, LCIS is not a precursor lesion 
for breast cancer (Rieger-Christ et al., 2001). The risk of developing invasive and/or 
malignant breast cancer increases with each stage. There are mainly two types of IBC, the 
invasive ductal carcinoma (IDC) and the invasive lobular carcinoma (ILC). IDC is the most 
common invasive mammary carcinoma (70% of cases) as compared to ILC, which represents 
about 10% of all breast cancer cases. Advanced mammary carcinoma is associated with 
degradation of basement membrane and disruption of the mammary myoepithelial cells. 
Tumor cells invade neighboring tissues, spread to distant organs, and subsequently metastases 
may be occurred via bloodstream or lymph nodes and subsequently led to dissemination of 
tumor cells to distant organs such as the bone, lung, liver, and less frequently the central 




Figure 9: Breast cancer progression. Normal breast duct is composed of a layer of epithelial 
cells and a layer of myoepithelial cells. Ductal carcinoma in situ (DCIS) is an abnormal 
outgrowth of carcinoma cells confined within the ducts and lobules of the breast. When the 
myoepithelial cell layer and basement membrane are completely lost, carcinoma cells escape 
from the barrier of ducts or lobules,  invade the surrounding breast tissues,  and becomes 




1.2.6 Microenvironment of mammary carcinoma 
 The microenvironment of mammary carcinoma plays an essential role in the control 
of neoplastic progression through dynamic reciprocity between cancer cells and their 
surrounding environment or tissues (Polyak and Kalluri, 2010). The mammary duct consists 
of epithelial cells surrounded by stroma components includes fibroblasts, myofibroblasts, 
endothelial cells, adipocytes, and various immune cells (Erler and Weaver, 2009). A thin 
layer of ECM lies between the epithelial cells and the stroma (Woodward et al., 1998). The 
ECM is a rich in matrix metalloproteinases (MMPs) and growth factors that participate in 
neoplastic dissemination (Finger and Giaccia, 2010). There are four different types of cellular 
connections essential in the maintenance of the epithelial layer, which include desmosomes, 
adherens junctions, gap junctions, and tight junctions (Ehmann et al., 1998). The functions of 
these structures are to restrict both cell movement and unlimited proliferation. Gap junctions 
act as a channel to mediate cell-to-cell communication and channeling cellular biological 
signals such as cytokines or products of tumor suppressor genes to the neighboring cells. 
Under normal physiological conditions, proper tissue architecture is preserved and/or retained 
by basement membrane and intercellular communication (Joyce and Pollard, 2009).  
 The normal tissue microenvironment acts as a barrier to tumorigenesis and exerts 
protective constraint against malignant transformation (Figure 10). The microenvironment 
can act as a permissive forces to tumor growth in the process of mammary carcinoma 
progression (Bissell and Hines, 2011). During invasion, tumor cells induce disruption of cell-
cell contacts and cell-ECM interactions mediated by cell adhesion molecules such as integrins 
and cadherins. The basement membrane undergoes degradation and structural changes that 
lead to the destruction of normal tissue boundaries and provide a path for invasion of cancer 
cells (Khamis et al., 2012). Therefore, the metastasis of mammary carcinoma is promoted by 
proteolytic degradation of neighboring tissue while motility of cancer cells is enhanced by the 
actions of chemokines, growth factors and also recruitment of stromal cells. (Friedl and Wolf, 
2003). Several studies have demonstrated that cancer-associated fibroblasts stimulated 
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motility and proliferation of cancerous epithelial cells when they had direct cell interaction in 
co-culture (Korohoda and Madeja, 1997, Olumi et al., 1998, Kalluri and Zeisberg, 2006). 
Endothelial cells are also recruited to the tumor microenvironment for ectopic blood vessels 
formation for metastasis (Folkman, 1992). The cellular transformation is regulated by 
interaction between epithelial cells, activated stromal cells as well as the ECM components 
(Khamis et al., 2012). These cellular components in tumor microenvironment may function 
either as suppressive or promotional forces in the progression of mammary carcinoma (Bissell 





Figure 10: Microenvironment of breast cancer development. In a healthy breast (left), the 
normal tissue microenvironment acts as a barrier to tumorigenesis and exerts suppressive 
forces to restrain the dormant tumors under normal tissue homeostasis. In invasive cancer 
(right), the microenvironment can turn to be permissive conditions for tumor growth, and the 
combination of mutagens, inflammation, growth factors and other tissue-associated 
promotional forces can breach the barrier to tumor formation, resulting in aggressive growth 








1.2.7 Oncogenes in pathogenesis of mammary carcinoma 
 Pathogenesis of mammary carcinoma is associated with the accumulation of 
alterations of the genome. Genetic alterations that repress tumor suppressor genes and activate 
oncogenes may prime the affected cancer cells to be more susceptible to gain additional 
genetic damage that eventually led to instability in the tumor genome (Al-Kuraya et al., 2004). 
Increased genetic alterations have been associated with clinicopathological features such as 
poorly differentiated pathology, metastasis and decreased survival (Al-Kuraya et al., 2004, 
Ellsworth et al., 2008a). Several oncogenes have been linked to mammary carcinoma 
progression including ER, PR, HER-2/neu (ErbB-2), and c-myc. These genes are the major 
drivers of cancer progression and therefore become targets for therapeutic intervention.  
 (i) Estrogen receptor 
 The ER is one member of the nuclear hormone family of intracellular receptors and is 
activated upon binding of its hormone ligand, 17β-estradiol (Dahlman-Wright et al., 2006). 
ER functions as a DNA-binding transcription factor that regulates gene expression (Levin 
2005). There are two main isoforms of ER namely ERα and ERβ that encoded by ESR1 and 
ESR2 genes, respectively. In response to the stimulation of estrogen, ERs dimerize to form 
functionally active homodimer or heterodimer which then activate the transcription of the 
reporter genes containing estrogen response elements (Cowley et al., 1997, Pace et al., 1997). 
ERs are overly expressed in about 70% of breast cancer cases (ER-positive breast cancer). 
Upon binding of estrogen, ER induces mammary cells proliferation that subsequently lead to 
a marked increase in cell division and mutation rate (Burns and Korach, 2012). Furthermore, 
the process of metabolizing estrogen may produce genotoxic byproducts, which can directly 
damage DNA and subsequently resulted in point mutations (Burns and Korach, 2012). ERα 
expression is associated with more differentiated tumors while the significance of ERβ 
expression in tumor remains controversial (Herynk and Fuqua 2004). One study suggested 




(ii) Progesterone receptor 
 The progesterone receptor (PR) is a transcription factor and a member of a group of 
intracellular steroid hormone receptors, which regulate gene expression at specific sites in 
DNA (Lange and Yee, 2008). There are two PR isoforms, PR-A (94 kDa) and PR-B (116 
kDa), produced by the same gene located on chromosome 11 (Law et al., 1987) that regulate 
different but overlapping target genes (Graham et al., 2005). Comparing with PR-A, PR-B is 
a more potent transcriptional activator. PR-B has an effect on cellular proliferation and also 
differentiation of mammary epithelium. The biological function of ovarian and uterine are 
dependent primarily on PR-A (Mulac-Jericevic et al., 2003). PR is expressed in reproductive 
tissue and has crucial roles in folliculogenesis, ovulation, implantation and pregnancy 
(Gadkar-Sable et al., 2005). Recent clinical studies have shown that progesterone possess 
proliferative property in the normal human breast that is independent of estrogen, and is also 
one of the risk factor for mammary carcinoma (Anderson, 2002, Lee et al., 2006). 
Furthermore, progesterone/PR acts in conjunction with mitogenic protein kinases and cell-
cycle mediators to stimulate regulation of PR target genes (Lange and Yee, 2008).  
 (iii) HER2/neu 
 The HER2/neu (ErbB-2 or ERBB2) is a member of the epidermal growth factor 
receptor (EGF-R) family with tyrosine kinase activity and HER2/neu gene is found on 
chromosome 17q12  (Coussens et al., 1985). HER2 is a membrane receptor tyrosine kinase 
implicated in the signal transduction pathways connected to cell growth and differentiation 
(Slamon et al., 1989). Presumably, HER2 is an orphan receptor, which do not have a known 
ligand and is thus not activated by EGF family ligands (Olayioye, 2001). However, HER2 
serve as a preferential dimerization partner for other members of the ErbB family (Olayioye, 
2001). An estimated of 30% of breast and ovarian cancers contained HER-2/neu gene 
amplification and/or over-expression of its protein (Zhou and Hung, 2003). Over-expression 
of HER2/neu receptor in breast cancer has been reported to be associated with increased 
disease recurrence as well as worse prognosis (Ellsworth et al., 2008b). This poor prognosis 
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may be due to genomic instability where breast cancer cells with higher frequencies of 
chromosomal modification is associated with enhanced cell proliferation and a more 
aggressive phenotype (Ellsworth et al., 2008b). Additionally, genetic changes of the proto-
oncogene ErbB-2 (HER2/neu) are connected with elevated invasive phenotype and poor 
prognosis in breast cancer patients (Wilson et al., 2002).   
 (iv) c-myc 
 The c-myc protein is a transcription factor and contains basic helix-loop-helix (bHLH) 
domain (Vennstrom et al., 1982). The c-myc oncogene is over-expressed in about 15 - 25% of 
breast tumors (Deming et al., 2000) and is implicated in breast cancer cell growth, 
transformation, angiogenesis, as well as cell cycle control (Chen and Olopade, 2008). 
Numerous studies have consistently observed the positive correlation between amplification 
of c-myc gene with breast cancer progression and poor clinical outcome (Chen and Olopade, 
2008). Therefore, c-myc gene amplification is identified as a strong prognostic marker in 
predicting early recurrence in patients with node-negative breast cancer (Schlotter et al., 
2003). 
 
1.2.8 Histological and molecular grading systems in mammary carcinoma 
 Histological-based grading system provides a method to distinguish well-
differentiated tumors from poorly differentiated tumors. Grade 1 refers to tumors that are 
well-differentiated and demonstrates good prognosis, whereas Grade 3 is poorly-
differentiated tumor and it is more likely to spread (Elston and Ellis, 1991). Although 
histological based grading system is widely used in the past, it may not be clinically 
informative as majority of breast cancer cases are fall under Grade 2 (Sotiriou et al., 2006). 
The American Joint Committee on Cancer (AJCC) staging system of breast cancer serves is a 
standard for grouping patients with respect to prognosis. Therapeutic options are chosen 
based on several factors such as tumor size, lymph node status, hormone receptor status, 
HER2/neu status, and menopausal status. The AJCC has designated the staging system by 
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TNM classification to define breast cancer, where T to tumor size, N to lymph node 
involvement and M to distant metastasis (Singletary et al., 2002). TNM refers to the presence 
of invasive or non-invasive tumor, the tumor size, the presence of cancer cells in lymph node 
and the presence of secondary metastasis of the tumor cells. In addition to the clinical TNM 
staging, current therapeutic options are preferably combined with histopathological grading, 
tumor size, lymph node, hormone receptor, HER2/neu and proliferation (Ki67) status. 
Therefore, molecular subtyping with immunohistochemistry (IHC) and fluorescence in situ 
hybridization (FISH) have later been established (Perou et al., 2000). This classification may 
provide additional information on patient survival outcome. There are four molecular 
subtypes including luminal-like (luminal A or luminal B), HER2 enriched/over-expression, 
basal-like (triple negative) and normal-like. According to this classification, ER-negative 
breast cancer comprises of two tumor subtypes: basal-like and HER2-positive. Recent studies 
have demonstrated that these molecular subtypes differ in their responses to treatment and 
survival outcomes (Blows et al., 2010, Dawood et al., 2011). Other studies have precisely 
classified these molecular subtypes of breast cancer with respect to their PR, ER, and HER2 
status and categorized them as luminal B (ER+ or PR+, and HER2+), luminal A (ER+ or PR+ 
and HER2-), basal (ER-, PR-, and HER2-) and HER2 (ER-, PR-, and HER2+) (Brenton et al., 
2005, Carey et al., 2006). The luminal subtypes are the most common breast cancer subtypes 
and present good prognosis. Conversely, HER2 and basal-like subtypes show poor prognosis 
(Brenton et al., 2005). As compared to other subtypes, the basal-like and HER2 tumors 
contain the highest rate of mutation. 80% of basal-like tumors with TP53 gene mutation 
which have been linked to poor outcomes (Cancer Genome Atlas Network, 2012). Currently, 
all breast cancers patients are tested for the ER, PR, and HER2 proteins expression. ER and 
PR are assayed by IHC while HER2/neu is examined by FISH. The protein profiling of 
tumors may provide useful information to design a better therapeutic treatment and predict 




1.2.9 Breast cancer diagnosis and treatment 
 There are different types of treatments available for breast cancer patients. The 
clinical symptoms observed in breast cancer patients are largely dependent on whether the 
tumor is confined to the breast or has metastasized. Primary therapies of local breast cancer 
include surgery (breast-conserving or mastectomy) and radiation therapy. Patients may opt for 
surgical removal of primary local tumor from the breast (breast-conserving) or to remove part 
of the breast (mastectomy). These patients may also be subjected to subsequent radiotherapy, 
chemotherapy, or hormone therapy to eradicate remaining cancer cells residing in the breast 
(Majure, 2000). Chemotherapy is an alternative treatment options that utilizes drugs to inhibit 
cell division and eventually the growth of cancer cells. Endocrine therapy involves blocking 
of hormones in order to attenuate cancer cells from growing (Majure, 2000). Some of 
endocrine therapies include competitors for ER and inhibitors of estrogen to counteract the 
effect of estrogen in breast cancer (Normanno et al., 2005). Patients with elevated levels of 
ER and/or PR (i.e., luminal subtype) are treated with endocrine therapy (Normanno et al., 
2005). Other anti-estrogen agents for breast cancer patients include synthetic selective 
estrogen modulators (SERMs), such as tamoxifen, which acts as ER antagonist in breast 
cancer tissue, and aromatase inhibitors which inhibit the action of the enzyme aromatase to 
convert androgens into estrogens (Osborne, 1999). Tamoxifen  has an agonist or antagonist 
effect depending on the molecular profile of its target (Jordan et al., 2001). It reduces the 
development of breast cancer in both pre- and post-menopausal women who are at risk for the 
disease (Schlotter et al., 2003). ER status is utilized as an indicator to deduce the sensitivity of 
breast cancer cells to tamoxifen and aromatase inhibitors (Fabian and Kimler, 2005). 
Raloxifene, which has anti-estrogenic behavior, is being widely used as a preventive 
chemotherapy for women who maybe at higher risk of developing of breast cancer (Oseni et 
al., 2008). Additionally, a new type of endocrine therapy with ER antagonist effect, known as 
Fulvestrant, has also been developed. Fulvestrant acted by both down-regulating and 





) (Raina, 2004, Nicholson et al., 2007). Targeted therapy is another 
treatment that utilizes drugs to identify and target specific cancer cells without causing any 
harm to normal cells. There are two types of targeted therapies available for treatment of 
breast cancer, which include the use of  monoclonal  antibodies and tyrosine kinase inhibitors 
(Crown et al., 2012). One example is the use of PARP inhibitors as targeted therapy against 
triple-negative breast cancer (Crown et al., 2012). Moreover, HER2/neu is the primary target 
of humanized monoclonal antibody trastuzumab (Herceptin
®
), which target the extracellular 
domain of this receptor and blocks the effects of HER2 in conveying growth signals to breast 
cancer cells (Kurokawa et al., 2000). Therefore, patients with HER2 amplified (HER2+) 
tumors are given trastuzumab as monotherapy. Alternatively, this targeted therapy can be 
supplied to patients in combination with standard chemotherapy (Slamon et al., 2001). 
However, majority of patients with HER2+ metastatic breast cancer who responded to 
trastuzumab at initial treatment stage eventually developed resistance within a year of 
treatment and some patients even relapse despite trastuzumab-based therapy (Cobleigh et al., 
1999, Vogel et al., 2002).  
 Although clinical trials for combinational therapies of anti-estrogen and anti-
HER2/neu treatment showed promising results (Kurokawa et al., 2000), it has been reported 
that HER2-positive breast cancers have lower sensitive to estrogen modulation due to HER2 
and ER cross-talk (Kurokawa and Arteaga, 2003). Development of resistance to therapeutic 
drugs (de novo or intrinsic resistance) is still a major barrier to effective treatment of breast 
cancer. It has been reported that some patients did not respond to therapy due to intrinsic drug 
resistance and multiple signaling pathways regulating the oncogenesis of breast cancer. 
Cross-talk between the ER and several growth factor signaling pathways has been widely 
recognized (Schiff et al., 2004). Even in the absence of estrogen, cancer cells can still use 
growth factor signaling pathways as a compensatory mechanism and acquire anti-estrogen 
drug resistance (Schiff et al., 2004).  
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 A new recombinant humanized monoclonal anti-HER2 antibody, Pertuzumab, is 
currently being investigated. Pertuzumab binds to extracellular dimerization domain of HER2 
and inhibits the heterodimerization of HER2 with other HER receptors or EGF receptors, 
thereby preventing activation of HER2 signaling pathways (Metzger-Filho et al., 2013). 
Formulation of small molecule tyrosine kinase inhibitor (TKI) may reduce the onset of 
resistance and can be used in combination with targeted therapies. Example of TKI includes 
Bevacizumab
®
 which is an anti-angiogenic molecules targeting VEGF-A, and anti-insulin 
growth factor 1 (IGF-1) therapy (Johnston, 2006). Hence, a multi-targeted therapeutic 
approach may offer a promising treatment for breast cancer patients. 
 
1.3 Trefoil factors 
 The human trefoil factors (TFFs) are a family of proteins comprising of three 
members, which comprise of TFF1 (pS2) that was firstly identified as an estrogen-responsive 
gene in MCF-7 human breast cancer cell line (Jakowlew et al., 1984, Nunez et al., 1987), 
TFF2 (Spasmolytic polypeptide, SP) (Tomasetto et al., 1990, Beck et al., 1996), and TFF3 
(intestinal trefoil factor, ITF) (Suemori et al., 1991, Schmitt et al., 1996). TFF1 was the first 
member of the family identified via cDNA cloning of estrogen-responsive gene from a breast 
cancer cell line (Masiakowski et al., 1982, Jakowlew et al., 1984). TFF2 was almost 
coincidentally isolated in porcine pancreas (Jørgensen et al., 1982, Thim et al., 1985). 
Subsequently, TFF3 from rat intestine was the third human trefoil factor described (Suemori 
et al., 1991). The trefoil proteins have also been identified in other mammals such as rat, 
mouse and chimpanzee (Thim and May, 2005). TFF peptides are specifically synthesized in 
mucin producing cells of gastrointestinal (GI) tract and thus are characteristic secretory 
products of the mucous epithelia. Physiologically, TFF1 and TFF2 are expressed in human 
stomach mucosa and TFF3 is predominantly expressed in GI tract and colon. Evidence 
indicated that TFF peptides are involved in maintaining the integrity of GI epithelium by 
supporting mucosal defense and repair mechanism (Taupin and Podolsky, 2003, Hoffmann, 
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2004). The gene encoding human TFF peptides are found on chromosome 21q22.3 in a 55 kb 
gene cluster region (Seib et al., 1997) (Figure 11). TFF peptides have seven conserved 
cysteines residues, of which six are connected to each other by disulfide bonds in a specific 
order, forming a three-cyclic structure, whereby the whole peptide chain is folded and shaped 
like a "clover". This structural motif domain is named as trefoil domain or P-domain (Thim, 
1989, Polshakov et al., 1997). Trefoil domain is cysteine-rich module that forms the 
functional unit for TFF peptides (Wright et al., 1997, Wright, 1998, Thim and May, 2005, 
Hoffmann, 2006) and confers proteolytic stability and resistance to acidic degradation 
(Suemori et al., 1991). TFF peptides contain either one or two trefoil domains, which consist 
of 42 - 43 of highly conserved or semi-conserved amino acids (Thim, 1989, Poulsom et al., 
1997). TFF1 and TFF3 each contain one trefoil domain, whereas TFF2 contains two (Figure 
11). Both TFF1 and TFF3 have a seventh cysteine residue at the carboxyl terminus of the 
peptides that facilitates homodimerization and intermolecular interactions with other proteins 
(Thim and May, 2005). TFF1 and TFF3 can exist in several different molecular forms such as 
monomers, homodimers and heterodimers. TFF dimers are predicted to be more biologically 
active than monomers. The monomer and homodimer of TFF1 are more asymmetric than that 
of TFF3 and such differences may account for the divergent biological activities and 






Figure 11: Human TFF peptides. Conserved cysteines residues (red circle) connected with 
each through disulfide bonds in a specific order to form a three-cyclic structure (Thim and 
May, 2005). Reproduced with permission. 
 
1.3.1 Gene structure and regulation of TFF 
 All three human TFF genes are located in clusters on chromosome 21q22.3 in a 
sequential arrangement within a single 55 kb genomic region in the order telomere-TFF1-
TFF2-TFF3-centromere (Hattori et al., 2000) (Figure 12). TFF1 and TFF3 genes contain three 
exons, while TFF2 contains four exons. These exons encode the amino terminal signal 
peptide, followed by the trefoil domain, and the carboxyl terminal acidic motif, respectively. 
Transcription of these three genes is directed towards the centromere. In mouse genome, a 40 
kb region located on chromosome 17q is found to resemble the human TFF gene (Ribieras et 
al., 2001). Conservation of TFF gene cluster between different organisms (mouse and human) 
implied that TFF expression is partially regulated by a locus activation region (Thim and May, 
2005). The promoter region consists of an estradiol responsive element (ERE) (Berry et al., 
1989), and also contains a complex enhancer region responsive to the proto-oncoproteins c-
Ha-ras, tumor promoter TPA, epidermal growth factor (EGF) and c-jun (Nunez et al., 1989). 
Several transcriptional factors, regulatory proteins and epigenetic factors including estrogens, 
progesterone, epidermal growth factor, basic fibroblast growth factor, upstream stimulating 
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factor (USF), hepatocytes nuclear factor, GATA-6 and Ha-Ras/AP-1 coordinately regulate the 
cell-type specific expression of TFF genes (Beck et al., 1999, Al-azzeh et al., 2002, 
Borthwick et al., 2003). 
 TFF1 promoter region contains an ERE that lies between 332 to 428 bp upstream of 
the transcriptional start site. Activation of TFF1 expression is induced by estrogen in ER+ 
mammary carcinoma cells, acting in a synergistic manner with the steroid receptor 
coactivator-1 (Src-1), via the AP-1 and ERE at the TFF1 promoter (Barkhem et al., 2002a, 
Barkhem et al., 2002b). Estradiol-mediated regulation of TFF1 gene expression has been 
observed in mammary carcinoma (Rio et al., 1987), but has not been conclusively 
demonstrated in other tissues. The presence of other regulatory elements may contribute to 
the expression of TFF1. An example is GATA-6, which is an endodermal transcription factor 
expressed in various tissues including pancreas gut, liver, pancreas, and lung. GATA-6 
activates expression of TFF1 and TFF2 but not TFF3 (Al-azzeh et al., 2000). Moreover, TFF1 
gene is down-regulated by NF-κB and C/EBPβ (Dossinger et al., 2002). In addition to the 
genetic regulation of TFF1 expression, epigenetic mechanisms also modulate TFF1 
expression levels. The proximal promoter/enhancer region of TFF1 gene contains several 
CpG islands. The TFF1 gene is subject to tissue-specific methylation of its proximal enhancer 
region and the extent of methylation correlates with its expression (Martin et al., 1997, 
Fujimoto et al., 2000, Carvalho et al., 2002). 
 TFF2 was identified as a side product from the purification of insulin from porcine 
pancreas (Sands and Podolsky, 1996). There is limited knowledge or literature on  the 
transcriptional regulatory elements of this gene but the transcription factors such as GATA-6, 
STAT-6, upstream stimulating factors (USF) and Peroxisome proliferator-activated receptor 
gamma (PPARγ) activate TFF2 gene expression (Al-azzeh et al., 2000, Baus-Loncar et al., 




 TFF3 promoter region contains two ERE (Baus-Loncar et al., 2004). Induction of 
TFF3 expression has been shown to be estrogen-dependent in breast cancer cells (May and 
Westley, 1997a). The pro-inflammatory cytokine IL-6 induces TFF3 gene expression via 
STAT3 transcription factor (Tebbutt et al., 2002). TFF3 promoter contains HIF-1 response 
elements that results in increased TFF3 expression mediated by HIF-1 under hypoxia (Furuta 
et al., 2001). As demonstrated in TFF1 and TFF2, NF-κB and C/EBPβ down-regulate the 
expression of TFF3 gene via four NF-κB and two C/EBPβ binding motifs (Dossinger et al., 







Figure 12: Chromosomal localization of human TFF genes.  A, TFF cluster on 
chromosome 21q22.3. The exons (e.g., E2 or E3) encode human trefoil domains and the first 
exon (E1) encodes the signal sequences of the precursors of TFF proteins. B. Regulatory 
elements  such as ERE at the promoter region of trefoil factors (Ribieras et al., 1998). 










1.3.2 TFF protein  
 Mammalian orthologous sequence analysis of TFF across different species, including 
human, rat, mouse, canine, pig, and chimpanzee, shows an overall amino acid sequence 
conservation of 52% with a 57% homology in the trefoil domain (Thim and May, 2005). The 
amino acid sequence of the trefoil domain in TFF3 is conserved among mammalian species 
with an orthology of 67% (Thim and May, 2005). TFF3 shares the relatively low level of 
amino acid sequence homology of 36% compared to TFF1. However, TFF3 contains many of 
similar elements that are common to members of TFF family (Sands and Podolsky, 1996). 
TFF peptides are synthesized with a signal sequence for secretion of 21 or 27 amino acid 
residues that are proteolytically spliced away when passaging through the endoplasmic 
reticulum. The secreted mature form of TFF peptides comprises a signal peptide, one or two 
trefoil domain (s), and a carboxy-terminal acidic domain. Despite having similar isoelectric 
points, TFF1 and TFF3 differs significantly in their hydrodynamic properties, distribution of 
surface amino acids and overall charge (Emami et al., 2004). 
 TFF1 possesses 60 amino acid residues, encoding a 9 kDa protein and a single trefoil 
domain consists of 42 amino acid residues. TFF2 contains 106 amino acid residues, encoding 
a 14 kDa protein, and two trefoil domains consisting 43 residues and 42 residues respectively 
in the first and second trefoil domains. The first trefoil domain in TFF2 differs as it contains 
an additional amino acid residue. TFF3 consists of 59 amino acid residues, encoding a 7 kDa 
protein, and contains a single trefoil domain of 42 amino acid residues (Figure 13). In 
addition to the six conserved cysteine residues in the trefoil motif, TFF1 and TFF3 contain a 
seventh cysteine residue located three amino acids away from the carboxyl terminus of the 
protein. This allows homodimerization, via a disulfide bond with the seventh cysteine residue 
of the other trefoil factors as well as heterodimerization, via intramolecular disulfide bonds 
with other proteins (May et al., 2003, Thim and May, 2005, Westley et al., 2005).  TFF2 has 




 The biological potencies and activities of TFF peptides are dependent on structural 
differences or interaction with other proteins. Homodimerization is critical for the biological 
functions of TFF, particularly its ability to stimulate cell migration and proliferation in vitro 
(Marchbank et al., 1998, Calnan et al., 1999, Prest et al., 2002) as well as protection of the 
gastric against damage in vivo. An in vitro wound healing model, TFF1 dimer significantly 
increased cell migration of human colorectal cell line as compared to TFF1 monomer 
(Marchbank et al., 1998). Dimeric TFF1 significantly reduced gastric damage in vivo, while 
monomeric TFF1 was ineffective. Previous studies utilizing a cell line model of epithelial 
barrier function have shown that specific mucins interacted with specific trefoil factors to act 
in a coordinate manner for protection of mucosa (Kindon et al., 1995). Heterodimerization of 
TFF1 with mucin MUC5AC through C-terminal disulfide interaction promotes mucosal 
protection in the normal GI tract where these two proteins are co-localized (Longman et al., 
2000, Ruchaud-Sparagano et al., 2004). An animal model study suggested that glycosylation 
of TFF2 is more effective than its non-glycosylated form in the projection against gastric 
damage (Playford et al., 1995). Homodimerization appears to be required for the protective 
functions of TFF3 in the GI tract (Carrasco et al., 2004). TFF3 and mucin MUC2 have been 
shown to co-localize in the GI tract although no direct protein-protein interactions have been 
elucidated (Longman et al., 2000). Formation of the heterodimer between trefoil factor 
interactions(z) 1(TFIZ1) and TFF1 is observed in the mucus secretory cells of the stomach. In 
gastric cancer, the co-expression of these two proteins is deregulated whereby the expression 
of TFF1 in the absence of TFIZ1 is correlated with both invasive and also metastatic 
phenotype (May et al., 2009). Piezo1 is a novel TFF1 binding protein which is crucial for 



















Figure 13: TFF protein. A, Conserved protein primary structure of the three human TFFs, 
including a signal peptide (PRE), one or two TFF domains (TFF) and a carboxy-terminal 
acidic domain (Ac). B, Trefoil secondary structure. The conserved cysteine residues in the 
trefoil domain formed disulfide bond in a C1-C5, C2-C4, and C3-C6 configuration to create 
three loops reminiscent of a cloverleaf. Conserved cysteine (C7) at the carboxy terminus 
facilities homo- hetero-dimerazation (Ribieras et al., 1998). Reproduced with permission. 
 
1.3.3 Normal expression patterns and localization of TFF proteins 
 TFF proteins have protective and restorative functions in normal tissue (GI tract) 
where they are normally expressed, but they exhibit adverse effect in cancerous tissues where 
they are pathologically expressed. Normal distribution of these proteins is primarily in the GI 
tract although they have specific localization within the tract to perform their functions in 
gastric mucosa. 
 TFF proteins are usually localized to the gastric mucosa with TFF1 and TFF2 
normally expressed in the gastric epithelia. TFF proteins are not only expressed in GI tissues, 
but are also expressed in other tissues such as bronchial and urogenitary tracts (May and 
Westley, 1997b, Oertel et al., 2001). TFF1 and TFF3 are expressed in human hypothalamus, 
gastric juice and urine, suggesting autocrine, paracrine and endocrine functions for these 
proteins (Rio et al., 1987, Hoffmann and Jagla, 2002). TFF proteins are major components 
found in the GI mucosa, but each is expressed differentially. TFF1 and TFF2 expression are 
38 
 
found in the gastric epithelial, while TFF3 in the goblet cells of intestine. Both TFF1 and 
TFF2 are expressed in the stomach but have different expression patterns within this organ. 
TFF1 is mainly expressed in the superficial cells of the GI tissue (Ruchaud-Sparagano et al., 
2004), whereas basal cells of the gastric tissue express TFF2 (Minegishi et al., 2007). TFF1 
expression is not observed in the uterus, spleen, muscle, small intestine, lung, kidney, brain, 
hepatocellular, testis, pancreas, colon, cardiac, and skin (Bonkhoff et al., 1995, Ribieras et al., 
1998). Low levels of TFF1 expression are seen in the mammary gland and breast epithelium 
(Piggott et al., 1991, Hanby et al., 1993). TFF2 is expressed in the Brunner’s glands of the 
duodenum (Ribieras et al., 1998) and TFF3 is predominantly expressed in the small and large 
intestine, particularly the colon and duodenum (Taupin and Podolsky, 2003). TFF3 has also 
been shown to be expressed in the lung, salivary glands, the cornea, conjunctiva tissue, brain, 
and lymphoid tissue (Cook et al., 1999, Jagla et al., 1999, Göke et al., 2001, Emami et al., 
2004) where they are postulated to possess function in inflammation and epithelial ulceration.  
 
1.3.4 Expression of TFF3 in human mammary carcinoma 
 Elevated expression of TFF proteins has been reported in a number of human cancers, 
including breast, prostate, esophagus, stomach, liver, pancreas and intestines (Emami et al., 
2004). Therefore, TFF proteins may have a pivotal function in the development and 
progression of human cancer. 
 In the human breast, TFF3 protein is normally present in breast epithelial cells at the 
lobules and ducts. The function of TFF3 in the human breast may be to protect and maintain 
the integrity of the epithelial surface (May and Westley, 1997a, Poulsom et al., 1997).  Co-
expression of TFF1 and TFF3 was observed in breast epithelial cells. Poulsom et al. (1997) 
analyzed the expression of TFF3 in breast cancer tissue by in situ hybridization and observed 
that TFF3 was highly expressed in both non-invasive and invasive lobular and ductal breast 
cancer. A recent cohort study on breast cancer patients has shown that increased TFF3 
expression in 89% of in situ mammary carcinoma and in 83% of invasive mammary 
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carcinoma (Ahmed et al., 2012). In breast cancer cells, TFF3 protein expression was observed 
to be strongly associated with the expression of estrogen and progesterone receptors. 
Additionally, it has been shown that the expression of TFF3 is regulated by estrogen (May 
and Westley, 1997a). 
 
1.3.5 TFF3 signaling 
 Although TFF3 plays a critical part in tumor progression, the signaling pathways of 
TFF3 are not fully understood. A receptor for TFF3 protein has not yet been identified to 
elucidate the mechanism of TFF3 in both normal and pathological contexts. Numerous studies 
have shown that TFF proteins may indirectly bind to other proteins or secreted factors that 
may activate signaling cascades for promoting the biological effects of TFF3 protein. Using 
immunoprecipitation followed by cross-linking, Chinery and Cox (1995) observed that TFF3 
binds to a phosphorylated tyrosine-containing peptide of 28 kDa. Another study has 
demonstrated that TFF3 binds to 50 kDa membrane glycoprotein in the small intestine crypts 
and also in the mucous cells of the gastric glands (Tan et al., 1997). A recent study speculated 
that Sp-1 binds to the core region of TFF3 promoter (positioned from -300 bp to -296 bp) 
resulting in increased TFF3 promoter activity and the subsequent stimulation of TFF3 
expression (Sun et al., 2014). Additionally, ERG is a ETS transcription factor and directly 
binds to ETS response elements in the TFF3 promoter in ERG-rearranged prostate cancer cell 
lines to induce invasive potential of castration-resistant prostate cancer (Rickman et al., 2010). 
Signaling pathways that have been identified for potentiating the biological functions of the 
TFF3 protein include EGF, G-protein, and cyclooxygenase (COX). 
(i) Epidermal Growth Factor (EGF) 
 
 Although TFF3 has not been reported to bind directly to a receptor, it is able to signal 
through specific pathways via indirect activation. Previous studies have proposed that TFF3 
transmits signal indirectly through the activation of EGF-R (Liu et al., 1997). EGF-R 
signaling pathway is important for tumor growth and over-expression of EGF-R is correlated 
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with metastasis potential, poor survival and higher relapse rates in human tumors (Radinsky 
et al., 1995, Ozgul et al., 1997). Upon stimulation by TFF3, EGF-R is activated and receptor 
tyrosine protein kinase activity is enhanced. Treatment of gastric cancer cell lines with TFF3 
resulted in phosphorylation of the EGF-R, indicating that TFF3 has the ability to indirectly 
activate EGF receptor (Liu et al., 1997, Kanai et al., 1998, Taupin et al., 1999, Kinoshita et 
al., 2000b). In addition, the pro-invasive effects of TFF1 and TFF2 were abrogated by 
treatment with EGF-R tyrosine kinase inhibitor and/or with the use of a dominant negative 
form of the EGF-R (lacking intracellular domain), suggesting that this pathway is essential for 
the pro-invasive function of these proteins. However, the pro-invasive effect of TFF3 was not 
affected by EGF-R tyrosine kinase inhibitors under the same experimental conditions, 
indicating that TFF3 induced invasion of kidney and colon cancer cells independent of EGF-
R (Rodrigues et al., 2003a). This raises the possibility that TFF3 may exert its functions 
through both receptors and signaling pathways (Rodrigues et al., 2003a). This observation is 
supported by Yong et al. (2013) have identified a TFF3 specific binding receptor in the 
intestinal epithelial cells. The authors believed that EGF-R is unlikely to be the TFF3 receptor 
(Yong et al., 2013). Several studies have demonstrated that TFF3 may transmit extracellular 
signals and promote cell proliferation and migration through activation of EGF-R (Hoffmann, 
2007, Li et al., 2011). Furthermore, the pro-angiogenic functions of TFF1 appear to be 
regulated in an EGF-dependent manner as pharmacological inhibition of EGF-R tyrosine 
kinase activity resulted in decreased TFF1-induced angiogenesis (Rodrigues et al., 2003b). 
 (ii) Heterotrimeric G‐proteins 
 
 Another potential signaling cascade activated by the TFF peptides is the 
heterotrimeric G-protein pathway. There is no experimental data to show that TFF peptides 
directly bind to G-protein receptors. Several studies indicate that the G-protein signaling 
pathway is important for the mitogenic functions of TFF1 and TFF3 (Faivre et al., 2001, 
Rodrigues et al., 2001). The TFF3- and TFF1-induced invasion of kidney and colonic 
epithelial cells were abrogated by the pharmacological inhibition of critical elements of the G-
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protein signaling machinery including Rho small GTPase and thromboxane A2 receptor 
(TXA2-R). In contrast, the constitutively activated forms of heterotrimeric G-proteins Gαq 
(AGαq), Gα12, Gα13 (AGα12/13) and TXA2-R mimetic led to increased invasion of kidney 
and colonic epithelial cells promoted by these two proteins (Rodrigues et al., 2001). 
Additionally, over-expression of TFF1 resulted in increased invasion mediated by Rho-
independent and TXA2-R-dependent pathways (Rodrigues et al., 2001) and ablation of Gβγ 
heterodimers resulted in decreased TFF-induced cellular invasion (Faivre et al., 2001). 
(iii) Cyclooxygenases COX‐1 and COX‐2 
 
 The pro-inflammatory molecules COX-1 and COX-2 have been identified as 
potential signaling mediators of the TFF peptides. Both molecules are proposed to contribute 
in the pro-invasive and pro-angiogenic functions of TFF peptides although experimental 
evidence is very limited. Expression of COX-2 has been postulated in tumor initiation and 
progression by regulating cell proliferation, migration, and invasion (Young et al., 1992). Its 
oncogenic effect can be induced by several growth factors and oncogenes such as EGF-R 
tyrosine kinase, and pro-inflammatory cytokines (Vane et al., 1998). It has been shown that 
inhibition of COX-1 and COX-2 led to the ablation of TFF1-induced invasion and 
angiogenesis (Rodrigues et al., 2001, Rodrigues et al., 2003a, Rodrigues et al., 2003b). 
Therefore, TFF1 induces COX-2 expression to promote cellular invasion in human colonic 
cells (Emami et al., 2001). TFF3 binds to intestinal mucosa and enhances production of nitric 
oxide via activation of cyclooxygenases (COX-2) pathway (Rodrigues et al., 2001). 
 
1.3.6 Biological functions of TFF3 
 TFF peptides have been implicated in stabilization of mucus and stimulation of 
normal epithelial restitution during mucosal repair. TFF peptides are rapidly expressed and 
secreted in an autocrine manner during GI injury. The secreted TFF peptides function as 
motogens to assist migration of epithelial cells into the wound, thereby providing a physical 
barrier in a process referred to restitution (Taupin and Podolsky, 2003) (Figure 14). 
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Additionally, TFF proteins are potent inhibitors that resist apoptosis and anoikis during the 
process of migration of the cell. Therefore, the biological functions of TFF proteins include (i) 
forming and stabilizing the mucus barrier, (ii) promoting rapid mucosal repair (restitution), 
(iii) modulating mucosal differentiation as well as (iv) modulating mucosal immune response 
(Hoffmann, 2004). 
 First lines of evidence suggesting that TFF proteins play a protective role arise from 
animal studies whereby rats were treated with the prostaglandin inhibitor indomethacin that 
causes ulceration of the GI tract. Combined prophylactic treatment of these animals with 
epidermal growth factor (EGF) and TFF3 led to remarkable reduction of gastric damage 
(Chinery and Playford, 1995, Playford et al., 1995). Subsequently, this observation was 
confirmed by in vivo studies which showed administration of TFF2 and TFF3 proteins to 
confer protective and beneficial effects against chemical-induced damage of the gastric 
mucosal at a level comparable to prostaglandin-mediated cytoprotection (McKenzie et al., 
2000, Babyatsky et al., 2009).  Furthermore, knockout mice lacking TFF3 expression were 
more susceptible to dextran sodium sulfate-induced colitis and had a higher mortality rate 
than wild-type mice (Mashimo et al., 1996). Mice with TFF1 and TFF3 deficiency exhibit 
impaired mucosal healing and eventually die due to high rate of apoptotic events of colon 
cells associated with severe colitis (Lefebvre et al., 1996, Mashimo et al., 1996). In vitro 
model systems also demonstrated that increased expression of TFF2 and TFF3 proteins 
significantly reduced colonic damage induced by multiple toxins insults on colon cancer cells 
and the protective effects of the TFF peptides were enhanced with co-expression of mucin 
glycoproteins (Kindon et al., 1995). The function of TFF2 and TFF3 are mediated through the 
epithelial (E)-cadherin/catenin complexes, which is one of the common motogenic targets 
during cell migration (Liu et al., 1997). TFF3 promoted cell migration by inhibition of E-
cadherin function and tyrosine phosphorylation of β-catenin (Liu et al., 1997, Efstathiou et al., 
1999). TFF3 also can stimulate down-regulation of E-cadherin, α- and β-catenin that inducing 
subsequent decrease in cell adhesion for enhancing cellular invasion and migration of cancer 
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cells (Liu et al., 1997). The prophylactic effects of TFF proteins have been demonstrated in 
both animal and cell line models of GI tract injury. These data support that TFF proteins serve 
as beneficial factors in the maintenance of the epithelium of GI tract. Several mechanisms 
have been shown would be contributed to the protective and tumor suppressive roles of TFF 
proteins. For example, transgenic mice with over-expression of growth hormone (GH) exhibit 
elevated expression of TFF3 in the colon with enhanced survival, and mucosal repair during 
recovery from experimental colitis. These observations suggested possible interaction or 
cross-talk between EGF-R signaling with TFF3 expression in mucosal repair mechanism 
(Williams et al., 2001). Furthermore, the motogenic function of TFF3 peptides in restitution 
of GI epithelium is probably through a TGFβ-independent pathway (Dignass et al., 1994, 




Figure 14: The different steps of mucosal restitution. a. Local mucosal damage. b, cellular 
detachment and apoptosis immediately occurred. c, activation of adjacent mucosal cells at the 
wounded areas to release motogenic agents (motogens; M) such as trefoil factors and to 
initiate the mechanism of restitution or repair. d, this process followed by migration of 
epithelial cells and inhibition of cell death. d, which is accompanied by mechanisms that 
prevent detachment-induced cell death. e, restoration of cell-matrix interaction and cell-cell 
interaction at the wounded areas (Taupin and Podolsky, 2003). Reproduced with permission. 
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1.3.7 Oncogenic potential of TFF3 
 TFF3 may serve as either tumor suppressor genes or potential tumor promoting 
factors depending on tissue localization. Although TFF3 protein play a protective and 
restorative role in the GI tract where it is normally localized, TFF3 protein is over-expressed 
in various tumor tissues including those of pancreatic, prostate, breast, liver, endometrium, 
ovary, uterus, esophagus, and bladder  (May and Westley, 1997b, Emami et al., 2004). Many 
reasons can account for this duality in function including the positive association between 
inflammation and increased TFF3 expression in the microenvironment of the tumor, 
epigenetic modification of TFF3 expression, or activation of oncogenes that increased the 
expression of TFF3. However, the mechanisms of TFF3-mediated activation of oncogenes in 
cancerous cells have yet to be elucidated. Increasing experimental studies demonstrated the 
tumor promoting actions of TFF peptides implicated in tumor growth and progression. 
(i) Proliferation 
 There is very few evidence demonstrating the role of TFF peptide in regulating cell 
cycle progression. Autocrine production of TFF3 significantly enhanced proliferative capacity 
in mammary carcinoma cells (Xu et al., 2005, Kannan et al., 2010). Forced expression of 
TFF3 in mammary carcinoma cell lines markedly increased the total cell number as a result of 
enhanced cell proliferation and survival (Kannan et al., 2010). However, over-expression of 
TFF3 suppressed growth of human colon cancer cells and was shown to function as an 
inhibitory factor for proliferation of colonic neoplasm (Uchino et al., 2000). Furthermore, 
depleted expression of TFF3 using an antisense oligonucleotide significantly reduced 
proliferation of human gastric carcinoma cell line (Chan et al., 2005a).  
 (ii) Apoptosis 
 Resisting apoptosis is one crucial characteristic during oncogenesis. Studies have 
shown that all the TFF family members play an anti-apoptotic role. TFF1 has been 
demonstrated to prevent gastric carcinoma cells from undergoing anoikis, chemical-induced 
apoptosis, as well as BCL-2-antagonist of cell death (BAD)-induced apoptosis (Bossenmeyer-
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Pourie et al., 2002). Forced expression of TFF3 in colon carcinoma cells prevented the cells 
against serum starvation-induced and drug-induced apoptosis, which is dependent on PI3K 
activity (Kinoshita et al., 2000a, Taupin et al., 2000a). Autocrine TFF3 stimulated survival of 
mammary carcinoma cells increased BCL-2 protein expression (Kannan et al., 2010). A study 
reported that TFF3 activated Akt/protein kinase B survival pathway in the process of mucosal 
repair (Taupin et al., 2000a). The p53-dependent apoptosis in gastric carcinoma cell lines 
following treatment with etoposide was markedly abrogated by forced expression of TFF3 
(Taupin et al., 2000a). Concordantly, antisense TFF3 significantly increased adriamycin-
induced apoptosis in gastric carcinoma cells (Chan et al., 2005a). 
(iii)  Anoikis 
 Anoikis is a form of anchorage-dependent cell death program induced by cell 
detachment. It is a relatively important event for oncogenic transformation as well as cancer 
progression. It has been observed that forced expression of TFF3 prevented anoikis in 
intestinal epithelial cells, which is mediated by a survival signaling pathway linked to NF-κB, 
a major mediator of TFF-promoted cell survival. Besides that, the stable expression of a 
mutant form of the NF-κB inhibitor (I-κB) in cells resulted in a significant reduction against 
anoikis effect of TFF3 (Chen et al., 2000). A study confirmed that TFF3 protected intestinal 
epithelial cells from anoikis (Regalo et al., 2005) and induced oncogenic transformation of an 
normal immortalized human mammary epithelial cell line (Xu et al., 2005). TFF3 over-
expression in mammary carcinoma cells prevented tamoxifen-induced anoikis (Kannan et al., 
2010). Depleted expression of TFF3 inhibited anchorage-independent growth of human 
mammary carcinoma cells. Additionally, over-expression of TFF3 greatly enhanced colony 
formation in tamoxifen-resistant mammary carcinoma cells, while depleted expression of 
TFF3 restored sensitivity of tamoxifen-resistant cells to the same drug (Kannan et al., 2010). 
Additionally, knockdown of TFF3 significantly inhibited colony formation of gastric 




 (iv) Migration and invasion 
 One of the protective functions of the TFF peptides is to serve as motogens to assist 
in the restitution of damaged mucosal or epithelial tissue but this function may be co-opted in 
tumor metastasis to promote tumor cell migration and invasion. TFF3 and TFF1 are 
motogenic in both normal and cancer cells. TFF3 greatly promoted and enhanced migratory 
and invasive capacities of human colon carcinoma cells (Rivat et al., 2005). Numerous 
studies have indicated over-expression of TFF3 to be involved in disrupting cell morphology 
and polarity in colon carcinoma cells by modulating the function of E-cadherin/catenin 
complex, which typically maintains normal cell to cell contacts (Efstathiou et al., 1998, 
Meyer zum Buschenfelde et al., 2004). Disruption of these cell to cell contacts and cell 
polarity resulted in EMT associated with the stimulation of cellular invasion and migration in 
the metastasis of colon carcinoma cells (Meyer zum Buschenfelde et al., 2004). TFF3 has 
been shown to promote migration and invasion by rat fibroblast cells by increased the 
expression of metalloproteinase-9 (MMP-9) and β-catenin as well as simultaneously 
decreased the expression of E-cadherin and tissue inhibitor of metalloproteinase-1 (TIMP-1) 
(Chan et al., 2005b). Furthermore, the TFF3-mediated migration of normal and oncogenically 
transformed bronchial epithelial cells was demonstrated to be p44/42 MAPK-dependent 
(Graness et al., 2002). 
(v) Angiogenesis 
 Besides the functional role of TFF3 in resisting apoptosis and promoting cell invasion 
and migration, another oncogenic effect of TFF3 is the ability to promote angiogenesis, which 
is necessary for tumor growth and dissemination (Andre et al., 2000). Physiological 
angiogenesis is fundamental in normal tissue homeostasis but this process is co-opted in 
tumorigenesis to promote survival and the growth of tumor. In vitro and in vivo studies have 
demonstrated that TFF peptides may serve as pro-angiogenic factors (Rodrigues et al., 2003b, 
Emami et al., 2004). Exogenous recombinant TFF protein (rhTFF1) promoted HUVEC tubule 
formation and the angiogenic responses of TFF1 similar to that observed with VEGF-A and 
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transforming growth factor-alpha. It has been shown that TFF1 was connected to the 
activation of VEGF receptor, cyclooxygenase (COX-2), and EGF-R pathways (Rodrigues et 
al., 2003b). The expression of COX-2 greatly reduced apoptotic activity, increased tumor de 
novo angiogenesis, and promoted invasion and metastasis (Tsujii et al., 1998). Nitric oxide 
(NO) is a growth factor for inflammation as well as tumor vascular formation (Tan et al., 
1999). Exogenous TFF3 has been reported to stimulate the formation of NO by inducing 
nitric oxide synthase for blood vessel formation (Rodrigues et al., 2001). Concordantly, IHC 
analysis of gastric carcinoma tissues (Dhar et al., 2005) and breast cancer tissue (Ahmed et al., 
2012) demonstrated that increased expression of TFF3 is significantly associated with 
enhanced tumor vascularity (Dhar et al., 2005, Ahmed et al., 2012). 
 
1.3.8 Clinical correlation of TFF3 in mammary carcinoma 
 Mounting evidence has recently indicated a clinical association between the 
expression of TFF3 and the prognosis of breast cancer patient. It has been shown that 
increased expression of TFF1 and TFF3 mRNA were observed in lobular carcinoma in situ, 
invasive lobular carcinoma and invasive ductal carcinoma (Emami et al., 2004). TFF3 mRNA 
has also been identified as a prognostic biomarker for breast cancers negative for both 
estrogen and progesterone receptor (Doane et al., 2006). Kaplan-Meier analysis of breast 
cancer patients (ER+) treated with tamoxifen has demonstrated that elevated TFF3 mRNA 
expression is significantly associated with worse disease-free survival (Miller et al., 2005, 
Kannan et al., 2010). Concordantly, Kannan et al. (2010) observed a positive correlation 
between increased TFF3 mRNA expression and poor survival outcome not only in breast 
cancer patients but also patients treated with tamoxifen (Kannan et al., 2010). IHC analysis of 
breast cancer tissues indicated that a negative association between TFF3 protein expression 
and labeling of cell proliferative biomarker Ki-67 (Ahmed et al., 2012).  
 The pro-angiogenic function of TFF peptides has been demonstrated using 
recombinant TFF peptides to induce formation of tube-like structures by HUVEC in the 
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Matrigel matrix substratum, and capillary vessel formation in CAM assay (Rodrigues et al., 
2003b). Thus, the angiogenic activity of TFF peptides is comparable to that stimulated by 
VEGF and transforming growth factor-alpha. Furthermore, the association between the 
expression of TFF3 protein and microvessel density (measured by CD34 biomarker staining) 
has previously been reported in gastric carcinoma tissue (Dhar et al., 2005). A recent cohort 
study on breast cancer patients, in which endothelial marker CD31 or CD34 expression were 
examined,  has also shown a strong positive correlation between TFF3 protein expression and 
microvessel density, (Ahmed et al., 2012).  
 TFF3 promotes invasive and metastatic phenotype in mammary carcinoma cells 
leading to tumor progression. During metastasis, TFF3 increases the penetration of neural 
sheath and the intravasation of lymphovasculature. The role of TFF3 protein expression in 
metastasis of breast cancer has not been extensively studied, but TFF1 and TFF3 mRNA had 
been identified as a marker for predicting micrometastatic breast cancer in a microarray 
analysis of early breast cancer patients (Mikhitarian et al., 2005). Another array-based study 
has shown TFF1 and TFF3 to be two genes most highly and significantly associated with 
breast cancer metastatic to bone (Smid et al., 2006). Concordantly, increased expression of 
TFF3 in mammary carcinoma cells was associated with invasive phenotype and metastatic 
potential, suggesting that continued involvement of TFF3 in the process of metastasis to 
facilitate the colonization of cancer cells in bone (Ahmed et al., 2012). Additionally, the 
expression profiling of breast cancer was analyzed using serial analysis of gene expression 
(SAGE), indicating TFF1 and TFF3 to be signature targets that are expressed in mammary 
carcinoma and absent in the circulation and bone marrow (Bosma et al., 2002). Therefore, 





1.4 Angiogenesis  
 Angiogenesis is an essential process where new blood vessels are formed or new 
capillaries are grown from pre-existing vasculature (Folkman, 1971). This phenomenon is a 
tightly controlled and regulated event, which occurs in several normal physiological processes 
such as reproduction, growth and development, and wound repair (Folkman, 1971). However, 
angiogenesis can switch to a pathogenic process during tumor growth and metastasis as well 
as in other diseases such as atherosclerosis and endometriosis (Banerjee et al., 2007). 
 The angiogenic process is pivotal in tumor growth whereby tumor progression highly 
dependent on blood vessel recruitment and tumors response to secretory angiogenic factors 
(Folkman et al., 1971). Therefore, inhibition of tumor angiogenesis can be a potential 
therapeutic strategy to regress tumor growth (Folkman, 1971). In the past, many research 
studies related to tumor angiogenesis have been performed to prove that inhibition of 
angiogenesis could attenuate tumor growth. Recently, preclinical studies of angiogenesis 
inhibitors have shown that anti-angiogenic therapies may have great potential in the treatment 
of cancers (Tabruyn and Griffioen, 2007). The Food and Drug Administration (FDA) has 
approved several therapeutics strategies for the treatment of angiogenesis-dependent diseases 
including Avastin for colorectal cancer and Tarceva for lung cancer (Tabruyn and Griffioen, 
2007).  
 
1.4.1 Mechanism of angiogenesis 
 Both normal and cancer cells require adequate oxygen and nutrient supply, and the 
removal of waste products from metabolic processes and sustaining survival. Normally, cells 
and tissues depend on physiological vasculogenesis referred to as de novo angiogenesis to 
generate vasculature that can meet their metabolic demands (Papetti and Herman, 2002). 
Cancer cells initially supply their own oxygen and nutrients from the pre-existing vasculature 
by mimicking normal angiogenesis. Consequently, tumors remain dormant and still able to 
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survive through the pre-existing vasculature and may not need to induce tumor angiogenesis 
(Holash et al., 1999).  
 Tumor angiogenesis is a pathological event resulting from the use of normal 
angiogenic mechanism, where vasculature is remodeled by new capillaries formation from 
pre-existing vessels (Papetti and Herman, 2002). Normal angiogenesis provides an adequate 
source of oxygen and nutrients to the developing or healing tissues. Within a tumor, there is 
limited amount of nutrients available for actively dividing cells (Folkman, 1971, Jain, 1987). 
Consequently, tumor cells induce development of new vessels from pre-established 
vasculature, thereby producing a vascular network that delivers oxygen and nutrients for 
survival and propagation of tumor cells.  
 In the physiological angiogenesis, new vessels develop regularly from normal 
vasculature comprised of mature vessels and maintained by the combination of pro- and anti-
angiogenic molecules (Jain, 2001). Endothelial cells (EC) are among the more quiescent and 
genetically stable cells in the body. Unlike normal blood vessels, tumor vessels generated in 
pathological angiogenesis are structurally and functionally abnormal. Characteristics of tumor 
angiogenesis include the presence of highly proliferative EC and atypical morphology of the 
intratumoral vasculature  (Rajotte et al., 1998). The hierarchy of capillaries, arterioles, and 
venules which is characteristics of normal vasculature is distorted in tumors (Baish and Jain, 
2000). EC, pericytes and smooth muscle cells, and the basement membrane of tumor blood 
vessels are poorly organized (Baluk et al., 2005). Under normal circumstances, EC do not 
associate with normal blood vessel. However, vasculature produced during tumor 
angiogenesis becomes hyperpermeable and poorly organized that generally results in high 
interstitial pressure in most tumors (Baluk et al., 2005). In addition, pericytes are not tightly 
attached to EC and the vessel wall  may weaken and increase the risk of metastasis of cancer 
cells (Baish and Jain, 2000).  
 The angiogenic event is highly toned by combination of pro-angiogenic and anti-
angiogenic factors (Huang and Bao, 2004, Adams and Alitalo, 2007). An imbalance of either 
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pro- and anti-angiogenic factors will thus trigger the tumor angiogenesis cascade. When the 
angiogenic state is favorable, new blood vessel is formed with activation of EC and the 
removal of mural cells (pericytes) from pre-established vasculature (Figure 15). The absence 
of these pericytes initiates MMPs to proteolytically degrade the basement membrane of the 
vasculature (VBM) and ECM (Moses, 1997). The growth of endothelial sprouts (also known 
as angiogenic sprouting) from pre-existing blood vessel requires a change of cell polarity, 
induction of motility and invasive capacity, the decrease of cell-cell contact and the 
degradation of the ECM. Angiogenic sprouting is then followed by an outgrowth of EC, 
which is regulated by a gradient of pro-angiogenic factors such as VEGF-A. These pro-
angiogenic factors are released or produced by VBM and a variety of cell types including 
tumor cells, fibroblasts, and immune cells. The EC continue to proliferate until they start to 
form microvessel. After formation of the small blood vessel, recruitment of mesenchymal 
cells to the vessels occurs, where the cells subsequently differentiated into pericytes and the 
cell to cell connections between pericytes and EC is substantially established. Finally, the 
development of stable and mature blood vessels terminates the process. The cells differentiate 
in a structure identical to capillaries in order to create a vascular network and blood flow that 





Figure 15: Tumor angiogenesis cascade. Tumor angiogenesis involved degradation and 
reformation of the vascular basement membrane (VBM). Basement membrane, fibroblasts 
and immune cells, and tumor cells release a variety of pro-angiogenic factors, such as 
vascular endothelial growth factor (VEGF). Pro-angiogenic factors and matrix 
metalloproteinases (MMPs) stimulate structural changes and degradation of basement 
membrane. These angiogenic factors also induce recruitment of pericytes to stabilize the 
newly formed blood vessels (Nussenbaum and Herman, 2010).  
 
1.4.2 Angiogenesis and tumor progression 
 Angiogenesis may influence the ability of tumor outgrowth and metastasis (Folkman 
et al., 1971). Folkman et al. (1971) first discovered the effect of angiogenic factors in tumor 
progression and also reported the induction of angiogenesis by angiogenic factors secreted 
from tumor cells. Tumor cells  require diffusion of nutrient supply from the interstitial space 
in the absence of angiogenic factors where tumor usually do not grow beyond 3 - 4 mm in 
diameter (Folkman, 1990). Laboratory experiments have been done to prove that tumors 
release angiogenic factors by transplantation of melanoma (Greenblatt and Shubi, 1968) or 
choriocarcinoma cells (Ehrmann and Knoth, 1968) and that blood vessel proliferation was 
promoted even in the presence of a filter barrier between host and tumor. These findings 
support that tumor angiogenesis is promoted by angiogenic factors that are synthesized by 
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tumor cells. In the absence of vascular support, tumors are restricted with an inadequate 
supply of oxygen and nutrient and undergo necrosis or apoptosis. Consequently, tumor 
growth is reduced or remains dormant (Holmgren et al., 1995, Parangi et al., 1996). To 
overcome this condition, tumor cells induce formation of capillaries by splitting from the 
original vessel (Carmeliet and Jain, 2000). Tumor angiogenesis significantly contributes to 
tumor progression by supplying nutrients and oxygen crucial for cancer growth as well as 
providing a route for dissemination of tumor cells through the bloodstream to secondary 
organs and form metastases (Cao, 2005).  
 The process of “angiogenic switch” describes the process of transition from a pre-
vascular hyperplasia to a highly vascularized tumor. It is highly regulated by the fine-tuned 
equilibrium between pro- and anti-angiogenic factors released from tumor cells and/or 
stromal cells in tumor interstitium (Bergers and Benjamin, 2003). The production of pro-
angiogenic factors are also influenced by external factors such as glucose deprivation, cellular 
acidosis, hypoxia or by deregulation of oncogenes or tumor suppressor genes (Arbiser et al., 
1997, Pugh and Ratcliffe, 2003, North et al., 2005). The equilibrium between pro- and anti-
angiogenic function prevents tumor outgrowth, which is known as tumor dormancy (Gelao et 
al., 2013).  The shift in equilibrium towards pro-angiogenic functions is associated with 






Figure 16: Angiogenic factors in tumor dormancy and growth. An equilibrium between 
pro-angiogenic and anti-angiogenic factors is found in the tumor dormancy. When this 
equilibrium is distorted by the prevalence of pro-angiogenic factors, tumor can grow and 
spread (Gelao et al., 2013).  
 
 The angiogenic switch can take place at different stages during tumor progression 
based on the specific characteristics of the tumor as well as the tumor interstitium (Figure 17). 
Majority of tumors begin growing as avascular nodules. The angiogenic switch that favors 
tumor angiogenesis is required to ensure exponential tumor growth. Tumor angiogenesis 
process involves perivascular detachment, recruitment of EC, activation of EC by angiogenic 
factors, angiogenic sprouting, stabilization new vessels by perivascular and finally 
vasculature formation (Cameron et al., 2005). This blood vessel formation allows nutrients to 
be delivered to hypoxic cells and to the necrotic areas of the tumor for tumor growth and 
expansion (Bergers and Benjamin, 2003). Therefore, the effect of angiogenic factors secreted 
by tumor and the regulatory molecules in ECM as well as proteolytic activities in ECM 
remodeling within the tumor interstitium may contribute to tumor angiogenesis for 






Figure 17: Angiogenic switch and the process of pathological angiogenesis in tumor 
progression. The angiogenic switch is a distinct step in tumor development that can occur at 
different stages in the process of tumor progression. a, tumor begins as an avascular masses 
(dormant). b, the 'angiogenic switch' has to occur to promote tumor growth. The switch 
started with perivascular detachment and vessel dilation. c, angiogenic sprouting. d, new 
vessel formation and maturation. e, formation of vasculature in tumor to supply oxygen and 
nutrient to the cancer cells (Bergers and Benjamin, 2003). Reproduced with permission. 
 
1.4.3 Regulators of angiogenesis 
 Regulators of angiogenesis are secreted from various cell types such as immune cells, 
tumor cells and stromal cells or (Folkman, 2003). In normal tissues, anti-angiogenic factors 
are in excess and maintain the tissue vascularization in a quiescent state. Tumor angiogenesis 
results from the up-regulation of pro-angiogenic factors and the down-regulation of normal 
expression level of anti-angiogenic factors (Hanahan et al. 1996; Sund et al. 2005).  
 Tumor cells produce many angiogenic factors to induce endothelial cells proliferation 
and differentiation. Example of angiogenic factors includes interleukin-8 (IL-8), VEGF-A, 
platelet-derived growth factor (PDGF), angiopoiteins (Ang), acidic and basic fibroblast 
growth factor (aFGF and bFGF) (Folkman 2003). Among these, IL-8 and VEGF-A are the 
most pivotal regulators of angiogenesis (Ferrara et al., 2003). FGF and PDGF induce EC 
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proliferation and migration by interaction with cognate receptors in the EC (Battegay et al., 
1994, Friesel and Maciag, 1995). Ang promotes sprouting of vascular remodeling and 
angiogenesis. Ang-1 promotes the maturation of blood vessel and thus inhibits angiogenesis. 
Ang-2 antagonizes Ang-1 activity and allows the growing blood vessel to be more responsive 
to additional angiogenic factors stimulation (Augustin et al., 2009).  
 Angiogenesis is inhibited by anti-angiogenic factors such as thrombospondins (Tsp), 
endostatin, angiostatin, interferon-α and -β (INF-α and -β) (Huang and Bao, 2004). TSP-1 is a 
large ECM glycoprotein and proteolytic fragments (Good et al., 1990). TSP-1 directly inhibits 
angiogenesis by decreasing EC migration and survival or through indirect action of TSP-1 
molecules on activation of transforming growth factor (TGF) and matrix metalloproteinases 
(MMPs) to inhibit tumor growth (Lawler, 2002, Huang and Bao, 2004). Endostatin is 
produced by cleavage of collagen XVIII (O'Reilly et al., 1994). Endostatin stabilizes newly 
formed endothelial tubes in the regions of the tumor where new blood vessel formation is 
occurring that specifically inhibits endothelial proliferation and tumor growth (Li et al., 
2003b). Finally, angiostatin is a fragment of plasminogen and has been demonstrated to be an 
inhibitor of both neovascularization and additionally metastatic dissemination (O'Reilly et al., 
1994). Thereby, the genetic and additional epigenetic events within the tumor interact with 
the cocktail of pro- and anti-angiogenic factors to induce an angiogenic phenotype in tumor 
cells (Hanahan et al. 1996) and thus initiate tumor angiogenesis. 
 
1.4.4 Vascular Endothelial Growth Factor A (VEGF-A) 
 VEGF-A is an angiogenic-promoting protein that has a pivotal role in regulating 
physiological and pathological angiogenesis. It is a member of the VEGF family comprise of 
seven members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and PlGF. The 
members possess a VEGF homology domain and bind to their tyrosine kinase receptors, 
VEGFR-1, -2, and -3 (Ferrara et al., 2003). VEGF-A is known as a tumor-produced cytokine 
and is implicated in normal tissue and tumor-associated angiogenesis. It promotes 
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proliferation and tube formation in endothelial cells (Ferrara et al., 2003, Rini and Small, 
2005). The VEGF gene is located on the short arm of chromosome 6 containing eight exons 
and may be differentially spliced to produce four mature isoforms (VEGF121, VEGF165, 
VEGF189 and VEGF206) (Holmes and Zachary, 2005). Other isoforms were later recognized 
such as VEGF145 and VEGF183 (Tischer et al., 1991). VEGF165 is identified as the most 
predominant isoforms and is overly expressed in a variety of solid tumors. It is a potent 
angiogenic factor for tumor vascularization (Nishi et al., 2005). VEGF-A exerts its biologic 
function by interacting with cell surface tyrosine kinase receptors consists of VEGFR-1/Flt-1 
and VEGFR-2/Flk-1 expressed on the endothelial cells and neuropilin receptors (NP-1 and 
NP-2) expressed in the vascular endothelium (Dvorak, 2002). When VEGF-A binds its 
receptor, a number of downstream pathways are activated upon receptor dimerization and 
autophosphorylation of the intracellular tyrosine kinase domains (Ferrara et al., 2003). 
VEGFR-2 was found to be the main receptor mediating the pro-angiogenic effects of VEGF-
A (Ferrara et al., 2003). Related molecules include VEGF-D and VEGF-C which are 
structurally similar, but are less homologous VEGF-A (Robinson and Stringer, 2001). These 
factors preferentially activate VEGFR-3 present predominantly on lymphatic EC and 
therefore promote lymphangiogenesis (Alitalo et al., 2005). Experimental studies on mouse 
models have demonstrated that inhibiting the biological functions of VEGF-A with adenoviral 
delivery of a soluble form of VEGFR-1/2, by depletion of VEGF-A, and by the use of a 
chemical inhibitor of VEGF signaling impaired tumor angiogenesis and growth (Vajkoczy et 
al., 1999, Inoue et al., 2002, Casanovas et al., 2005). 
 
1.4.5 Interleukin-8 (IL-8) 
 Interleukin-8 is a member of the chemokine family, which is specific cytokines 
secreted by both normal cells and cancer cells. Generally, secretion of this cytokines is 
dependent on growth factors, inflammatory cytokines, and pathophysiological conditions 
(Koch et al., 1992, Strieter et al., 1992). IL-8 is  known as a chemotactic protein secreted by 
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macrophages and activated monocytes that function to promote the directional migration of T 
lymphocytes, basophils, and neutrophils (Zlotnik and Yoshie, 2000). IL-8 possesses important 
functions in infectious diseases, autoimmune, and inflammatory (Koch et al., 1992, Harada et 
al., 1994). Due to strong inflammatory properties, IL-8 expression is controlled tightly with 
undetectable or low expression under normal circumstances. Over-expression of IL-8 has 
been demonstrated in a number of human cancers including those of melanoma, breast, and 
ovarian (Xu and Fidler, 2000, Freund et al., 2003, Singh et al., 2010). IL-8 plays a crucial role 
in angiogenesis in both physiologic and pathological conditions (Koch et al., 1992, Strieter et 
al., 1995a). Previous studies showed that IL-8 promoted tumor growth and increased 
metastatic potential of cancer cells (Miller et al., 1998, Gomperts and Strieter, 2006). 
Additionally, IL-8 exhibited profound roles in tumor progression due to its ability to affect 
different cell of the tumor microenvironment (Xie, 2001, Waugh and Wilson, 2008). 
 (i) IL-8 structure 
 IL-8 is a small peptide (8 - 10 kDa), belonging to the CXC chemokine family and 
secreted by stromal (endothelial cells and fibroblasts) and tumor cells. The CXC chemokine 
family is further categorized based on conserved cysteines within the N-terminal amino acid 
sequence (Baggiolini et al., 1997) as well as absence or presence of a three amino acid 
sequence, glutamic acid-leucine-arginine (ELR motif) which precedes the first cysteine 
residue in the CXC sequence. The ELR motif is important because the ELR (containing 
ELR+) CXC chemokines are potent promoters of angiogenesis and on the contrary, non-ELR 
(containing ELR−) CXC chemokines are anti-angiogenic (Strieter et al., 1995a). Among these 
(ELR+) CXC chemokines, IL-8 is a potent angiogenic-promoting factor that stimulates 
formation of blood vessel in tumors. IL-8 gene is clustered on chromosome 4 between 4q12 
and 4q21, consisting sequence identity between 24% to 46% with other CXC family members 
(Brat et al., 2005). Transcription of the IL-8 gene produces a 99 amino acids protein which is 
processed through post-translational modification to yield two biological active IL-8 isoforms, 
with peptides of 72 and 77 amino acid residues (Hébert  and Baker, 1993). The 72 amino acid 
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peptide is secreted by monocytes and macrophages. The 77 amino acid variant is the most 
abundant isoform of non-immune cells. The peptide structure of IL-8 is monomeric and 
composed of an NH2-terminal loop that is important for receptor activation, a central three 
anti-parallel beta sheet-strands connected by loops that provides a stable scaffold, and a C-
terminal alpha helix that stabilizes the overall structure by folding over the small beta-sheet 
(Figure 18). IL-8 forms dimers although the monomer is a prevalent and active moiety of this 
chemokine (Rajarathnam et al., 1994, Horcher et al., 1998). Experimental data has 
demonstrated that IL-8 binds to its receptor N-domain as a monomer (Lowman et al., 1997, 
Fernando et al., 2004). 
 
 
Figure 18: Primary structures of IL-8. Primary structure for interleukin-8 (PDB code: 
3IL8). The N-terminal loop, which is responsible for receptor recognition, is restrained by 
two disulfide bonds. This is followed by a short turn of a 310 helix (H1) that leads to a three-
stranded anti-parallel β-sheet. The C-terminal α-helix folds over the β-sheet (H2) and helps to 
stabilize the overall tertiary structure (Kanagarajadurai and Sowdhamini, 2008). 
 
 The regulatory sequences have been categorized from -1 to -2500 bp of the 5'-
flanking region of the IL-8 gene. One of the most characterized regions occurs at -425 to -70 
bp and which possesses binding sites for the transcription factors C-EBP/NF-IL-6, AP-1, and 
NF-κB, as well as potential binding sites for the interferon regulatory factor-1, glucocorticoid 
receptor, and hepatocyte nuclear factor-1 (Mukaida et al., 1994, Hoffmann et al., 2002) 
(Figure 19). A recent study has identified a putative STAT3 binding site that positioned from 
-245 to -237 bp in the IL-8 promoter region (Oka et al., 2010). Additionally, the estrogen 
response elements and C-EBP/NF-IL-6 consensus sites have been identified in the IL-8 
promoter, and are involved in the activation of IL-8 production (Mukaida et al., 1994, 
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Roebuck, 1999). NF-κB binding is required for promotion of IL-8 promoter activity 
(Matsusaka et al., 1993). C-EBP/NF-IL-6 and AP-1 may contribute to transcriptional activity 
but dependent on the particular cell type (Mukaida et al., 1990). Additionally, the expression 
of IL-8 is partially regulated by other stimuli such as environmental stresses (e.g., exposure to 
chemotherapy agents and hypoxia), chemical and steroid hormones, and inflammatory signals 
(e.g., tumor necrosis factor α) (Brat et al., 2005). 
 
 
Figure 19: Binding sites for transcriptional factors in IL-8 promoter region. The 
consensus DNA-binding sites for known transcription factors in the promoter region of IL-8 
gene. The putative STAT3 binding site is positioned from - 245 to -237 bp in the IL-8 
promoter (Oka et al., 2010). Adapted from Oka et al., 2010. 
 
 
(ii) Roles of IL-8 and its cognate receptors in tumor microenvironment 
 The biological roles of IL-8 are produced by two different G protein–coupled 
receptors, termed as CXCR1 and CXCR2. IL-8 binds CXCR1 and/or CXCR2, with the same 
affinity, and thereby activates downstream signaling cascades that regulate cellular function 
(Murphy and Tiffany, 1991). CXCR1 and/or CXCR2 are known to be the only mammalian 
receptors of IL-8 with the specific amino acid sequence of ELR motif at the N-domain. 
CXCR1 receptor is activated solely in response to IL-8 but may also be activated by 
granulocyte chemotactic protein-2. Alternatively, activation of CXCR2 requires multiple 
CXC chemokines including neutrophil-activating peptide, growth-related oncogenes (GROα, 
β, and γ), and granulocyte chemotactic protein-2. They share 78% amino acid sequence 
homology and are also considered biologically active IL-8 cognate receptors (Ahuja and 
Murphy, 1996). The CXCR1 and CXCR2 receptors are highly expressed in 
neutrophils/tumor-associated macrophages, endothelial cells, and cancer cells. Multiple 
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reports have demonstrated that the over-expression of IL-8 by cancer cells was promoted by 
chemotherapeutic treatment or environmental stresses such as hypoxia. The increased 
synthesis and secretion of IL-8 from tumor cells exert profound effects on the tumor 
microenvironment (Figure 20). IL-8 secreted from cancer cells promotes cellular proliferation 
and survival. Additionally, IL-8 activates endothelial cells in tumor vasculature to stimulate 
de novo angiogenesis and promote chemotactic infiltration of neutrophils into the tumor. In 
addition to its capacity to promote cell invasion and migration, IL-8 also induces tumor-
associated macrophages to secrete other growth factors to enhance cancer cell proliferation 
and invasion within the tumor (Waugh et al. 2008). Activation of IL-8 downstream signaling 
pathways include PI3K/Akt, Src-kinases and FAK, and MAPK signaling cascades, resulting 
in enhanced transcriptional activity of the signaling proteins implicated in angiogenesis, 
proliferation, migration and invasion (Todorović-Raković and Milovanović, 2013).  
 
 
Figure 20: The role of IL-8 signaling in the tumor microenvironment. Tumor-derived IL-
8 is able to exert profound effects on the tumor microenvironment. Secretion of IL-8 from 
cancer cells can enhance the proliferation and survival of cancer cells through autocrine 
signalling manner. In addition, tumor-derived IL-8 will activate endothelial cells in the tumor 
vasculature to promote angiogenesis and induce a chemotactic infiltration of neutrophils into 
the tumor site. IL-8 also stimulates tumor-associated macrophages to release growth factors 




(iii) Biological effects of IL-8 in tumor angiogenesis and metastasis 
 
 IL-8 has an autocrine and/or paracrine tumor-promoting role in modulating the 
survival and proliferation of tumor cells. The biological activity of IL-8 in tumors and the 
tumor microenvironment may contribute to tumor progression through leukocyte infiltration, 
stimulation of cancer cell motility, angiogenesis, cancer cell growth and survival (Yuan et al., 
2005). Accordingly, Ewington et al. (2012) has recently demonstrated that the pathogenesis 
of endometrial carcinoma was positively associated with the expression of IL-8 and/or its 
cognate receptors (Ewington et al., 2012). Additionally, Nastase et al. (2011) has suggested 
that IL-8 is useful to diagnose early stage colon cancer and to monitor the progression of 
colon tumors (Nastase et al., 2011). The expression of IL-8 and IL-8 receptors in melanoma 
was shown to be positively correlated with disease progression (Singh et al., 2010). Increased 
the expression of IL-8 and IL-8 receptors is associated with worse prognosis in breast cancer 
patients, indicating that the metastatic capacity of breast cancer cells was strongly correlated 
with the expression level of IL-8 (Miller et al., 1998, De Larco et al., 2001). Furthermore, a 
study has suggested that polymorphism of IL-8 and CXCR2 genes in breast cancer, which 
modulates the expression of IL-8 could promote tumor progression in breast cancer (Snoussi 
et al., 2010). It has been reported that the effect of sex steroid in the regulation of IL-8 is 
contradicting and apparently varies in different tissues (Kanda and Watanabe, 2001, 
Bengtsson et al., 2004). Increased IL-8 expression was observed in ER- breast cancer cells 
(MDA-MB-231) as compared to ER+ breast cancer cells (MCF-7) (Freund et al., 2003, Lin et 
al., 2004). Estrogen did not affect IL-8 expression in ER- or ER+ breast cancer cells, whereas 
it strongly induced TFF1 expression (a marker of estrogen responsiveness) in ER+ breast 
cancer cells.  These observations support that the expression of IL-8 is associated with a 
higher invasiveness potential of cancer cells in vitro and therefore confirming the invasion-
promoting effect of IL-8 (Freund et al., 2003). 
 IL-8 plays a direct role in angiogenesis by promoting endothelial cell proliferation 
and survival as well as stimulating the expression of matrix metalloproteinase in endothelial 
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cells expressing CXCR1 and CXCR2 (Li et al., 2003a). IL-8 stimulates endothelial 
proliferation and also capillary tube formation and these effects are inhibited by monoclonal 
antibodies to IL-8. A recent report has demonstrated that IL-8 stimulated VEGF A expression 
in endothelial cells via CXCR2, and hence increased the activation of VEGF receptors in an 
autocrine manner (Martin et al., 2009). Moreover, IL-8 has been shown to enhance secretion 
of matrix metalloproteinase MMP-2 and MMP-9, suggesting that IL-8 can modulate 
invasiveness and/or ECM remodeling in the tumor microenvironment (Inoue et al., 2000a, 
Inoue et al., 2000b). As processes such as migration, cell proliferation, invasion, and 
angiogenesis are involved in metastasis, IL-8 expression by tumor cells can therefore have an 
effect on their metastatic capabilities. The expression of IL-8 is reported to correlate with the 
metastatic potential of cancer cells. The highly metastatic melanoma cells expressed higher 
level of IL-8 mRNA than melanoma cells with low metastatic capacity, suggesting that 
increased IL-8 mRNA expression is associated with the metastatic potential of cancer cells 
(Singh and Lokeshwar, 2009). Increased IL-8 in the tumor interstitium was shown to promote 
colon cancer growth and metastasis (Lee et al., 2012). Conversely, the growth of colon cancer 
is prevented by the absence of its receptor CXCR2 in the tumor microenvironment (Lee et al., 
2012). In xenograft model, colon cancer cells expressing IL-8 formed significantly larger 
tumors with increased microvessel density when compared with the control cells (Ning et al., 
2011). Increased IL-8 expression promotes invasion and angiogenesis of breast cancer cells 
(Lin et al., 2004). Additionally, over-expression of IL-8 in non-metastatic melanoma cells 
enhanced their invasion through Matrigel-coated filters and produced highly malignant and 
metastatic neoplasms in mice models (Kitadai et al., 1999). When gastric carcinoma cells that 
secrete low levels of IL-8 protein were stably transfected with a IL-8 gene, the transfected 
cells produced more rapidly growing, highly vascular neoplasms as compared with the control 
cells (Kanayama et al., 1999). Furthermore, treatment of HUVEC with conditioned medium 
from the IL-8 expressing cells stimulated HUVEC proliferation, suggesting that IL-8 is 
64 
 
pivotal in promoting endothelial cell proliferation and tumor vasculogenesis (Beierle et al., 
2001). 
 Accumulating clinical studies have reported that IL-8 expression to be associated 
with the advanced stages of cancers and therefore suppressing the effects of IL-8 has 
important clinical implications for tumor progression. Neutralizing antibodies to IL-8 
receptors, humanized antibody against IL-8, small molecule IL-8 receptor inhibitor and 
repertaxin have already been employed in preclinical studies, where their ability to inhibit 
angiogenesis, tumor growth, and metastasis of various xenograft tumor models have been 
demonstrated (Ginestier et al., 2010).  
 
1.4.6 Lymphangiogenesis 
 Although both the blood and lymphatic systems have been implicated in metastasis, 
preclinical experimental data suggest that the majority of initial metastasis site is via the 
lymphatic (Stacker et al., 2002, Sleeman and Thiele, 2009). Clinical evidence has also 
demonstrated that lymphatic vessel density, both in and around the tumors, was significantly 
associated with lymphatic metastasis and also worse survival outcomes (Ran et al., 2010). 
Lymphangiogenesis is implicated in some of the physiological processes such as homeostasis, 
metabolism and immunity. In contrast, regional lymph node metastasis is common in cancer 
and is utilized as a marker for tumor dissemination, stage, and prognosis (Sundar and 
Ganesan, 2007). Migration of cancer cells to regional lymph nodes is enhanced by 
lymphangiogenesis, a process in which lymphatic vessels are generated from pre-existing 
lymphatics (Ran et al., 2010). Lymphangiogenesis is a complex and coordinated process to 
induce proliferation, migration and tube formation as is observed in tumor angiogenesis 
(Sundar and Ganesan, 2007, Ran et al., 2010). Lymphangiogenic factors are often expressed 
in tumor-infiltrating and stromal cells, promoting optional conditions for production of new 
lymphatic vessels. The most crucial lymphangiogenic factor that induces lymphangiogenesis 
is VEGFR-3, which is activated by VEGF-C and VEGF-D. Experimental studies have 
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demonstrated that VEGF-C/VEGF-D/VEGFR-3 signaling can promote lymphangiogenesis 
and dissemination from the primary tumor (Achen et al., 2006). VEGFR3 expression is 
confined to lymphatic EC and facilitates the actions of VEGF-C and D (Shibuya and 
Claesson-Welsh, 2006). VEGF-C and -D are the most predominant growth factors in 
regulating this process (Nagy et al., 2002, Bjorndahl et al., 2005). Cancer cells potentially 
utilized the same chemokine ligands and its chemokine receptors for metastasis (Muller et al., 
2001). For example, human mammary carcinoma expressed chemokine receptors CXCR4 and 
CCR7, and their respective receptor CCL21 (secondary lymphoid chemokine) and CXCL12 
(stromal-cell derived factor 1) are highly expressed in the target organs of metastasis (Muller 
et al., 2001). Similarly, lymphatic EC synthesized chemokine CCL21, which activates CCR7 
leading to chemoattraction and migration to lymph nodes. Breast cancer which expresses 
CXCR4 or CCR7 exhibit enhanced lymphatic metastasis as a consequence of chemoattraction 
and directional migration toward the ligand over-expressing lymph nodes (Ran et al., 2010). 
Similar to angiogenesis, lymphangiogenesis promotes tumor metastasis. 
 
1.4.7 Clinical implications on angiogenesis therapy 
 As angiogenesis is important and critical for cancer growth and metastasis, it is 
therefore a promising approach in controlling or limiting cancer progression (Weis and 
Cheresh, 2011). The association of the VEGF-A/VEGFR-2 signaling pathway as a pivotal 
regulator of tumor angiogenesis has resulted in generation of angiogenesis inhibitors against 
VEGF-A-mediated signal transduction. Some of the angiogenesis inhibitors have been 
approved for clinical use in cancer treatment. (Ellis and Hicklin, 2008).  
 Angiogenesis inhibitors can be defined as direct and indirect inhibitors. Direct 
angiogenesis inhibitors act directly on the tumor-derived endothelial cells by inhibiting their 
proliferation and migration. Indirect angiogenesis inhibitors are used to block the angiogenic 
factors and/or pathways that promote angiogenesis (Gasparini et al., 2005). The indirect 
angiogenesis inhibitors that directly target VEGF-A, include Iressa (tyrosine kinase inhibitor), 
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Avastin or Bevacizumab (humanized anti-VEGF-A monoclonal antibody) and SU11248 
(VEGF receptor blocking agent). In contrast, direct angiogenesis inhibitors abrogate the 
vascular endothelial cell proliferation, migration and/or resistance to apoptosis when in the 
presence of angiogenic proteins (Kerbel et al., 2002). Angiogenic inhibitors such as 
endostatin also directly targets microvascular endothelial cells by preventing stimulation of 
angiogenesis-promoting factors (Kerbel et al., 2002, Folkman, 2003). Depending on cancer 
type, treatment against angiogenesis may produce 3 - 6 months increase in patient 
progression-free survival. However, these angiogenic therapies may not provide enduring 
therapeutic efficacy, and confer only transitory clinical benefits to cancer patients. In these 
patients, revascularization may occur followed by enhanced metastasis (Baeriswyl and 
Christofori, 2009, Paez-Ribes et al., 2009) (Figure 21). More importantly, inhibition of 
VEGF-A function may produce hypoxia-mediated increases in FGF expression to restart 
angiogenesis and tumor growth. Concomitant blockade of VEGF and FGF signaling, however, 
impeded the adaptive resistance to anti-angiogenic therapy of VEGF (Casanovas et al., 2005). 
Hence, the emergence of resistance against anti-angiogenic therapies could be prevented by 




Figure 21: Adaptive resistance to anti-angiogenic therapies in cancers. Anti-angiogenic 
therapies produce transitory tumors shrinkage and reduction in tumor angiogenesis. Tumors 
subsequently are adapted to the angiogenic inhibitors. The emergent mechanisms of evasive 
resistance in tumors include revascularization via alternative pro-angiogenic signals, 
increased local invasiveness, and/or enhanced distant metastasis (Paez-Ribes et al., 2009). 
Reproduced with permission. 
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1.5 Rationale and objectives of this study 
 Mounting evidence has shown that TFF3 protein is over-expressed in human 
mammary carcinoma where it is normally localized in mammary epithelial cells, suggesting 
that TFF3 exerts oncogenic effect on tumor growth and progression (May and Westley, 1997a, 
Poulsom et al., 1997). TFF3 functions as a pro-survival and pro-invasive factor in mammary 
carcinoma (Emami et al., 2001, Kannan et al., 2010). Exogenous recombinant TFF3 induced 
HUVEC tubule formation in vitro (Rodrigues et al., 2003b). The biological effects of TFF3 in 
the progression of mammary carcinoma have been extensively studied. However, the 
potential angiogenic effect of TFF3 has not been defined with the underlying mechanism is 
still not yet fully delineated. I propose that TFF3 promotes angiogenesis in mammary 
carcinoma and that underlying mechanism of TFF3 may involve modulation of targeted 
angiogenic factors and its transcription factors. The aims of this study are to investigate the 
stimulatory effects of TFF3 secreted from mammary carcinoma cells on the angiogenic 
activities of HUVEC as well as to delineate the mechanism of TFF3 in mammary carcinoma 
angiogenesis. The objectives of this study are:  
1. To define the functional effects of TFF3 secreted from mammary carcinoma cells on 
the angiogenic behaviors of HUVEC; 
2. To determine the in vivo angiogenic effect of TFF3 to stimulate microvessel density 
in mammary carcinoma cells-derived xenograft; 
3. To identify the TFF3-stimulated angiogenic factors and the underlying mechanism of 
TFF3 in mammary carcinoma angiogenesis; 
4. To determine the exogenous recombinant human TFF3 (rhTFF3) stimulation on the 
angiogenic behaviors of HUVEC; and 
5. To define the functional effects of TFF3 secreted from HUVEC on the angiogenic 





Materials and Methods 
2.1 Materials 
The list of chemicals and reagents were enlisted in Table 1. The formulations and 
compositions of media, solutions, and buffers were also outlined in the Appendices. All water 
was purified through a Milli-Q purification system (Millipore Corporation, Billerica, MA, 
USA) and solutions were either autoclaved or filtrated through a 0.2 μm membrane. 
 
Table 1: Chemicals and reagents 
Chemicals and reagents Source 
100 bp or 1kb plus DNA ladder 





 Life Technologies, Carlsbad, 
CA 
2x Laemmli Sample Buffer  
Bio-Rad Laboratories, Inc., Hercules, 
CA, USA 
3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide (MTT) 
Invitrogen Life Technologies, 
Carlsbad, CA, USA 
4',6-diamidino-2-phenylindole (DAPI) 
Vector Laboratories, Burlingame, 
USA 
5-bromo-2-deoxyuridine (BrdU), Calbiochem, Darmstadt, Germany 
Acrylamide/Bis solution (37.5:1) 
Bio-Rad Laboratories, Inc., Hercules, 
CA, USA 
Agarose (ultra pure) 
Bio-Rad Laboratories, Inc., Hercules, 
CA, USA 
AlamarBlue 
Invitrogen Life Technologies, 
Carlsbad, CA, USA 
Ammonium persulfate (APS) 
Sigma Chemical Company, St Louis, 
MO, USA 
Ampicillin 
Sigma Chemical Company, St Louis, 
MO, USA 
Anti-mouse CD31 (550274, BD)  
BD Biosciences, Franklin lakes, NJ, 
USA 
Anti-mouse IgG (BA-9200) 
Vector Laboratories, Inc. Burlingame, 
CA, USA 
Anti-mouse IgG, HRP-linked Antibody (Cat no. 
#7076) 
Cell Signaling Technology Inc., 
Beverly, Massachusetts, USA 
anti-rabbit IgG (BA-100) 




Anti-rabbit IgG, HRP-linked Antibody (Cat 
no. #7074) 
Cell Signaling Technology Inc., 
Beverly, Massachusetts, USA 
Anti-β-actin mouse monoclonal antibody (Cat 
no.C4: sc-47778) 
Santa Cruz Biotechnology, Inc., 
Texas, USA 
Bacto tryptone 
BD Biosciences, Franklin lakes, NJ, 
USA 
Bacto Yeast extract 
BD Biosciences, Franklin lakes, NJ, 
USA 
Blue/Orange Loading Dye, 6x  
Promega Corporation, Madison, WI, 
USA 
Boric acid 
Sigma Chemical Company, St Louis, 
MO, USA 
Bovine immunoglobulin 
Bio-Rad Laboratories, Inc., Hercules, 
CA, USA 
Bovine serum albumin (BSA) 
Sigma Chemical Company, St Louis, 
MO, USA 
Bradford reagent  
Bio-Rad laboratories, Inc., Hercules, 
CA, USA 
Bromophenol Blue 
Sigma Chemical Company, St Louis, 
MO, USA 
Chloroform Merck Group, Darmstadt, Germany 
Protease inhibitor Cocktails 
Roche Diagnostics GmbH, 
Mannheim, Germany 
DC protein assay reagents 
Bio-Rad laboratories, Inc., Hercules, 
CA, USA 
DH5α™ strain of Escherichia coli (E. coli) 
Invitrogen Life Technologies, 
Carlsband, CA, USA 
Diethylpyrocarbonate  
Sigma Chemical Company, St Louis, 
MO, USA 
Dimethyl-sulphoxide (DMSO) MP Biomedicals, CA, USA 
Disodium Phosphate 
Sigma Chemical Company, St Louis, 
MO, USA 
Dithiothreitol (DTT) 
Sigma Chemical Company, St Louis, 
MO, USA 
Dual-Luciferase
® Reporter (DLR™) Assay System  Promega Co., Madison, WI, USA 




Clonetics, Walkersville, MD 
Ethanol (absolute, analytical grade) Merck Group, Darmstadt, Germany 
Ethidium bromide 
Sigma Chemical Company, St Louis, 
MO, USA 
Ethylenediaminetetraacetic acid (EDTA) 
Sigma Chemical Company, St Louis, 
MO, USA 
Fetal Bovine Serum (FBS) Biowest Inc., Utah, USA 
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FuGENE 6  or  FuGENE HD Transfection reagents 





Sigma Chemical Company, St Louis, 
MO, USA 
GelRed™  Biotium, Hayward, CA  
Glycerol 
Sigma Chemical Company, St Louis, 
MO, USA 
Glycine 
Bio-Rad laboratories, Inc., Hercules, 
CA, USA 
Growth factor reduced Matrigel  
BD Biosciences, Franklin lakes, NJ, 
USA 
Hoechst 33258 
Sigma Chemical Company, St Louis, 
MO, USA 




Biolegend, San Diego, CA 
Hydrochloric acid 
Sigma Chemical Company, St Louis, 
MO, USA 
Hydrogen peroxide 





 Life Technologies, Carlsbad, 
CA 








 RNAiMAX  
Invitrogen Life Technologies, 
Carlsbad, CA, USA 
Magnesium Chloride 
Sigma Chemical Company, St Louis, 
MO, USA 
Mercaptoethanol 
Sigma Chemical Company, St Louis, 
MO, USA 
Methanol  Merck Group, Darmstadt, Germany 
Mouse anti-BrdU  Roche Applied Science, Germany 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide) 
Invitrogen Life Technologies, 
Carlsband, CA, USA 
N-lauryl sarcosine (Sarkosyl) 
Sigma Chemical Company, St Louis, 
MO, USA 
Paraformaldehyde 





 Life Technologies, Carlsbad, 
CA 
Phosphatase Inhibitor Cocktail 




 PCR SuperMix High Fidelity 
Invitrogen Life Technologies, 
Carlsbad, CA, USA 
Podoplanin (ab11936, Abcam)  Abcam, Cambridge, United Kingdom 
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Potassium phosphate  
Sigma Chemical Company, St Louis, 
MO, USA 
Prestained protein ladder, ExtraPro Broad Range 
(10-245 kDa)  
1st BASE Pte Ltd, Singapore 
PureLink
TM
 HiPure plasmid purification kit  
Invitrogen Life Technologies, 
Carlsband, CA, USA 
PVDF membrane 
Bio-Rad laboratories, Inc., Hercules, 
CA, USA 
Restriction enzymes and CutSmart™ Buffer  New England BioLabs®, MA, USA 
RNeasy
® 
Mini Kit  Qiagen, Limburg, Netherlands 
RPMI 1640 medium Nacalai Tesque, Inc., kyoto, Japan 
SIGMAFAST
™
 3,3′-Diaminobenzidine tablets 
Sigma Chemical Company, St Louis, 
MO, USA 
Sodium chloride 
Sigma Chemical Company, St Louis, 
MO, USA 
Sodium dodecyl sulfate (SDS) 
Sigma Chemical Company, St Louis, 
MO, USA 
Sodium hydroxide 
Sigma Chemical Company, St Louis, 
MO, USA 
Sodium Phosphate 
Sigma Chemical Company, St Louis, 
MO, USA 
Sodium Tetraborate 
Sigma Chemical Company, St Louis, 
MO, USA 
Streptomycin (1000 µg/mL) 
Gibco
®




 III One-Step RT-PCR System with 
Platinum
®
 Taq DNA Polymerase 
Invitrogen Life Technologies, 
Carlsband, CA, USA 
SuperScript® VILO™ cDNA Synthesis Kit 
Invitrogen Life Technologies, 
Carlsbad, CA, USA 
SuperSignal West Pico Chemiluminescent Substrate 
kit  








Invitrogen Life Technologies, 
Carlsband, CA, USA 
T4 DNA ligase 
Roche Diagnostics GmbH, 
Mannheim, Germany 
Tetramethylethylenediamine (TEMED) MP Biomedicals, CA, USA 
Tris(hydroxymethyl) aminomethane (Tris) 
Sigma Chemical Company, St Louis, 
MO, USA 
Triton X-100 





Invitrogen Life Technologies, 




 Life Technologies, Carlsbad, 
CA 
Tween-20 
Sigma Chemical Company, St Louis, 
MO, USA 
Vectashield Elite ABC kit standard (PK-6100 )  
 Vector Laboratories, Inc. 
Burlingame, CA, USA 
Vectastain
® 
Elite ABC Kit In Vitro technologies, NZ 
Wizard
®
 SV Gel and PCR Clean-Up System  
Promega Corporation, Madison, WI, 
USA 




2.2.1 Human cell lines 
The human mammary carcinoma cell lines, T47D and MCF-7 were obtained from the 
American Type Culture Collection (Manassas, VA, USA). These cell lines were cultured in 
RPMI 1640 media (Nacalai Tesque, Kyoto, Japan) supplemented with 100 μg/mL 
streptomycin, 100 IU/mL penicillin, 10% heat-inactivated fetal bovine serum, and 2 mM L-
glutamine at 37°C in a humidified 5% CO2 incubator (Thermo Scientific, Waltham, MA). 
Human umbilical vein endothelial cells (HUVEC) (Clonetics Solingen, Germany) were a 
generous gift from Dr. Lim Yoon Pin, (Department of Biochemistry, National University of 
Singapore). HUVEC were cultured on a culture flask coated with 0.1% gelatin and were 
grown in endothelial cell basal medium (Clonetics, Walkersville, MD) supplemented with 
Bullet Kit (EBM
TM
-2 SingleQuots), 10% heat-inactivated fetal bovine serum, 100 IU/ml 
penicillin, and 100 μg/mL streptomycin at 37°C in a humidified 5% CO2 incubator. HUVEC 
cultured from 4 - 8 passages were used for the experiments. Generation of MCF-7 and T47D 
cells with forced expression of TFF3 or depletion of TFF3 by siRNA have been previously 
described (Kannan et al., 2010). The characteristics of the human mammary carcinoma cell 




Table 2: Human cell lines description 
Cell lines Description 
MCF-7 Mammary carcinoma cell line derived from a pleural effusion of an 
infiltrating ductal carcinoma (Dickson et al., 1986). This cell line is well 
differentiated, epithelial, ER positive and non-invasive. 
T47D 
 
The T47D cell line is a ER+ mammary carcinoma cell line. It was isolated 
by Keydar et al. (1979) from a pleural effusion from a 54 year old female 
patient with an infiltrating ductal carcinoma of the breast. This differentiated 
epithelial substrain comprised cytoplasmic junctions and receptors for 
estrogen, other steroids and calcitonin.  
HUVEC  Clonetics
® 
Umbilical Vein Endothelial Cell (HUVEC) are tested positive for 
CD105 and CD31 endothelial markers, acetylated LDL uptake, von 
Willebrand factor VIII related antigen. It tested negative for alpha smooth 
muscle actin marker at passage four. HUVEC assayed for angiogenesis and 
vascular cell health markers. 
 
 
2.2.2 Growth of human cell lines 
The human cell lines were maintained using ATCC recommended conditions. 
Penicillin and streptomycin were also added to the media to prevent bacterial infection. Cells 
were grown in Greiner tissue culture treated flasks or plates at 37ºC in humidity 5% CO2 
incubator. All tissue culture work was undertaken in a laminar flow hood with sterile 
conditions. 
 
2.2.3 Passaging and harvesting of human cell lines 
 All cell lines were grown in 75 cm
2
 culture flasks containing approximately 20 mL of 
recommended growth media until cells were 85 - 95% confluent, after which a portion was 
passaged into a new flask to allow continuation of stock cultures. The confluent cells were 
then passaged by removing the media and subsequently rinsing the cells twice with PBS. A 
sufficient volume of 1x trypsin/EDTA (approximately 1 mL) to cover the surface of the cells 
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was added and the flask incubated at 37ºC in a humidified 5% CO2 for two to five minutes. 
Cells were checked under the microscope to ensure that the cells had detached from the flask 
and most of them are individual cells. Following trypsinization, 5 - 8 mL of serum 
supplemented media was added to flask to neutralize the trypsin and the surface rinsed using a 
serological pipette. The cell suspensions were subsequently transferred to a 15 mL sterile 
Falcon tube and centrifuged at 1000 rpm for 5 min. The supernatant was discarded and cells 
pellet were resuspended in 10 mL of fresh serum-supplemented media. For maintaining of 
stock cultures, an appropriate cell number was seeded into a fresh culture flask and 
approximately 15 - 20 mL fresh media added, after which the cells were cultured at 37ºC in a 
humidified 5% CO2 incubator. For cell counting, 20 μL of the cells suspension (total volume 
10 mL media) was transferred to an Eppendorf tube and mixed with 20 μL of trypan blue dye 
(0.4%). Cell counts were then carried out using a haemocytometer. The number of cells 
contained in four quadrants of 16 squares was counted (twice). The counted squares were sum 
up and averaged, upon which the resulting number was used to determine the amount of 
cells/mL using the following formula: 
 
Concentration of cells (cells /mL) = (Cells per 4 quadrants/4) x 10,000 x dilution factor  
 
Total number of cells = Cells/mL x final volume  
 
2.2.4 Storage of cell lines 
Cells were trypsinized and resuspended in 10 mL media, counted and then 
centrifuged. Following removal of the supernatant, cells were resuspended in approximately 3 
mL of ice cold freezing media. Aliquots of the cells suspension (1 mL) were transferred into 
cryogenic vial (Nalgene, Rochester, NY, USA). All vials were placed into an isopropanol 
containing freezing chamber (Nalgene, Rochester, NY, USA) and kept in a -80°C freezer for 
24 hours to allow gradual cooling and freezing for cells preservation. The frozen cells were 




2.2.5 Revival of cell lines from liquid nitrogen storage 
Cell aliquots from each cryogenic vial were thawed immediately in 10 mL of 37°C 
serum supplemented culture media and centrifuged at 1000 rpm for 5 min. The cells pellet 
was resuspended in 10 mL fresh serum supplemented culture media, transferred into a 25 cm
2
 
tissue culture flask, and cultured at 37°C incubator in humidified 5%CO2. Media was changed 
the next day and every two days to allow growth of revived cells. 
 
2.2.6 Transfection of mammalian cells 
Transfection of specific DNA vectors was performed using FuGENE 6 (Promega, 
Madison, WI) as recommended by manufacture's instruction. Stable transfection required the 
additional selection of transfectants with appropriate antibiotics. 
 (i) Transient transfection: 
 Cells were plated at density of 400,000 cells per six-well plates one day before 
performing the transfection. When the cells reached 70 - 80% confluent, transient transfection 
was carried out to increase the transfection efficiency. For generation of mammary carcinoma 
cells with depletion of TFF3, mammary carcinoma cells were transiently transfected with a 
pSilencer 2.1-U6 hygro (Ambion, Austin, TX) expression vector that containing human TFF3 
siRNA (Target DNA sequence: AAACAACGGTGCATAAATGAG) or control siRNA that 
encoding a siRNA comprises non-significant sequence similarity to human gene sequences. 
The expression vectors was constructed as previously described (Kannan et al., 2010).  
 FuGENE 6 transient transfection was performed according to manufacturer's 
instruction. To prepare transfection solution required for 6-well plate, 12 μL of FuGENE 6 
was diluted in 200 μL with serum free culture media and incubated for 10 minutes at room 
temperature. After that, 4 μg plasmid DNA was added into the diluted transfection reagent 
(FuGENE 6 reagent and plasmid DNA in serum free culture media at a 3:1 ratio). The 
FuGENE 6/DNA complex was incubated at room temperature for 20 minutes. The culture 
media was removed from cells and 1 mL of serum-free media was added to each well.  The 
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FuGENE 6/DNA complex solution was added directly to the cells drop-wise. Following three 
to four hours incubation at 37ºC, 500 µL of complete media was applied to each well. The 
transfected cells were cultured at 37
o
C in humidified 5% CO2 incubator for 24 hours or 48 
hours prior performing any assays. 
(ii) Stable transfection: 
 For stable transfection, cells were cultured to 70 - 80% confluence in a 75 cm
2
 culture 
flask and stably transfected with FuGENE 6 (Promega, Madison, WI) according to the 
manufacturer's instructions. For generation of the stable cell line expressing TFF3, the MCF-7 
or T47D cells were stable transfected with an pIRESneo3 expression vector containing the 
TFF3 cDNA (designated as MCF7-TFF3 or T47D-TFF3) or an empty pIRESneo3 vector as a 
control (designated as MCF7-Vec or T47D-TFF3). Pooled stable transfectants were selected 
with RPMI media, containing 800 μg/mL G418 for 21-28 days. Depending on the cell lines 
utilized, pooled stable transfectants were selected in varying concentration of Geneticin 
(G418). Initially when cell death was maximal, the media was changed every two days. 
Following that media was changed every three-four days. After three-four weeks, cells were 
trypsinized and transferred into a new 25 cm
2
 culture flask. Stable expression was confirmed 
by semi-quantitative RT-PCR and Western blot analysis. Cell lines were then expanded and 
10 vials of each cell lines were frozen. Cells were maintained in culture for a maximum of 
four months, following which a new vial was revived to avoid clonal selection. 
 
2.3 Co-culture assays 
 In order to determine the functional effects of TFF3 secreted from mammary 
carcinoma on endothelial cells, an indirect co-culture transwell system was employed, in 
which mammary carcinoma cells were plated into the membrane of transwell insert (0.4 μm 
pore size polyester transwell insert) (Corning, NY, USA) co-cultured with HUVEC seeded in 
the bottom well of companion plate. Mammary carcinoma cells with forced expression of 
TFF3 or depletion of TFF3 co-cultured with HUVEC to determine the stimulatory effects of 
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TFF3 on HUVEC monolayer proliferation, cell cycle progression, survival, and tubule 
formation in vitro. To determine the effects of TFF3 secreted from mammary carcinoma cells 
on HUVEC migration and invasion, modified Boyden migration/invasion chamber assays 
using 8 μm transwell inserts (Greiner Bio-One GmbH, Germany) were conducted. Whereby, 
HUVEC were plated into the membrane of transwell insert co-cultured with mammary 
carcinoma cells seeded in the bottom well of companion plate. 
 
2.3.1 RNAi transfection 
The On-Target anti-IL-8 siRNA and control siRNA (non-targeted, random sequence) 
were purchased from Dharmacon (Chicago, IL) (Table 3). The Smartpool On-Targetplus 
Human IL-8 siRNA was a mixture of 4 SMART selection designed siRNA species targeting 
human IL-8 gene. Smartpool On-Target siRNAs designed to hybridize and destroy human IL-
8 mRNA (Gen Bank Accession No. NM_000584). Subsequently, it silenced the human IL-8 
gene or protein expression. The sequences of these Smartpool siRNAs were verified to be 
specific to human IL-8, thus eliminating the off-target effects. On-Targetplus non-targeting 
pool was a negative control siRNA with at least 4 mismatches to any rat, mouse, and human 
gene and microarray tested. The Smartpool On-Target siRNA and negative control were 
transfected into human mammary carcinoma cells using Lipofectamine® RNAiMAX Reagent 
(Invitrogen
®
, Carlsbad, CA, USA) according to manufacturer's instruction with slight 
modification. Briefly, mammary carcinoma cells were plated to be 70 - 80% confluent on a 6 
well plate (400,000 cells/well) in complete media and incubated at 37
o
C for 24 hours prior 
transfection. Final concentration of siRNA and negative control was 20 nM as recommended. 
4 µL of Lipofectamine® RNAiMAX Reagent was diluted in 200 µL serum-free media. 
Similarly, 2 µL of siRNA and negative control was diluted in 200 µL serum-free media. 
Gently mixed the contents of each tube by pipetting carefully up and down and incubated at 
room temperature for 5 minutes. The diluted siRNA or negative control was added to 
respective tubes containing diluted Lipofectamine® RNAiMAX Reagent (1:1 ratio). Gently 
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mixed the contents of each tube by pipetting carefully up and down and incubated at room 
temperature for 20 minutes. The culture media was removed from cells and 1 mL of serum-
free media was added to each well. The siRNA-lipid complex solution was then added 
directly to the cells drop-wise. Following three to four hours incubation at 37ºC, 500 µL of 
complete media was applied to each well. The transfected cells were cultured at 37
o
C in 
humidified 5% CO2 incubator for 24 hours or 48 hours prior performing assays. The silencing 
of IL-8 gene mRNA expression after 24 hours transfection was measured by semi-
quantitative RT-PCR to identify the efficiency of siRNA. Additionally, conditioned medium 
from the cells were collected after 48 - 72 hours transfection and the silencing of IL-8 protein 
expression was measured by Human IL-8 ELISA kit (ELISA MAX
TM 
Deluxe Sets, Biolegend, 
San Diego, CA). 
 
Table 3: The gene sequence of validated siRNAs and negative control 
Smartpool On-Targetplus  
Human IL-8 siRNA, 10 nmol 
Target sequence 
On-Targetplus Smartpool siRNA J-004756-05, IL-8 GCAUAAAGACAUACUCCAA 
On-Targetplus Smartpool siRNA J-004756-06, IL-8 GGACCACACUGCGCCCAACA 
On-Targetplus Smartpool siRNA J-004756-07, IL-8 GCCAAGGAGUGCUAAAGAA 
On-Targetplus Smartpool siRNA J-004756-08, IL-8 UGAAGAGGGCUGAGAAUUC 
On-Targetplus Non-targeting pool, 5 nmol  
Source: Product datasheet from ThermoScientificBio.com/resource-library 
 
2.3.2 Monolayer cell proliferation (Total cell number) 
Mammary carcinoma cells with forced or depletion of TFF3 were trypsinized and 
seeded into six-well cell culture plates at a density of 50,000 cells/well. Cells were cultured in 
complete media for 24 hours at 37°C in 5% CO2 incubator to ensure that they attached to the 
culture surface. Cell culture media was then changed into either 0.2% FBS or 10% FBS 
supplemented media. Assays were set up in triplicate and cells were counted every 24 hours 
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over two or three day periods. For HUVEC with forced or depleted expression of TFF3, 
counts were conducted over two or three days periods both for 0.2% FBS EBM or 10% FBS 
supplemented EBM medium, respectively. For co-culture assays, mammary carcinoma cells 
with forced or depleted expression of TFF3 (80,000 cells per transwell insert) were plated into 
the membrane of transwell insert (0.4 μm membrane pore size) (Corning Inc, NY, USA) in 
10% FBS RPMI and incubated at 37
o
C for 24 hours after which the media was replaced with 
serum-free medium. HUVEC at density of 50,000 cells in serum-free EBM were seeded in 
bottom well of the companion plate. Assays were carried out for two to three days. Cells in 
each well were trypsinized with 0.5% trypsin and collected in 15 mL Falcon
 
tubes. Cells were 
centrifuged at 1,000 rpm for 5 minutes to discard the supernatant and cell pellets was 
collected. Cells were then resuspended in 1 mL of supplemented media and counted using a 
haemocytometer. 
 
2.3.3 5-bromo-2-deoxyuridine (BrdU) assay 
Entry into S-phase of the cell cycle was determined by measuring the incorporation of 
5-bromo-2-deoxyuridine (BrdU) (Kaulsay et al., 2001). BrdU labeling cells were trypsinized 
and seeded in triplicate into 24-well cell culture plates at a density of 200,000 – 250,000 cells 
per well. Cells were incubated overnight at 37°C in 5% CO2 incubator, and after 12 hours the 
media was removed and the cells washed 3 times with PBS. Cells were then incubated in 
serum-free media for 18 - 20 hours. Co-culture experiments were performed as described for 
the total cell number assay. After 18 - 20 hours incubation at 37°C in 5% CO2, the cells were 
pulse labeled with 20 μM BrdU (10 μL of 10 mM BrdU in 5 mL of media) was for 30 
minutes at 37ºC in 5% CO2. The media was discard and cells were washed 3 times with PBS. 
The procedure for detection of BrdU labeled cells is as below: 
(i) Fixing 
 
 Cells were fixed by 4% formaldehyde diluted in PBS for 30 minutes at 4ºC and were 
washed 3 times with PBS. The endogenous peroxidase in the cells was blocked by 3% H2O2 
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in methanol. 1 mL of freshly prepared 3% H2O2 was added to each well and plates were 
incubated on a rocker at room temperature for 30 minutes. At the end of incubation, H2O2 was 
removed and wells were washed 3 times with PBS for 5 minutes each wash. Cells were then 
incubated with 2N HCl (1 mL per well) on a rocker at room temperature for 1 hour. After 
removing HCl, cells were washed 2 times with 0.1 M borate solution followed by a 5 minutes 
PBS wash. 
(ii) Blocking and incubation with antibodies 
 
 Cells were incubated with 1 mL blocking solution (2% horse serum in PBS) per well 
for 1 hour at room temperature on a rocker and then washed 3 times with PBS for 5 minutes 
each wash. 1 mL of primary antibody at 1:100 dilution (mouse anti-BrdU antibody, Roche 
Applied Science, Germany) was added into the cells and incubated overnight at 4ºC. The 
Vectastain® Elite
®
 ABC Kit (Vector Laboratories, Inc. Burlingame, CA, USA) was used in 
the following steps that included 2 hours incubation with 1 mL per well of secondary 
antibody solution at room temperature and 1 hour incubation with 1 mL per well of tertiary 
antibody solution at room temperature. All these incubations with different antibodies were 
performed with gentle agitation followed by 3 x 15 minutes washes with PBS. 
(iii) Staining 
 
 The substrate solution was prepared by dissolving FAST 3,3-Diaminobenzidine 
hydrochloride (DAB) tablets (Sigma-Aldrich, MO, USA) in MilliQ water. 400 μL was added 
to each well and color development monitored. Staining was stopped with a PBS wash. 
Finally, cells were fixed in 70% cold ethanol at 4
o
C for 30 minutes, washed twice with PBS, 
and stored at 4ºC until counted.  
 (iv) Determination of the BrdU labeling index 
 
 A total population of over 1000 cells was analyzed in ten arbitrarily chosen 
microscopic fields. Results were expressed as the percentage of cells synthesizing DNA 
(BrdU labeling index). Stained cells were counted using an OLYMPUS
® 
IX71 Inverted 




2.3.4 Apoptosis assay 
Bisbenzimides are cell-permeable, A-T specific dyes, which can intercalate in the 
minor groove of A-T regions thereby fluorescently labeling DNA. In this assay, one member 
of the bisbenzimides, Hoechst 33258, was employed. Apoptotic cell death was determined by 
fluorescent microscopic analysis of DNA staining patterns with Hoechst. Cells were plated at 
a density of 200,000 - 250,000 cells per well. After an overnight incubation at 37°C in 5% 
CO2 in complete growth media to allow cells to attach, cells were treated with stimulation 
media (serum or serum-free; with or without drug treatment). Co-culture experiments were set 
up as described for the total cell number assay. After a culture period of 24 hours in serum-
free media, media was carefully removed and the cells were fixed in 4% formaldehyde in 
PBS at 4
o
C for 30 minutes.  The cells were subsequently stained the karyophilic dye Hoechst 
33258 (4 μg/mL Hoechst 33258, 1% Triton X-100 in PBS) at room temperature in the dark 
for 30 minutes. The staining solution was removed, washed twice with PBS, and culture plate 
was stored at 4°C. Apoptotic nuclear morphology was determined and examined under an 
inverted UV fluorescence microscope (Olympus). As compared to viable cells, the nuclear 
morphology of apoptotic cells characterized with nuclear fragmentation and condensation as 
well as the higher intensity of blue fluorescence of the nuclei. For statistical analysis, over 
1,000 cells were counted in ten random microscopic fields at 200x magnification. 
 
2.3.5 Invasion and migration assays 
 Migration and invasion assays were performed using modified Boyden chamber 
consisting cell culture transwell inserts (8 μm pores, Greiner Bio-One, Germany) and 
companion plates (24-well format) according to the manufacturer's instructions. For invasion 
assays, inserts were coated with growth factor reduced Matrigel (BD Bioscience) before 
plating the cells. Matrigel was diluted in serum-free media at 1/10 for MCF-7 and 1/50 for 
HUVEC respectively.  HUVEC (30,000 cells) or mammary carcinoma cells with forced or 
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depleted expression of TFF3 (50,000 cells) in serum-free media was seeded into the 
membrane of transwell inserts and complete media was added to the bottom well of the 
companion plate. For co-culture assays, mammary carcinoma cells with forced or depleted 
expression of TFF3 (250,000 cells) in 10% FBS RPMI media were plated in the bottom well 
of the companion plate and incubated at 37
o
C for 24 hours after which the media was replaced 
with serum-free media. A total of 30,000 HUVEC in serum-free EBM media were seeded 
into the membrane of transwell inserts. For migration and invasion assays using anti-IL-8 
monoclonal antibody, mammary carcinoma cells with forced or depleted expression of TFF3 
(250,000 cells) plated in 10% FBS RPMI media were plated in the bottom well of the 
companion and incubated at 37
o
C for 24 hours after which the media was replaced with 
serum-free medium containing anti-IL-8 monoclonal antibody (50 µg/mL) and IgG control. A 
total of 30,000 HUVEC in serum-free media were seeded into the membrane of transwell 
inserts. For assays using exogenous human recombinant TFF3 (rhTFF3), different dilution of 
rhTFF3 in serum-free media and Bovine serum albumin (BSA) used as control were added to 
the bottom well of the companion plate. After 24 hours incubation at 37
o
C, cells that had 
migrated or invaded to the lower surface of the transwell inserts were washed twice with PBS, 
fixed with 4% paraformaldehyde for 20 minutes, and stained with Hoechst 33258 (4 μg/mL 
Hoechst 33258, 1% Triton X-100 in PBS) at room temperature in the dark for 30 minutes. 
The staining solution was then discard, washed twice with PBS, and culture plate was stored 
at 4°C. The cells migrated to the lower surface of the entire transwell inserts were counted 
(OLYMPUS
®
 IX71 Inverted Laboratory System Microscope, Olympus Optical Co., Tokyo, 
Japan). 
 
2.3.6 Tubule formation in vitro 
 Growth factor reduced Matrigel (BD Bioscience) was thawed overnight in the fridge. 
The thawed Matrigel spread evenly over each well (300 μL) of a 24-well plate. The plates 
were incubated at 37ºC for 30 minutes in a cell culture incubator to allow the Matrigel to 
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solidify. A total of 30,000 HUVEC (30,000 cells/well for 24-well plate) in serum-free media 
were seeded in the Matrigel, incubated at 37
o
C for 12 hours, and fixed with 4% 
paraformaldehyde at room temperature for 20 minutes. Tubules were visualized under the 
microscope at low magnification (x40). For co-culture experiments, mammary carcinoma 
cells with forced or depleted expression of TFF3 were plated at 50,000 cells per transwell 
inserts (0.4 μm pores) (Corning Inc, NY, USA) in 10% FBS for 24 hours after which the 
media was replaced with serum-free media. The mammary carcinoma cells plated into the 
transwell inserts co-cultured with HUVEC seeded in the Matrigel. The plate was incubated at 
37
o
C for 12 hours and tubules were visualized under the microscope at low magnification 
(x40). For data analysis, tubules formed by HUVEC in Matrigel of the entire transwell insert 
was photographed and analyzed by using ImageJ software (version 2.02; University of Texas 
Health Scientific Center at San Francisco). 
 
2.3.7 Luciferase reporter assay  
(i) Plasmids 
 Several plasmids such as pGL3-basic vector, pGL-IL-8-152 reporters were generous 
gifts from Prof. Takashi Tokino (Department of Molecular Biology, Cancer Research Institute, 
Sapporo Medical University, Sapporo, Japan). The pGL3-basic vector was used as control 
plasmid. Fragment containing 5' flanking regions of the IL-8 gene were subcloned upstream 
of a luciferase reporter gene. pGL-IL8-152 reporter construct encompassing nucleotides -152 
to +44 of the IL-8 promoter, which containing transcription factors, AP-1, NF-IL-6 and NFκB 
binding sites. The TATA box, and the NF-IL-6, NFκB and AP-1 binding sites are located at -
13, -70, -80 and -120, respectively. Human IL-8 promoter reporter vector (full length, -4800 
to + 104 bp) was a generous gift from Dr. Suswam A. Esther (Department of Neurology, 
University of Alabama in Birmingham, USA), and pRL-CMV control reporter vector 
(Promega, Madison, WI, USA) was used as an internal control for transfection efficiency of 
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luciferase reporter assay. The pcDNA 3.1 empty vector and pcDNA 3.1 expression vector 
containing human STAT3 siRNA have been previously described (Mohankumar et al., 2008). 
(ii) Luciferase reporter assay 
 Cells with forced or depleted expression of TFF3 were plated at a density of 200,000 
cells per well in 12-well plate in triplicates and cultured in RPMI medium supplemented with 
10% FBS at 37°C for 24 hours before transfection. Luciferase reporter assay was performed 
as previously described (Fan and Wood, 2007). Briefly, cells with forced expression of TFF3 
or depletion of TFF3 transiently transfected with 2 µg of a reporter plasmids including human 
IL-8 promoter reporter vector (-4800 to + 104 bp) or pGL-IL8-152 reporter (-152 to +44 bp) 
and 40 ng pRL-CMV control reporter vector (Promega, Madison, WI, USA) using FuGENE 6 
reagent according to the manufacturer's instructions. Renilla luciferase reporter vector used as 
control for transfection efficiency. For determination of IL-8 promoter activity in MCF7-Vec 
and MCF7-TFF3 with depletion of STAT3, MCF-7 cells with forced expression of TFF3 
transiently transfected with 1 µg pcDNA3.1 empty vector containing control siRNA or 
pcDNA3.1 expression vector containing STAT3 siRNA, 1 µg human IL-8 promoter reporter 
(-4800 to + 104 bp), and 40 ng pRL-CMV control reporter vector (Promega, Madison, WI, 
USA) using FuGENE 6 reagent.  
 After 24 hours transient transfection, the reporter activities were measured by 
luciferase reporter assay using Dual-Luciferase® Reporter (DLR™) Assay System (Promega, 
Madison, WI, USA). Renilla luciferase activity was used as an internal control. Briefly, 250 
μL of 1x Passive Lysis Buffer (PLB) was added to each well of 12-well plate. Cells were 
incubated with PLB for 15 minutes on shaker and the cell lysate was then transferred to 
Eppendorf tubes.  The cell lysate (20 μL) was added to each well of a white 96-well microtiter 
plate (Greiner Bio-One, Frickenhausen, Germany). Luciferase Assay Buffer (50 μL) was 
dispensed into each well and mixed by tapping the plate gently. Firefly luciferase activity of 
the samples were measured by an Infinite 200 PRO micro plate reader (Tecan, Maennedorf, 
Switzerland), which was programmed to two sec measurement delay followed by a 10 second 
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measurement read for luciferase activity of samples. Subsequently, Stop & Glo
®
 reagent (50 
µL) was immediately added to each well mixed by tapping the plate gently. The Renilla 
luciferase activity was measured for normalization of transfection efficiency.  
 
2.4 Biochemistry and molecular biology methods 
2.4.1 IL-8 ELISA 
 A human IL-8 ELISA kit (ELISA MAX
TM
 Deluxe Sets, Biolegend, San Diego, CA) 
was used to quantify the human IL-8 protein in conditioned medium of mammary carcinoma 
cells with forced expression of TFF3, depletion of TFF3, depletion of IL-8, and depletion of 
STAT3. Mammary carcinoma cells were grown to 70 - 80% confluence in a six-well plate. 
The cells were washed with PBS, pH 7.4 and the media was changed to serum-free for 24 
hours. The media was collected after 24 hours and the ELISA assay was performed as per 
manufacturer’s instructions. Briefly, the 96-well flat clear bottom of polystyrene microplate 
(Nunc
TM
, Thermo Scientific) was coated with 100 µL diluted IL-8 specific monoclonal 
antibody and incubated overnight at 4
o
C. The plate washed 4 times with 300 µL Wash Buffer 
(0.05% Tween-20 in PBS, pH 7.4) per well and the residual buffer was blotted by firmly 
tapping plate upside down on absorbance paper. The plate was then blocked with 200 µL 1x 
Assay Diluent A to block non-specific binding and reduce background. The plated was then 
sealed with adhesive film and incubated for 1 hour at room temperature with shaking at 200 
rpm on a plate shaker. While the plate is being blocked, the appropriate sample dilutions 
(1/100 dilution for conditioned media from HUVEC and conditioned media from mammary 
carcinoma cells can be used directly) and standards were prepared. A 1,000 µL of top 
standard recombinant human IL-8 at 1,000 pg/mL was prepared from stock solution (5ng/ mL) 
in 1x Assay Diluent A. Six two-fold serial dilutions of the 1,000 pg/mL top standard with 1x 
Assay Diluent A in separate tubes. After diluting, the human IL-8 standard concentrations 
were 1,000 pg/mL, 500 pg/mL, 250 pg/mL, 125 pg/mL, 62.5 pg/mL, 31.3 pg/mL, and 15.6 
pg/mL, respectively. 1x Assay Diluent A served as the zero standard (0 pg/mL). The plate 
86 
 
washed 4 times with 300 µL Wash Buffer. A total of 100 µL of standards and conditioned 
medium of samples were added to the appropriate wells. The plate was sealed with adhesive 
film and incubated at room temperature for 2 hours with shaking at 200 rpm on a plate shaker. 
The plate was then washed with 4 times with Wash Buffer. Biotinylated Detection Antibody 
diluted at 1:200 dilution in 1x Assay Diluent A was added into each well (100 µL/well), 
sealed the plate, and incubated at room temperature for 30 minutes with shaking. The plate 
was washed 4 times with Wash Buffer. Avidin-HRP diluted at 1:1,000 in 1x Assay Diluent A 
was added to each well (100 µL/well), sealed the plate, and incubated at room temperature for 
30 minutes with shaking. The plate was then washed 5 times with Wash Buffer. For this final 
wash, soaked wells in Wash Buffer for 1 minute for each wash to minimize background noise. 
TMB Substrate Solution C was added into each well (100 µL/well) and incubated in the dark 
for 15 minutes. Positive wells turned blue color. The reaction was stopped by adding 100 µL 
of Stop Solution (2N H2SO4) to each well. Positive wells turned from blue to yellow. 
Absorbance reading was read at 450 nm within 30 minutes. The reference absorbance at 570 
nm was subtracted from the absorbance at 450 nm. Results were expressed as concentration 
of IL-8 in the conditioned media (ng/mL). 
 
2.4.2 RNA isolation 
 (i) RNA isolation using TRIzol reagent 
 Total RNA was extracted from exponentially growing cells (70% confluence) using 
TRIzol reagent. Cells were lysed by adding 1 mL TRIzol per 10 cm
2
 culture flask. The 
homogenized sample was incubated at room temperature for 5 minutes. Next, 0.2 mL of 
chloroform per mL of TRIzol reagent was added to each tube and mixed vigorously for 15 
seconds. After centrifugation at 12,000g for 15 minutes at 4ºC, the aqueous phase (RNA) was 
pipette out to a fresh tube and precipitated by adding 0.5 mL of 100% isoproponol per mL of 
TRIzol and incubated at room temperature for 10 minutes. A second centrifugation (at 
12,000g for 15 minutes, 4ºC) was performed and the supernatant was discarded. The RNA 
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pellet was washed in 1 mL of 75% ethanol per mL TRIzol reagent used in the initial 
homogenization by centrifugation at 7,500 g for 5 minutes at 4ºC to remove salt. A third 
centrifugation was then performed at 7,500 g for 5 minutes at 4ºC and the pellet was air dried 
at room temperature and resuspended in RNase-free water or Diethylpyrocarbonate (DEPC) 
dH2O. RNA sample was incubated in a water bath or heat block set at 55 - 60
o
C for 10-15 
minutes to increase the solubility of the RNA. The RNA sample can be used for downstream 
application or stored at -80
o
C. The concentration and purity of RNA was determined 
spectrophotometrically using the ratios A260/A280 nm and A260/A230 nm. A ratio less than 
1.8 may indicate the presence of contaminants within the sample. 
 (ii) RNA isolation using RNeasy
® 
Mini Kit 
 Total RNA was isolated from exponentially growing cells (70% confluence) using 
RNeasy
® 
Mini Kit (Qiagen, Limburg, Netherlands) as described by manufacturer's instruction. 
Briefly, cells were lysed by adding an appropriate volume of Buffer RLT containing either 
1% β-mercaptoethanol or 2% 2M dithiothreitol (2M DTT), centrifuged at 12,000 rpm for 3 
minutes, transferred the supernatant to a new microcentrifuge tube. Equal volume of 70% 
ethanol was added to the lysate (1:1 ratio), and mix well by pipetting. A total volume of 700 
μL of the sample including any precipitate was transferred to an RNeasy Mini spin column 
placed in a 2 mL collection tube, centrifuged at 12,000 rpm for 1 minute, and flow-through 
was discarded. RNeasy spin column washed by adding 700 μL Buffer RW1, centrifuged at 
12,000 rpm for 1 minute, and flow-through was discarded. After first washing, 500 μL Buffer 
RPE was added to the RNeasy spin column and centrifuged at 12,000 rpm for 1 minute. 
Addition of 500 μL Buffer RPE to the RNeasy spin column, centrifuged at 12,000 rpm for 2 
minutes, and flow-through was discarded. The residual of buffer was removed out from the 
spin column by centrifuged at 12,000 rpm for 1 minute. The RNA sample was eluted by 
adding 30-50 μL RNase-free water directly to the spin column membrane and centrifuged at 
12,000 rpm for 2 minutes. The concentration and purity of RNA was determined 
spectrophotometrically using the ratios A260/A280 nm and A260/A230 nm. 
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2.4.3 cDNA synthesis 
 Total RNA was converted to cDNA using SuperScript
®
 VILO™ cDNA Synthesis Kit, 
which provides the high-temperature capability of SuperScript
®
 III Reverse Transcriptase in 
an optimized conditions for generation of first-strand cDNA that commonly used in real-time 
quantitative RT-PCR (qPCR).  For a single reaction, all components were combined in a tube 
on ice which included 5x VILO™ Reaction Mix (4 μL), 10x SuperScriptR Enzyme Mix (2 
μL), RNA (up to 2.5 μg), DEPC-treated water to 20 μL reaction. The contents of the tube 
were gently mixed and reactions were incubated at 25ºC for 10 minutes and followed by 42ºC 
for 60 minutes. The reaction was terminated at 85ºC for 5 minutes. 1 μL (2 U) of E. coli 
RNase H was added and the tube was incubated at 37ºC for 20 minutes. The cDNA was 
stored at -20ºC until use. 
 
2.4.4 PCR 
 Amplification of DNA templates was carried out using Platinum
®
 PCR SuperMix 
High Fidelity (Invitrogen). The PCR mixture contains 22 U/ml Pyrococcus species GB-D 
thermostable polymerase, complexed recombinant Taq DNA polymerase and Platinum
®
, Taq 
Antibody in PCR buffers. For a single reaction, all components were combined in a reaction 
tube on ice (Table 4). 
 




PCR SuperMix High Fidelity 10.0 µL 
DNA template (1-2 µg) 2.0 µL 
Sense primer (10 µM) 1.0 µL 
Anti-sense primer (10 µM) 1.0 µL 
Autoclave MiliQ water 6.0 µL 




 RT-PCR reactions were performed on a Peltier PCR Thermal Cycler (PTC-100, MJ 
research, Ramsey, MN). A negative control, including every component similar to normal 
reaction except template RNA, was included in each experiment. Each reaction started with 
two-step amplification program of initial denaturation at 95°C for 10 minutes, followed by 
PCR thermal cycle. The PCR cycling consisted of three steps including denaturation at 94
o
C 
for 30 seconds, annealing at specified temperature for 60 seconds, and extension at 72
o
C for 1 
minute for the indicated cycles. The specific annealing temperature, number of cycles, and the 
primer sequences for individual reaction are listed in Table 6. Amplified β-actin served as an 
internal control for RNA quantity and quality. Amplified reactions were separated on a 1.5% 
agarose gel prepared in Tris-Boric acid-EDTA buffer (TBE 1x) containing of 1x GelRed™ 
(Biotium, Hayward, CA) or 1% ethidium bromide solution. 
 
2.4.5 Semi-quantitative RT-PCR 
 Semi-quantitative RT-PCR was performed by using Invitrogen
TM
 OneStep RT-PCR 
System with Platinum
®
 Taq DNA polymerase Kit (Invitrogen). A master mix was prepared 
according to the following protocol to avoid localized differences in salt concentration (Table 
7). Invitrogen
TM 
OneStep RT-PCR Enzyme Mix was the last component added into the master 
mix In order to keep the maximum enzyme activity. The reaction components in master mix 
were enlisted as following (Table 5):  
 
Table 5: Reaction components for semi-quantitative RT-PCR 
Component Volume 
2x Reaction Mix 12.5 µL 
Template RNA (0.01 pg - 1 µg) variable 
Sense primer (10 µM) 1 µL 
Anti-sense primer (10 µM) 1 µL 
SuperScript
®
 III RT/ Platinum
®
 Taq Mix 2 µL 




 RT-PCR reactions were performed on Peltier PCR Thermal Cycler (PTC-100, MJ 
research, Ramsey, MN). A negative control, including every component similar to normal 
reaction except template RNA, was included in each experiment. Each reaction started with 
30 minutes reverse transcription at 50
o
C followed by 15 minutes at 95
o
C. The PCR cycling 
consisted of three steps including denaturation at 94
o
C for 30 seconds, annealing at specified 
temperature for 30 seconds, and extension at 72
o
C for 2 minutes for the indicated cycles. The 
specific annealing temperature, number of cycles, and the primer sequences for individual 
reaction are listed in Table 6. Amplified β-actin used as an internal control for RNA quantity 
and quality. Amplified reactions were separated on a 2% agarose gel prepared in Tris-Boric 
acid-EDTA buffer (TBE 1x) containing of 1x GelRed™ (Biotium, Hayward, CA) or 1% 
ethidium bromide solution. When the gel was polymerized, it was placed onto the GT agarose 
gel electrophoresis system that filled with 1x TBE buffer. A defined amount of RT-PCR 
product (approximately 10-20 µL) was mixed with 1.5 - 3.0 μL 6x DNA loading dye and then 
loaded into each lane of the agarose gel. A 100 bp or 1 Kb plus DNA ladder was used as a 
base pair marker. Electrophoresis was performed at 80 - 100 V for 20 - 40 minutes. RT-PCR 
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2.4.6 Real-time quantitative PCR 
 Total RNA was isolated from mammary carcinoma cells with forced expression of 
TFF3. Total RNA was then converted to cDNA by using SuperScript
®
 VILO™ cDNA 
Synthesis (Invitrogen, CA) as described in section 2.4.3. Real-time qPCR was performed 
using the SYBR
®
 GreenER™ qPCR SuperMix for ABI PRISM® (Invitrogen, CA) following 
the manufacturer’s protocol. The q-PCR experiment and data analysis were conducted by an 
ABI 7700
®
 real-time PCR system (Applied Biosystems, USA). Multiple gene markers and 
three housekeeping genes (HKG) were utilized for real-time qPCR analysis. Real-time qPCR 
reaction mixture (20 L ) comprised of 12.5 L SYBR® GreenER™ qPCR SuperMix, 2 L 
of 200 nM primer (forward and reversed primers), and 3.5 L RNase-free water was prepared. 
5 ng of total cDNA (2 L) was then added to the Real-time qPCR reaction mixture. Each 
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gene marker (Table 7) was added to a qPCR 365-well plate and run in triplicate. Real-time 
qPCR was performed using a two-step amplification program of initial denaturation at 95°C 
for 10 minutes, followed by 40 cycles of 95°C for 20 seconds, 60°C for 30 seconds and 70°C 
for 30 seconds. At the end of the amplification, a melting curve analysis consisted of 
denaturation at 95°C for 1 minute and re-annealing at 55°C for 1 minute was performed. 
Standard curves were constructed from each experimental plate using serial 5-fold dilutions 
of untreated cDNA. The Ct-value for each reaction was calculated in order to obtain their 
geometric mean. The equation E = 10
(- 1/slope)
 was used to calculated the amplification 
efficiencies and ranged from 90 - 104% for all gene markers(Heid et al., 1996). Melting curve 
analysis was used to ensure that there was no unspecific amplification or primer dimer in any 
of the reactions. Each experiment was carried out at least three times with independent 
samples. The gene expression of the gene marker was expressed as “fold change” and the 
gene expression of the gene marker in three repeated experiments were averaged (P value < 
0.05 indicated statistically significant). Fold change > 2.0 indicated significant increased in 
mRNA level. The relative expression was calculated to compensate potential differences 
between markers, based on the efficiency (E), normalized by three housekeeping genes 
included β-actin, HPRT and GAPDH, and the Ct difference (Δ) of sample versus control (ΔCt 
sample-control). Relative expression = 2 
- (Ct,Sample - Ct,HKG) - (Ct,Control - Ct,HKG)
; Relative expression = 2 
- 
ddCt












Table 7: Oligonucleotide primers of angiogenic markers for real time qPCR 







































2.5 Plasmid DNA amplification  
2.5.1  Bacterial strains 
 The Escherichia coli (E.Coli) strain DH5αTM was obtained from Invitrogen 
(Groningen, The Netherlands). The genotype is DH5α: φ80dlacΔZM15, Δ(lacZY A-
argF)U169, deoR, recA1, endA1, hsdR17(r-k, mk+), phoA, supE44, thi-1, gyr A96, rel A1 λ. 
 
2.5.2 Growth of bacterial cultures 
 All bacterial cultures were grown aerobically in either liquid Luria-Bertani (LB) or on 
solid LB/agar plates at 37ºC. Depending on the specific experiments, as indicated in 
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appropriate sections, relevant antibiotics and additives were further added for selective 
growth. 
 
2.5.3 Bacterial transformation of plasmids 
 Plasmids were amplified by transforming into a DH5α™ strain of Escherichia coli 
(Invitrogen, Carlsbad, CA, USA). Heat-shock competent DH5α™ bacteria were mixed with 
the plasmid and incubated on ice for 30 minutes. Transformation was performed using a heat 
shock method by placing the mixed bacteria and DNA in 42
o
C water bath (Grant Instruments 
Ltd., Cambridge, UK) for 2 minutes, immediately followed by cooling on ice for 5 minutes. 
LB Broth (1 mL) was added to each Eppendorf tube and incubated in the 37°C incubator 
(Sanyo Electric Co. Ltd., Japan) for 1 hour. Cultures were then spread on a LB agar plates. 
Due to the presence of a specific cassette present on the cloned plasmid (such as ampicillin in 
pIRES vector), transformed bacteria were resistant to the corresponding antibiotic and could 
be utilized as a selectable marker for positively transformed colonies. For instance, 100 
μg/mL ampicillin is employed in selection of bacteria transformed with the pIRES plasmid. 
After bacterial plates were incubated in the 37°C incubator for 20 hours, a single colony from 
each petri dish was picked and placed in 200 mL of LB Broth containing 100 μg/mL 
ampicillin. Cultures were grown at 37°C with vigorous shaking (250 rpm) in a Bioline® 
automatic incubator shaker (Edwards Instrument Co., Narellan, NSW, Australia) for 20 hours. 
 
2.5.4 Plasmid DNA purification 
 Bacterial transformation of plasmid DNA was initially performed by 20 hours 
incubation at 37°C with vigorous shaking in antibiotic-supplied LB broth. Next, extraction 
and purification of plasmid DNA from transformed DH5α™ bacteria was carried out using a 
PureLink
TM
 HiPure plasmid purification kit (Invitrogen, CA). The bacterial cells were 
harvested by centrifugation at 4,000 rpm for 10 minutes at 4ºC using a TOMY MX-300 high 
speed refrigerated centrifuge (TOMY SEIKO CO., LTD, Japan). The pellet was collected and 
95 
 
resuspended in 10 mL chilled Suspension Buffer S1 with RNase by vortexing until 
homogenous, followed by addition of 10 mL Lysis Buffer (B7) and mixing thoroughly by 
gently inverting the capped Falcon tube 4-6 times until the lysate mixture was thoroughly 
homogenous. After 5 minutes incubation at room temperature, 10 mL Precipitation Buffer 
(N3) was immediately mixed with the lysate by inverting the tube until the mixture was 
thoroughly homogeneous. The mixture was then centrifuged at 15,000g for 10 minutes at 
room temperature. During this period, 30 mL of Equilibration Buffer (EQ1) was applied to 
equilibrate the PureLink
TM
 HiPure Maxi Column. The DNA containing supernatant was 
loaded onto the equilibrated PureLink
TM
 HiPure Maxi Column and allowed the solution in the 
column to drain by gravity. Columns were washed with 60 mL Wash Buffer (W8) and 
allowed the solution in the column to drain by gravity. Subsequently, the plasmid DNA was 
eluted with 15 mL Elution Buffer (E4). Isopropanol (10.5 mL) was mixed with the eluate at 
room temperature and centrifuged at 15,000g for 30 minutes at 4ºC to precipitate the DNA. 
The DNA pellet was washed with 5 mL of 70% ethanol at room temperature and then re-
precipitated by centrifugation at 12,000 g for 10 minutes at 4ºC. The supernatant was 
carefully decanted and the pellet allowed to air dry before being redissolved in a suitable 
volume (50 - 200 μL) of ultrapure water. The concentration and purity of DNA measured 
using NanoDrop
®
 ND-1000 Spectrophotometer (Thermo Scientific) and determined 
spectrophotometrically by UV absorbance at 260 nm or ratios A260/A280 nm. The purified 
DNA was stored at -20ºC.  
 Small-scale plasmid DNA preparation was carried out using a Qiagen Miniprep Kit 
(Qiagen, Germany) according to the manufacturer’s instructions. The 5 mL overnight bacteria 
culture was harvested by centrifugation at 16,000g for 15 minutes. The cell pellet was 
resuspended in Resuspension Solution, followed by the addition of Lysis Solution (0.2 M 
NaOH and 1% SDS) and Neutralization Solution. The lysate was centrifuged at 16,000 rpm 
for 10 minutes at room temperature, and the supernatant was transferred to a spin column. 
After spin for one minute, the column was washed by Washing Solution diluted with 95% 
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ethanol (162.8 mM potassium acetate and 27.1 mM Tris-HCl, pH 7.5). The column was 
centrifuged at 16,000 rpm for 1 minutes. The plasmid DNA was eluted in 50 μL ultrapure 
water. 
 
2.5.5 DNA purification from agarose gel 
 DNA subjected to agarose gel electrophoresis, as described above, was visualized 
under UV light and the desired band excised with a sterile scalpel. The gel fragment was 
placed in a sterile Eppendorf tube and membrane binding solution from the Wizard
®
 SV Gel 
and PCR Clean-Up System (Promega) was added (ratio of 10 μL solution per 10 mg of 
agarose gel slice). The mixture was vortexed and incubated at 50-60ºC until the gel was 
dissolved. DNA purification was processed by centrifugation. The gel mixture was transferred 
to the SV minicolumn and centrifuged for 1 minute at 16,000 g. The liquid was discarded and 
the column was washed 2 times for 25 minutes at 16,000 g. The SV column was carefully 
transferred to a clean microcentrifuge tube and 50 μL of nuclease free water was added. The 
tube was then centrifuged for 1 minute at 16,000g and the microcentrifuge tube containing the 
eluted DNA was stored at -20ºC. 
 
2.6 Determination of protein expression 
2.6.1 Protein extraction 
 Cells were plated in supplemented media at 60 - 70% confluence and incubated at 
37
o
C for 24 hours.  Cells were washed once with ice cold PBS and harvested by mechanical 
scraping. The cells were resuspended in RIPA buffer (50 mM Tris-HCL pH 7.4, 1% Nonidet 
P-40, 150 mM NaCl, 1 mM EDTA, 1 mM NaF, 1mM PMSF, 1 mM Na3VO4, 1x protease 
inhibitor) and incubated for 30 minutes on ice with vortexing every 5 minutes. From this step 
onwards, all procedures were performed on ice to avoid protein degradation. Lysates were 
centrifuged for 15 minutes at 16,000g and the supernatant collected. Lysis buffer (2% SDS, 
20% glycerol, 60 mM Tris-HCl pH 6.8, 1x protease inhibitor) was used for proteins 
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containing a significant amount of disulfide bonds and subsequently harder to lyses. In this 
case, cells were washed three times with ice cold PBS for 10 minutes, dried and placed at -
80ºC for one hour. 200 μL of lysis buffer was added to the petri dish and cells were harvested 
by mechanical scraping. Cell lysate was collected into an individual pre-chilled Eppendorf 
tube and sonicated in an 80T SONICLEAN benchtop ultrasonic cleaner (Soniclean Pty. Ltd., 
SA, Australia) for 1 minute. Finally, centrifugation was performed at 16,000g for 15 minutes 
at 4ºC. The supernatants were transferred to new Eppendorf tubes and stored at -80ºC or use 
immediately in subsequent assays. The protein concentration was measured in triplicates 
using DC protein assay (Bio-Rad). 
 
2.6.2 Conditioned medium for concentration of protein 
 Cells were seeded in a 6-well plate at density of 200,000 cells in supplemented media 
and incubated at 37
o
C for 24 hours or 48 hours.  After which, media were changed to serum-
free medium and incubated at 37
o
C for 24 hours. Conditioned medium from the cells were 
collected and stored at -80
o
C or proceed to ultrafiltration for concentration of protein using an 
Amicon
®
 Ultra-0.5 centrifugal filter unit with a nominal molecular weight limit (NMWL) of 3 
KDa (Milipore, Darmstadt, Germany). Sample recovery was 90% and molecular weight of 
the protein > 3 kDa retained by the membrane. Conditioned medium was loaded into the 
Amico
®
 Ultra filter device and centrifuged at 14,000g for 15 minutes at 4
o
C. To recover the 
concentrated solute, Amico
®
 Ultra filter device was placed upside down in a clean 
microcentrifuge tube and centrifuged at 1,000g for 2 minutes in order to transfer the 
concentrated sample from the device to the tube. The protein concentration in the conditioned 
medium was determined by Bradford Assay. 
 
2.6.3 Bradford assay 
 Bradford assay was used to determine the total protein concentration of a sample. 
This method is based on the proportional binding of the Coomassie dye to protein. Bovine 
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serum albumin (BSA) dissolved in water to a concentration of 4 mg/mL and a serial diluted of 
BSA standard solutions were prepared. Bradford reagent (Bio-Rad laboratories, USA) was 
diluted at a 1:5 ratio with water. 20 μL of the standards (in triplicates) were loaded into a 96-
well microtitre plate (Greiner Bio-One, Germany). Solubilized protein samples were diluted 
1:10 in RIPA buffer and 20 μL samples loaded in triplicates into the subsequent columns. 
Bradford reagent (200 μL) was added to each well. After incubation for 5 minutes at room 
temperature, absorbance of the standards and samples were read at 595 nm using an Infinite 
200 PRO micro plate reader (Tecan, Maennedorf, Switzerland). The standard curve was 
plotted and absorbance of the unknown protein sample was calculated from the standard 
curve. 
 
2.6.4 Bio-Rad DC protein assay 
 Working reagent A was prepared by adding 20 μL of reagent S to each mL of reagent 
A from the Bio-Rad Reagent package (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and 
mixing thoroughly. Standard used for Bio-Rad DC protein assay was BSA and 2 mg/mL BSA 
was diluted to make a series of standards containing from 0.2 mg/mL to 1.5 mg/mL protein 
with the RIPA buffer, which was the same buffer used for protein extraction. The standard 
curve was constructed from the serial diluted BSA in a range of 0 mg/mL to 1.5 mg/mL. 
Unknown protein samples can be used directly or diluted five times with RIPA buffer. 
Standards and unknown samples (5 μL) were transferred into a 96-well microtiter plate. 25 μL 
of working reagent (Reagent A + Reagent S) was then added into each well, followed by 200 
μL Reagent B. The microtiter plate was incubated for 15 minutes with gentle agitation in the 
dark at room temperature. After removing any bubbles, absorbance readings were read at 750 
nm using an Infinite 200 PRO microplate reader (Tecan, Maennedorf, Switzerland). Based on 
the absorbance of standards, the standard curve was plotted, and the absorbance of unknown 




2.6.5 Plate reading 
 The plate was placed onto an Infinite 200 PRO micro plate reader (Tecan, 
Maennedorf, Switzerland) with an appropriate absorbance wavelength setting. Standard 
curves were prepared by measuring the absorbance of BSA in a serial dilution. The 
calibration curves were linear (r
2 
 > 0.99) over the concentration range tested (0 – 2000 μg/mL) 
and the precision of all standards was reproducible with coefficient of variation, CV < 5%. 
The protein concentration was calculated by comparing the absorbance of the known protein 
BSA standards with those from the unknown samples. 
 
2.6.6 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
 A Laemmli SDS-polyacrylamide gel was cast using the Bio-Rad Mini-PROTEAN II 
system. The resolving gel was composed of 12% acrylamide (37.5: 1) in 0.375 M Tris-HCl, 
pH 8.8 and 0.1% SDS. The stacking gel was composed of 4% acrylamide in 0.125 M Tris-
HCl, pH 6.8, and 0.1% SDS. The gels were polymerized by the addition of freshly prepared 
0.1% ammonium persulfate and 0.01% Tetramethylethylenediamine (TEMED). Protein 
samples were mixed with an equal volume of 2x sample buffer (65.8 mM Tris-HCl, pH 6.8, 
2.1% SDS, 26.3% (w/v) glycerol, 0.01% bromophenol blue) (Bio-Rad) and heated at 100ºC 
for 10 minutes before being loaded into the gel. Electrophoresis was carried out in 1x running 
buffer (25 mM Tris, pH 8.3, 192 mM glycine and 0.1% SDS) at a constant voltage of 100 V 
for 2 hours. After electrophoresis was completed, the gel was removed from the gel cassette 
sandwich. After cutting off the stacking gel portion, the gel was equilibrated in transfer buffer 
for two minutes. Meanwhile, the Polyvinylidene Difluoride (PVDF) membrane (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA), cut to the dimensions of the gel, was incubated in 
methanol for 1 minute and transferred into transfer buffer for another 3 minutes incubation. 
The filter paper and fiber pads were soaked in transfer buffer for 5 minutes. The 
electrophoresis transfer cassette was assembled in the following order: black side of the gel 
holder cassette; pre-wetted fiber pad; pre-wetted filter paper; gel; membrane; pre-wetted filter 
100 
 
paper; pre-wetted fiber pad; red side of the gel holder cassette. To optimize protein 
electrophoresis transfer, air bubbles were removed. The cassette was firmly closed and set in 
buffer tank filled with cold electrophoretic transfer buffer. The proteins separated by SDS-
PAGE were transferred from the gels onto PVDF membrane for 2 hours at a constant voltage 
of 50 V. 
 
2.6.7 Immunodetection of protein 
 Proteins were resolved in the SDS-PAGE gel and transferred to PVDF membranes. 
The membranes were blocked with 5% Bovine serum albumin in TBS with 0.1% Tween-20 
(TBST) or non-fat dry milk in PBS with 0.1% Tween-20 (PBST) for 2 hours at room 
temperature. The blots were washed 4 times with PBST for 15 minutes and subsequently 
immunolabeled with the desired primary antibodies for 2 hours at room temperature or 
overnight at 4°C (Table 8). After the primary antibodies incubation, the blots were washed 4 
times with PBST for 15 minutes and incubated with corresponding secondary Horseradish 
Peroxidase (HRP)-conjugated IgG antibody diluted in blocking buffer for 1 hour at room 
temperature. Following incubation, the blots were washed 4 times with PBST for 15 minutes 
before incubation with the SuperSignal West Pico Chemiluminescent Substrate kit (Thermo 
Scientific) for 5 minutes in the dark. Blots were then exposed to X-ray film for 1 - 5 minute 
exposures and the film was developed by Konica SRX-101A processor (Konica Minolta Inc., 
Tokyo, Japan) for detection of protein band. For re-blotting, membranes were stripped for 5 
minutes in stripping buffer (0.2 M NaOH). Blots were washed for 10 minutes with Milli-Q 
water followed by PBST at room temperature. Blots were blocked with 5% non-fat dry milk 
in PBS with 0.1% Tween-20 (PBST) for 2 hour at room temperature. Thereafter, blots were 
immunolabeled with loading control such as β-actin monoclonal antibody. The procedure for 
immunodetection of the loading control was the same as described above. The recommended 










VEGF-A C-1: sc-7269, Santa Cruz Biotechnology 21/42 1:2000 
TFF3  
Anti-PGM 3 (animal 3105) polyclonal 
antibody was generated by Amiry et al. 
(2009) and synthesized by Biogenes, 
GmBH D, Berlin 
7 1:2000 
pSTAT3 B-7: sc-8058, Santa Cruz Biotechnology 86/91 1:2000 
STAT3 C-20: sc-482, Santa Cruz Biotechnology 86/91 1:3000 
IL-8 MAB-208, R&D systems 8 1:2000 
 
2.5.8  Densitometric analysis of intensity of band 
 The amplified PCR products resolved in the agarose gel were captured by GelDoc 
imaging system (Bio-Rad) and intensity of the band of interest was analyzed by QuantityOne 
program (version 1.0.1, Bio-Rad). The protein bands developed in X-ray film were captured 
and analyzed by ImageJ. Bands of interest in the agarose gel or X-ray films were marked and 
their total integrated volumes were quantified against the background. Density was the 
corrected intensity integrated with volumes (in arbitrary units).  
 
2.6 In vivo study 
2.6.1 Angiogenesis in vivo assay 
 The angiogenesis in vivo assay using tumor xenograft models was performed in 
collaboration with Dr Tao Zhu (University of Science and Technology of China, Hefei). All 
the in vivo work related to mice models were performed under a standard protocol approved 
by the institutional animal care and use committee. MCF7-Vec and MCF7-TFF3 (5 x 10
6
) 
were suspended in 100 μL Matrigel and injected into the first mammary (axillary) fat pad of 
six-week-old athymic (nu/nu) mice (Shanghai Slaccas Co.). Tumor xenografts produced by 
MCF7-Vec and MCF7-TFF3 were dissected and stored at -80°C for immunohistochemical 
(IHC) analysis and protein extraction. Tumor sections were prepared by fixing the tumor 
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tissues in 4% PFA (pH 7.4) overnight, embedded in paraffin, and cut into less than 5-μm thick 
paraffin (or frozen) sections. For IHC analysis, tissue sections of the tumors were mounted on 
glass slides, deparaffinised and rehydrated. The slides were rehydrated and incubated with 3% 
hydrogen peroxide for 30 minutes. The sections were blocked with 10% goat serum (Sigma) 
in PBS for 30 minutes and then incubated at room temperature for 90 minutes with the 
following antibodies: Anti-mouse CD31 (550274, BD) (1:100 dilution), anti-
CD34/podoplanin (ab11936, abcam) (1:200 dilution), and anti-IL-8 antibody (R&D System) 
(1:100 dilution). The sections were washed with PBS and incubated with the respective 
biotinylated secondary antibodies such as anti-mouse IgG (BA-9200) or anti-rabbit IgG (BA-
100) (1:300 dilution) at room temperature for 1 hour. Subsequently, an Elite ABC 
immunoperoxidase kit (PK-6100 vector Laboratory) was added to the sections and incubated 
for 30 minutes at room temperature, followed by visualization with diaminobenzidine (DAB) 
(ImmPACT DAB Substrate SK-4105 vector lab) (1 - 10 minutes at room temperature). 
Finally, the slides were mounted in DakoCytomation fluorescent mounting media and 
observed under a microscope (OLYMPUS AX70). Five different fields were chosen 
randomly from seven sections of each xenograft across the whole tumor. Photographs were 
captured with identical settings for all sections. Statistical analysis of protein expression was 
determined as previously described (Araneda et al., 2005). A common threshold level was 
selected for all analyzed images to prevent intra-assay variations and the background level of 
the control sections was calculated for image analysis. ImageJ Program, version 1.45s 
(National Institute of Health, USA) was used to analyze the images (JPEG or TIFF files). 
 
2.7 Bioinformatics Tools 
2.7.1 Software for statistical analysis 
 The statistics software program Sigma Stat 3.1 was used in conjunction with 
Microsoft Excel for statistical analyses. The graphical presentations were generated using 
GraphPad Prism 5 (GraphPad Software, Inc., CA, USA). All experiments were performed for 
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three or four times. Numerical data were expressed as mean +/- SEM of triplicate 
determinants. Experiments were  repeated for three times and data were analyzed by unpaired 
two-tailed student's t test or analysis of variance (ANOVA). A representative figure for each 
experiment is shown.  
 
2.7.2 BLAST 
 Basic Local Alignment Search Tool (BLAST) was utilized for both DNA and protein 
sequence database searches (Altschul et al., 1990). The basic algorithms of BLAST were used 
for gene identification searches, gene alignment searches, as well as transcription start site 
(TSS) estimations of various genes with uncharacterized promoter regions, specifically 
utilizing the EST-search function. BLAST was accessed via the National Centre for 














TFF3 Promotes de novo Angiogenesis in Mammary Carcinoma 
3.1 Introduction 
De novo angiogenesis is associated with tumor growth and metastasis (Schneider and 
Miller, 2005, Fox et al., 2007, Paez-Ribes et al., 2009). Adequate vascularization of the tumor 
is required for delivery of nutrients and oxygen to the growing tumor (Folkman, 1985, Risau, 
1997). In a tumor microenvironment, the tumor is deprived of oxygen because of its distance 
from the nearest blood vessels and this hypoxic environment triggers the cancer cells to 
produce angiogenic factors or growth factors (Bergers and Benjamin, 2003, Gelao et al., 
2013).  Angiogenic factors secreted from tumors or stromal cells stimulate neovascularization 
by activating endothelial cell proliferation, migration, survival, and degradation of cell to cell 
contact and cell to matrix adhesion (Gupta and Qin, 2003). Establishment of highly permeable 
and disorganized vasculatures in the tumor facilitates dissemination of cancer cells through 
the bloodstream to distant organs to form metastases (Baeriswyl and Christofori, 2009, 
Valastyan and Weinberg, 2011). Importantly, the survival and proliferation of the tumor 
depends on angiogenesis that is mediated by numerous of angiogenic factors, particularly 
vascular endothelial growth factors (VEGF)  (Ferrara, 2004, Ferrara, 2005, Shibuya, 2008) 
and interleukin 8 (IL-8) (Koch et al., 1992, Ning et al., 2010).  
 A number of studies have reported that TFF3 expression was significantly associated 
with pro-survival and pro-invasive activities of mammary carcinoma cells (Emami et al., 
2001, Rodrigues et al., 2003a, Kannan et al., 2010, Ahmed et al., 2012). Increased TFF3 
expression in mammary carcinoma cells promoted cell proliferation, survival, oncogenicity, 
migration and invasion. (Kannan et al., 2010, Ahmed et al., 2012, Pandey et al., 2014). TFF3 
mRNA expression has been demonstrated to predict micrometastatic mammary carcinoma 
(Weigelt et al., 2004, Mikhitarian et al., 2005). The gene expression of TFF1 and TFF3 are 
associated with metastasis of breast cancer as reported by a microarray analysis of breast 
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cancer tissues (Smid et al., 2006). Another recent studies displayed similar observations, 
increased TFF3 expression promotes metastasis and predicts poor survival outcomes of 
patients with mammary carcinoma (Kannan et al., 2010, Pandey et al., 2014). Inevitably, 
TFF3 may serve as an independent predictive biomarker for metastasis of mammary 
carcinoma.  
 In addition to its metastatic properties, TFF3 has recently been identified as a 
potential pro-angiogenic factor implicated in tumor angiogenesis. Immunohistochemical (IHC) 
analysis of tumor tissues has demonstrated that increased TFF3 expression was positively 
correlated with enhanced microvessel density (vessels labeled with CD31 marker) in gastric 
carcinoma (Dhar et al., 2005) and breast carcinoma (Ahmed et al., 2012). These observations 
were concordant with a study by Rodrigues et al. (2003b) who demonstrated that recombinant 
human TFF3 induced vessel formation in a chick chorioallantoic membrane (CAM) assay. 
However, the role of TFF3 in de novo angiogenesis in mammary carcinoma has not been 
determined. 
 IL-8 is a potent angiogenic factor involved in angiogenesis and metastasis of 
mammary carcinoma (Basolo et al., 1993, Green et al., 1997, Youngs et al., 1997, De Larco 
et al., 2001). It has been reported that elevated expression of IL-8 in mammary carcinoma 
cells was correlated with metastatic potential and tumor angiogenesis (Lin et al., 2004). A 
clinical study has reported that triple negative (ER-PR-HER2-) breast cancer patients with 
elevated IL-8 expression were characterized by increasing invasiveness and metastatic 
potential that contributed to high risk of recurrence and poor prognosis (Rody et al., 2011). 
The IL-8 serum concentration in patients with advanced breast cancer was higher than that of 
healthy subjects. Increased IL-8 expression was associated with worse survival outcome, a 
higher tumor load, and involvement of liver or lymph node (Benoy et al., 2004). The presence 
of bone metastasis in patients with advanced breast cancer was positively correlated with 
increased IL-8 expression (Simeone et al., 2007), suggesting that IL-8 is an independent 
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predictive marker for breast cancer patients with high metastatic capacity and poor survival 
outcome (De Larco et al., 2003, Simeone et al., 2007).  
 It has also been shown that IL-8 and its cognate receptors namely CXCR1 and 
CXCR2 were positively associated with poor prognosis in patients with breast cancer (Miller 
et al., 1998, Benoy et al., 2004). The ability of IL-8 to elicit angiogenic activity depends on 
the expression of its receptors by endothelial cells (Singh et al., 2010). IL-8 stimulates 
endothelial cell proliferation and capillary tube formation in a concentration-dependent 
manner, and these angiogenic effects can be abrogated by monoclonal antibodies inhibitory to 
IL-8 (Heidemann et al., 2003, Li et al., 2005). Neutralizing antibodies to CXCR1 and CXCR2 
inhibit migration of endothelial cells promoted by IL-8, suggesting that these two receptors 
are critical for activation of the angiogenic responses of IL-8 (Salcedo et al., 2000a, Li et al., 
2005). Tumor cells exploit the expression of IL-8 and its receptors to enhance tumor 
progression through regulation tumor growth, angiogenesis, and immune response. Increased 
Il-8 expression alters the tumor microenvironment to be favorable for cancer cells to 
metastasize and colonize at the targeted organs (Yuan et al., 2005, Singh et al., 2010, Lee et 
al., 2012). Inhibition of IL-8 by humanized anti-IL-8 antibodies attenuated tumor growth, 
angiogenesis and metastasis of human melanoma (Huang et al., 2002). Administration of a 
humanized monoclonal antibody against IL-8 has been shown to suppress the growth of 
bladder cancer in xenograft models (Mian et al., 2003). 
 IL-8 signaling activated growth factor receptors and stimulated the activity of MAPK 
signaling cascade, which is related to the promoting effect of IL-8 on cell proliferation and 
survival of cancer (Brew et al., 2000, Luppi et al., 2007) and endothelial cell lines (Li et al., 
2003a, Waugh and Wilson, 2008). It is known that PI3K is involved in the regulation of IL-8. 
Activation of PI3K/Akt signaling pathway is modulated by IL-8 to promote cell survival, 
angiogenesis, and migration of mammary carcinoma cells (Cheng et al., 2008, Waugh and 
Wilson, 2008, Todorović-Raković and Milovanović, 2013). IL-8 signaling is likely to 
promote the transcriptional activity of multiple genes that involved in angiogenesis, migration, 
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invasion and the evasion of apoptosis (Waugh and Wilson, 2008). In addition to IL-8, VEGF-
A and TFF3 were connected to signal transducers and activators of transcription 3 (STAT3) 
signaling as these two peptides promote activation of STAT3 by tyrosine phosphorylation at 
705 amino acid residues (Rivat et al., 2005, Pandey et al., 2014). As a result, the expression 
of TFF3 and VEGF-A was up-regulated by STAT3 (Niu et al., 2002, Tebbutt et al., 2002). 
The persistent STAT3 activity enhanced by growth factors as well as additional oncogenes 
which promote oncogenic transformation and invasion of cancer cells such as Src family 
kinases and RhoA (Turkson et al., 1998, Simon et al., 2000, Goiot et al., 2001). The activated 
dimeric STAT3 translocates into the nucleus, where it binds to the targeted DNA response 
elements within the promoter region of a specific gene and subsequently activate its gene 
transcription (Horvath et al., 1995, Darnell, 1997). TFF peptides directly induced cell 
scattering and cellular invasion of kidney and colonic carcinoma cells through autocrine loops 
(Emami et al., 2001). Alternatively, the pro-invasive activity of TFF3 was controlled by 
activation of Src and Rho-dependent signaling pathways that led to tyrosine phosphorylation 
of STAT3, suggesting that STAT3 may be a crucial transcription factor involved in the 
mechanistic action of TFF peptides (Emami et al., 2001). A recent study observed that TFF3 
expression in mammary carcinoma cells stimulated tyrosine phosphorylation of c-Src, which 
subsequently increased STAT3 activity and led to the down-regulation of E-cadherin to 
promote cell invasion (Pandey et al., 2014). Blockade of STAT3 signaling by a dominant-
negative element (STAT3β), depletion of STAT3 by siRNA and inhibition of STAT3 
activation by STAT3 inhibitory peptide abrogated cellular invasion and growth of colon 
cancer in xenograft models (Rivat et al., 2005). Inhibition of STAT3 activity using STAT3 
inhibitors and depletion of STAT3 by siRNA largely inhibited the ability of TFF3 to stimulate 
invasion of mammary carcinoma cells (Pandey et al., 2014).  
 The persistent STAT3 activity exhibits anti-apoptotic, mitogenic, and angiogenic 
effects in cancer cells. STAT3 stimulates tumor angiogenesis by increasing the promoter 
activity of VEGF-A (Bromberg et al., 1999, Shen et al., 2001, Niu et al., 2002). Furthermore, 
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STAT3 has been suggested as a regulator of IL-8 at the transcriptional level by direct binding 
to the IL-8 promoter (Oka et al., 2010). However, the underlying mechanism by which TFF3 
promote de novo angiogenesis in mammary carcinoma has not yet been determined. The role 
of STAT3 in TFF3-stimulated angiogenesis in mammary carcinoma remains elusive. I 
postulate that a similar STAT3 signaling pathway between TFF3 and the TFF3-stimulated 
pro-angiogenic factor, which can be a target gene of STAT3 and coordinately mediates TFF3 
to promote angiogenesis in mammary carcinoma. Herein, I have determined the effect of 
TFF3 secreted from mammary carcinoma cells on the angiogenic behaviors of endothelial 
cells to promote de novo angiogenesis in mammary carcinoma and delineated the underlying 
mechanism by which TFF3 promotes de novo angiogenesis in mammary carcinoma.  
 In this study, I utilized two human mammary adenocarcinoma cell lines, namely 
MCF-7 and T47D cells, as in vitro models, by stable forced expression of TFF3 or depletion 
of TFF3 in these cell lines. These cell lines are easily propagated and are amendable to 
genetic manipulation (Masters, 2000). Additionally, these cell lines can be implanted into 
immunodeficient mice as xenograft models and the effects of altered gene function and 
pharmacological inhibition of tumorigenicity in breast cancer both in vitro and in vivo can 
be determined (Lacroix and Leclercq, 2004). Additionally, the effect of TFF3 secreted from 
mammary carcinoma cells on endothelial cells was determined by using an indirect co-culture 
transwell system, in which mammary carcinoma cells plated on the membrane of transwell 
inserts were co-cultured with endothelial cells seeded in the bottom well of the companion 
plate. This indirect co-culture system enables two different type of cells to culture together, 
which is mimic to the in vivo situation and allows the soluble factors from mammary 
carcinoma cells to diffuse through the pore of the membrane to the endothelial cells and 
subsequently modulate the angiogenic behaviors of endothelial cells. To examine the 
angiogenic potential of TFF3, a tubule formation assay was performed in which mammary 
carcinoma cells plated on the membrane of transwell inserts co-cultured with endothelial cells 
seeded in the Matrigel coated in the bottom well of the companion plate. Tubules formed by 
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HUVEC in the Matrigel can be quantified to assess the angiogenic activity of  TFF3 on the 
endothelial cells (Bishop et al., 1999) and the morphology of tubules generated by endothelial 
cells is representative of capillary vessel formation in vivo (Donovan et al., 2001, Bagley et 
al., 2003). By using this approach, the roles of TFF3 secreted from mammary carcinoma cells 
on the angiogenic activities of HUVEC can be determined. 
 
3.2 Results 
3.2.1 Expression of TFF3 mRNA in mammary carcinoma cells  
 The expression of TFF3 mRNA in several ER+ mammary carcinoma cell lines 
(MCF-7, T47D, MDA-MB-361, and BT474) and one ER- mammary carcinoma cell line 
(MDA-MB-231) were analyzed by semi-quantitative RT-PCR. ER+ mammary carcinoma cell 
lines expressed higher TFF3 mRNA as compared to the ER- mammary carcinoma cell line 
(MDA-MB-231) (Figure 22A). The expression of TFF3 in mammary carcinoma cell lines was 
consistent with the previous studies reported that TFF3 was associated with ER status (May 
and Westley, 1997a, Doane et al., 2006, Pandey et al., 2014). MCF-7 and T47D cells 
expressed moderate levels of TFF3 mRNA were chosen to be utilized as mammary carcinoma 








Figure 22: TFF3 mRNA expression in several of mammary carcinoma cell lines. A, 
Semi-quantitative RT-PCR analysis of TFF3 mRNA expression in several mammary 
carcinoma cell lines including MCF-7, T47D, MDA-MB-316, and BT474 (ER+ mammary 
carcinoma cells) and MDA-MB-231 (ER- mammary carcinoma cells). β-ACTIN was used as 
a loading control in semi-quantitative RT-PCR and Western blot analysis.  
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3.2.2 Forced expression of TFF3 in mammary carcinoma cells increased TFF3 
expression 
To determine the stimulatory effect of TFF3 secreted from human mammary 
carcinoma cells on the angiogenic behavior of HUVEC, MCF-7 and T47D cells were stable 
transfected with a pIRESneo3 expression vector containing TFF3 cDNA (designated as 
MCF7-TFF3 and T47D-TFF3) or a pIRESneo3 empty vector (designated as MCF7-Vec and 
T47D-Vec). The expression of TFF3 mRNA and protein in MCF-7 and T47D with forced 
expression of TFF3 was verified by semi-quantitative RT-PCR and Western blot analyses. 
Forced expression of TFF3 in MCF-7 and T47D cells increased TFF3 mRNA (Figure 23A-B) 




       
       
 
 






Figure 23: Forced expression of TFF3 in mammary carcinoma cells increased TFF3 
expression. A-B, semi-quantitative RT-PCR analysis of TFF3 mRNA in MCF-7 and T47D 
cells with forced expression of TFF3. C-D, Western blot analysis of TFF3 protein in MCF-7 
and T47D cells with forced expression of TFF3. β-ACTIN was used as a loading control in 
both semi-quantitative RT-PCR and Western blot analysis. 
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3.2.3 Forced expression of TFF3 in mammary carcinoma cells promoted HUVEC 
monolayer proliferation, cell cycle progression, and survival 
 A previous study has reported that TFF3 secreted from human mammary carcinoma 
cells is oncogenic and promoted proliferation of mammary carcinoma cells in vitro and 
increased tumor growth in xenograft models in vivo (Kannan et al., 2010). Therefore, the 
stimulatory effect of TFF3 secreted from mammary carcinoma cells on the angiogenic 
activities of HUVEC was determined by using an indirect co-culture system, in which MCF7-
TFF3 and T47D-TFF3 were plated on the membrane of the transwell inserts (0.4 μm 
membrane pores) and co-cultured with HUVEC seeded in the bottom well of the companion 
plate. Co-culturing HUVEC with MCF7-TFF3 and T47D-TFF3 increased HUVEC 
monolayer proliferation in both 10% FBS conditions for 72 hours and 0.2% FBS conditions 
for 48 hours, when compared with HUVEC co-cultured with respective control MCF7-Vec 
and T47D-Vec. TFF3 secreted from MCF7-TFF3 and T47D-TFF3 increased HUVEC 
monolayer proliferation by 35% and 40%, respectively after 72 hours when compared with 
the respective control cells (Figure 24A-B). TFF3 secreted from MCF7-TFF3 and T47D-
TFF3 promoted a small increase of HUVEC monolayer proliferation by 12% and 13%, 
respectively after 48 hours when compared with the respective control cells (Figure 24C-D). 
TFF3 secreted from mammary carcinoma cells promoted HUVEC monolayer proliferation. 
 Endothelial cell proliferation and survival are the most essential components to 
support and maintain vasculature in the tumor (Nor et al., 1999). Increased monolayer cell 
proliferation is achieved by increased cell cycle progression and/or decreased apoptotic cell 
death. The effect of TFF3 secreted from mammary carcinoma cells on HUVEC cell cycle 
progression and apoptotic cell death was determined by co-culturing HUVEC with MCF7-
TFF3 and T47D-TFF3. Cell cycle progression was analyzed by 5-bromo-2-deoxyuridine 
(BrdU) incorporation assay. BrdU labeling is as a marker of DNA synthesis. BrdU can be 
incorporated into nuclear DNA during the S-phase of the cell cycle as a substitute for 
thymidine during DNA replication (Miller and Nowakowski, 1988). TFF3 secreted from 
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MCF7-TFF3 and T47D-TFF3 increased HUVEC cell cycle progression in serum-free 
conditions by 28% and 21%, respectively when compared with the respective control cells. 
TFF3 secreted from MCF7-TFF3 and T47D-TFF3 significantly increased HUVEC 
proliferation in 10% FBS conditions by 43% and 21%, respectively when compared with the 
respective control cells (Figure 25A-B). TFF3 secreted from MCF-7 and T47D with forced 
expression of TFF3 promoted HUVEC cell cycle proliferation in both serum-free and 10% 
FBS conditions.  
 In addition to cell proliferation, resistance to apoptosis is the other essential 
component for the survival of endothelial cells. TFF3 secreted from MCF7-TFF3 and T47D-
TFF3 significantly decreased HUVEC apoptotic cell death by 52% and 39%, respectively 
when compared with the respective control cells in serum-free conditions. TFF3 secreted 
from MCF7-TFF3 and T47D-TFF3 decreased HUVEC apoptotic cell death by 61% and 50% 
respectively when compared with the respective control cells in 10% FBS conditions (Figure 
25C-D). TFF3 secreted from mammary carcinoma cells inhibited HUVEC apoptotic cell 
death in both serum-free and 10% FBS conditions. Additionally, TFF3 secreted from 
mammary carcinoma cells protected HUVEC from apoptosis induced by serum starvation. 
Therefore, TFF3 secreted from mammary carcinoma cells promoted proliferation of HUVEC 


















































































A Monolayer proliferation in 10% FBS B Monolayer proliferation in 10% FBS
C Monolayer proliferation in 0.2% FBS D Monolayer proliferation in 0.2% FBS
Figure 24: Forced expression of TFF3 in mammary carcinoma cells increased HUVEC 
monolayer proliferation. A, monolayer proliferation of HUVEC after co-culture with MCF-
7 cells with forced expression of TFF3 in 10% FBS conditions. MCF-7 cells with empty 
vector were used as control. B, monolayer proliferation of HUVEC after co-culture with 
T47D cells with forced expression of TFF3 in 10% FBS conditions. T47D cells with empty 
vector were used as control. C, monolayer proliferation of HUVEC after co-culture with 
MCF-7 cells with forced expression of TFF3 in 0.2% FBS conditions. D, monolayer 
proliferation of HUVEC after co-culture with T47D cells with forced expression of TFF3 in 





































































































































A BrdU incorporation B BrdU incorporation
C Apoptotic cell death D Apoptotic cell death
Figure 25: Forced expression of TFF3 in mammary carcinoma cells increased HUVEC 
cell cycle progression and survival. A, HUVEC cell cycle progression after 24 hours co-
culture with MCF-7 cells with forced expression of TFF3 in serum-free (SF) and 10% FBS 
conditions. MCF-7 cells with empty vector were used as control. B, HUVEC cell cycle 
progression after 24 hours co-culture with T47D with forced expression of TFF3 in serum-
free (SF) and 10% FBS conditions. T47D cells with empty vector were used as control. C, 
HUVEC apoptotic cell death after 24 hours co-culture with MCF-7 cells with forced 
expression of TFF3 in serum-free (SF) and 10% FBS conditions. D, HUVEC apoptotic cell 
death after 24 hours co-culture with T47D cells with forced expression of TFF3 in serum-free 
(SF) and 10% FBS conditions. **,  P < 0.01; ***,  P < 0.001. 
 
3.2.4 Forced expression of TFF3 in mammary carcinoma cells promoted HUVEC 
migration, invasion, and tubule formation in vitro 
 During the process of de novo tumor angiogenesis, the surrounding tissue are invaded 
by endothelial cells to generate neovascularization the tumor (Lamalice et al., 2007). I 
therefore determined the effects of TFF3 secreted from mammary carcinoma cells on the 
migratory and invasive behavior of HUVEC. Transwell migration and invasion assays were 
conducted in which HUVEC seeded on the membrane of transwell inserts (8.0 μm membrane 
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pore) were co-cultured with MCF-7 and T47D with forced expression of TFF3 plated in the 
bottom well of companion plate. TFF3 secreted from MCF7-TFF3 and T47D-TFF3 
significantly increased HUVEC migration by 121% and 100%, respectively as compared to 
the respective control cells (Figure 26A-B). Additionally, TFF3 secreted from MCF7-TFF3 
and T47D-TFF3 significantly increased HUVEC invasion by 80% and 98% respectively as 
compared to the respective control cells (Figure 26C-D). TFF3 secreted from mammary 
carcinoma cells promoted HUVEC migration and invasion.  
 HUVEC retains the ability to form three-dimensional tubules in the Matrigel thereby 
stimulating angiogenesis in vitro (Bouïs et al., 2001, Bagley et al., 2003).  The morphology of 
tubules formed by HUVEC in the Matrigel is representative of the capillary vessel formation 
in vivo (Donovan et al., 2001, Bagley et al., 2003). To determine if TFF3 secreted from 
mammary carcinoma cells stimulated angiogenic behavior of HUVEC, a tubule formation 
assay was conducted in which mammary carcinoma cells with forced expression of TFF3 
were plated on the membrane of transwell insert co-cultured with HUVEC seeded in the 
Matrigel that coated in the bottom well of the companion plate. TFF3 secreted from MCF7-
TFF3 and T47D-TFF3 significantly increased tubule length and tubule number when 
compared with the respective control cells. TFF3 secreted from MCF7-TFF3 and T47D-TFF3 
increased tubule length by 72% and 41%, respectively (Figure 27A-C) and tubule number by 
28% and 30%, respectively (Figure 27B-D) when compared with the respective control cells. 
Co-culturing HUVEC with MCF7-TFF3 and T47D-TFF3 increased tubules formed by 
HUVEC in the Matrigel when compared with HUVEC co-cultured with the respective control 
cells (Figure 27E-F). Therefore, TFF3 secreted from mammary carcinoma cells promoted 















































































A Migration B Migration
C Invasion D Invasion
 
Figure 26: Forced expression of TFF3 in mammary carcinoma cells increased HUVEC 
migration and invasion. A, HUVEC migration after 24 hours co-culture with MCF-7 cells 
with forced expression of TFF3 in serum-free conditions. MCF-7 cells with empty vector 
were used as control. B, HUVEC migration after 24 hours co-culture with T47D cells  with 
forced expression of TFF3 in serum-free conditions. T47D cells with empty vector were used 
as control.  C, HUVEC invasion after 24 hours co-culture with MCF-7 cells with forced 
expression of TFF3 in serum-free conditions. D, HUVEC invasion after 24 hours co-culture 
with T47D cells with forced expression of TFF3 in serum-free conditions.  **, P < 0.01; ***, 

















































Figure 27: Forced expression of TFF3 in mammary carcinoma cells increased HUVEC 
tubule formation in vitro. A-B, HUVEC tubule formation in vitro on Matrigel after 12 hours 
co-culture with MCF-7 cells with forced expression of TFF3. MCF-7 cells with empty vector 
were used as control. Total tubule length (A) and total tubule number (B) were assessed. C 
and D, HUVEC tubule formation in vitro on Matrigel after 12 hours co-culture with T47D 
cells with forced expression of TFF3. T47D cells with empty vector were used as control. 
Total tubule length (C) and total tubule number (D) were assessed using ImageJ analysis 
software. E and F, representative light microscopy images of HUVEC tubule formation in 
vitro in the Matrigel after 12 hours co-culture with MCF-7 and T47D cells with forced 
expression of TFF3. The light microscopy images were taken at ×40 magnification.  **, P < 


































































































































































A Tubule length B Tubule number C Tubule length
D Tubule number E Tubule formation
F Tubule formation
T47D-TFF3 T47D-Vec 200 μm 200 μm 
MCF7-TFF3 MCF7-Vec  200 μm 200 μm 
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3.2.5 Forced expression of TFF3 in mammary carcinoma cells promoted angiogenesis 
in vivo 
 To determine the potential in vivo role of TFF3 in de novo angiogenesis in mammary 
carcinoma, MCF7-Vec or MCF7-TFF3 cells were implanted into the mammary fat pad of 
immunodeficient nude mice and allowed to grow for 28 days. As previously reported, the 
tumors produced by MCF7-TFF3 were larger than those formed by MCF7-Vec After 4 weeks, 
indicating that TFF3 enhanced tumorigenicity in vivo (Kannan et al., 2010). The proteins 
expression of IL-8, CD31, and CD34 in xenografts derived from MCF7-TFF3 and control 
MCF7-Vec were examined by IHC analysis. In xenograft models, MCF-7 cells with forced 
expression of TFF3 produced tumors with increased the expression of IL-8 protein as 
compared to tumors formed by control cells (Figure 28A), suggesting that TFF3 secreted 
from MCF-7 cells with forced expression of TFF3 promoted IL-8 protein expression. Tumor 
vasculature formed in xenografts was determined by analyzing microvessel density, which 
can be quantified by the area of CD31 and/or CD34 labeled cells. Endothelial cell surface 
marker, CD31 is an indicator of angiogenesis, cells expressing CD31 have higher angiogenic 
properties (Kim et al., 2010). MCF-7 cells with forced expression of TFF3 produced tumors 
with increased area of CD31 labeled cells as compared to tumors formed by control cells 
(Figure 28A-B),  indicating TFF3 secreted from mammary carcinoma cells significantly 
increased tumor microvessel density. CD34 (podoplanin) is a small transmembrane protein of 
lymphatic endothelium and molecular marker of lymphangiogenesis (Kahn and Marks, 2002). 
Lymphatic vasculature was determined by analyzing the area of CD34-labeled cells. IHC 
analysis demonstrated that a significantly increase area of CD34 labeled cells in tumors 
derived from MCF7-TFF3 when compared with tumors derived from control MCF7-Vec 
(Figure 28A-C), indicating that TFF3 secreted from mammary carcinoma cells increased 
lymphatic vascularization. These observations suggested that TFF3 secreted from mammary 







































Figure 28: Forced expression of TFF3 in mammary carcinoma cells promoted 
angiogenesis in vivo. A, IHC analysis of IL-8, CD31, and CD34 proteins expression in 
xenograft tumors produced by control MCF7-Vec and MCF7-TFF3. B, Microvessel density 
(CD31) was assessed by quantifying percentage area of CD31 labeled cells in xenografts 
formed by control MCF7-Vec and MCF7-TFF3. C, CD34 was assessed by quantifying 
percentage area of CD34 labeled cells in xenografts formed by control MCF7-Vec and 
MCF7-TFF3. **, P < 0.01; ***, P < 0.001. 
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3.2.6 Depletion of TFF3 in mammary carcinoma cells by siRNA decreased TFF3 
expression  
 The effects of depletion of endogenous TFF3 in mammary carcinoma cells on 
angiogenic behavior of HUVEC were also determined. MCF-7 and T47D cells were 
transiently transfected with a pSilencer 2.1-U6 hygro expression vector containing TFF3 
siRNA (designated as MCF7-siTFF3 and T47D-siTFF3) or with a pSilencer 2.1-U6 hygro 
empty vector containing control siRNA (designated as MCF7-siVec and T47D-siVec) 
(Pandey et al., 2014). The expression of TFF3 mRNA and protein in MCF-7 and T47D cells 
with depletion of TFF3 was verified by semi-quantitative RT-PCR and Western blot analysis. 
Depletion of TFF3 by siRNA in MCF-7 and T47D cells decreased TFF3 mRNA (Figure 29A-
B) and decreased TFF3 protein (Figure 29C-D) when compared with the respective control 
cells. These data indicated that the endogenous expression of TFF3 in MCF-7 and T47D cells 



























       
 
 
Figure 29: Depletion of TFF3 in mammary carcinoma cells decreased TFF3 expression. 
A, semi-quantitative RT-PCR analysis of the TFF3 mRNA expression in MCF-7 cells with 
depletion of TFF3. B, semi-quantitative RT-PCR analysis of the TFF3 mRNA expression in 
T47D cells with depletion of TFF3. C, Western blot analysis of TFF3 protein in MCF-7 cells 
with depletion of TFF3. D, Western blot analysis of TFF3 protein in T47D cells with 
depletion of TFF3. β-ACTIN was used as a loading control in both semi-quantitative RT-PCR 
and Western blot analysis. 
 
 
3.2.7 Depletion of TFF3 in mammary carcinoma cells decreased HUVEC monolayer 
proliferation, cell cycle progression and survival 
The effect of depletion of TFF3 in mammary carcinoma cells on HUVEC 
proliferation and survival were determined by co-culturing HUVEC with mammary 
carcinoma cells with depletion of TFF3. When compared with the respective control cells co-
cultured with HUVEC, depletion of TFF3 in MCF-7 and T47D cells decreased HUVEC 
monolayer proliferation when compared with the respective control cells, in both 10% FBS 
conditions for 72 hours and 0.2% FBS conditions for 48 hours, respectively. Depletion of 
TFF3 by siRNA in MCF-7 and T47D cells significantly decreased HUVEC monolayer 
proliferation in 10% FBS conditions by 48% and 43%, respectively after 72 hours when 
compared with the respective control cells (Figure 30A-B). MCF-7 and T47D cells with 
depletion of TFF3 decreased HUVEC monolayer proliferation in 0.2% FBS condition by 18% 
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and 25%, respectively after 48 hours as compared with the respective control cells (Figure 
30C-D). Depletion of TFF3 in mammary carcinoma cells decreased HUVEC monolayer cell 
proliferation.  
 Co-culturing HUVEC with MCF-7 and T47D cells with depletion of TFF3 
significantly decreased HUVEC cell cycle progression, in both serum-free and 10% FBS 
conditions, when compared with HUVEC co-cultured with the respective control cells. 
Depletion of TFF3 by siRNA in MCF-7 and T47D cells significantly decreased HUVEC cell 
cycle progression in serum-free conditions by 27% and 30%, respectively as compared with 
the respective control cells (Figure 31A-B). MCF-7 and T47D cells with depletion of TFF3 
significantly decreased HUVEC cell proliferation in 10% FBS conditions by 32% or 26%, 
respectively as compared with the respective control cells (Figure 31A-B). Furthermore, co-
culture of HUVEC with MCF-7 and T47D cells with depletion of TFF3 significantly 
increased HUVEC apoptotic cell death in both serum-free and 10% FBS conditions, when 
compared with HUVEC co-cultured with the respective control cells. Depletion of TFF3 by 
siRNA in MCF-7 and T47D cells significantly increased HUVEC apoptotic cell death in 
serum-free conditions by 53% and 50%, respectively as compared with the respective control 
cells (Figure 31C-D). MCF-7 and T47D cells with depletion of TFF3 significantly increased 
HUVEC apoptotic cell death in 10% FBS conditions by 50% and 43%, respectively as 
compared with the respective control cells (Figure 31C-D). Depletion of TFF3 in mammary 






















































































B Monolayer proliferation in 10% FBS
D Monolayer proliferation in 0.2% FBSC Monolayer proliferation in 0.2% FBS
A Monolayer proliferation in 10% FBS
Figure 30: Depletion of TFF3 in mammary carcinoma cells decreased HUVEC 
monolayer proliferation. A, HUVEC monolayer proliferation after co-culture with MCF-7 
cells with depletion of TFF3 in 10% FBS conditions. MCF-7 cells with siRNA control vector 
were used as control. B, HUVEC monolayer proliferation after co-culture with T47D cells 
with depletion of TFF3 in 10% FBS conditions. MCF-7 cells with siRNA control vector were 
used as control. C, HUVEC monolayer proliferation after co-culture with MCF-7 cells with 
depletion of TFF3 in 0.2% FBS conditions. D, HUVEC monolayer proliferation after co-














































































































































D Apoptotic cell deathC Apoptotic cell death
A BrdU incorporation
Figure 31: Depletion of TFF3 in mammary carcinoma cells decreased HUVEC cell cycle 
progression and survival. A, HUVEC cell cycle progression after 24 hours co-culture with 
MCF-7 cells with depletion of TFF3 in serum-free (SF) and 10% FBS conditions. MCF-7 
cells with siRNA control vector were used as control. B, HUVEC cell cycle progression after 
24 hours co-culture with T47D cells with depletion of TFF3 in serum-free (SF) and 10% FBS 
conditions. T47D cells with siRNA control vector were used as control. C, HUVEC apoptotic 
cell death after 24 hours co-culture with MCF-7 cells with depletion of TFF3 in serum-free 
(SF) and 10% FBS conditions. D, HUVEC apoptotic cell death after 24 hours co-culture with 







3.2.8 Depletion of TFF3 in mammary carcinoma cells decreased HUVEC migration, 
invasion, and tube formation in vitro 
 The effect of depletion of TFF3 in mammary carcinoma cells on the migratory and 
invasive behavior of endothelial cells were determined by co-culturing HUVEC with 
mammary carcinoma cells with depletion of TFF3. Depletion of TFF3 in MCF-7 and T47D 
cells significantly decreased HUVEC migration by 41% and 45%, respectively (Figure 32A-B) 
and HUVEC invasion by 36% and 33%, respectively as compared with the respective control 
cells (Figure 32C-D). These data indicated that depletion of TFF3 diminished HUVEC 
migration and invasion.  
 To determine the effect of depletion of TFF3 by siRNA in mammary carcinoma cells 
on the angiogenic behaviors of HUVEC, a tubule formation assay was conducted by co-
culturing depletion of TFF3 in MCF-7 and T47D cells with HUVEC seeded in the Matrigel. 
Depletion of TFF3 in MCF-7 and T47D cells by siRNA significantly decreased tubule length 
by 46% and 36%, respectively (Figure 33A-C) and tubule number by 38% and 30%, 
respectively (Figure 33B-D) when compared with the respective control cells. Depletion of 
TFF3 in MCF-7 and T47D cells decreased tubules formed by HUVEC in the Matrigel when 
compared with the respective control cells (Figure 33E-F). These data indicated that depletion 
of TFF3 inhibited HUVEC tubule formation in vitro. Depletion of TFF3 by siRNA in 
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Figure 32: Depletion of TFF3 in mammary carcinoma cells decreased HUVEC 
migration and invasion. A, HUVEC migration after 24 hours co-culture with MCF-7 cells 
with depletion of TFF3. MCF-7 cells with siRNA control vector were used as control.  B, 
HUVEC migration after 24 hours co-culture with T47D cells with depletion of TFF3. T47D 
cells with siRNA control vector were used as control. C, HUVEC invasion after 24 hours co-
culture with MCF-7 cells with depletion of TFF3. D, HUVEC invasion after 24 hours co-




























































Figure 33: Depletion of TFF3 in mammary carcinoma cells decreased HUVEC tubule 
formation in vitro. A and B, HUVEC tubule formation in vitro on Matrigel after 12 hours co-
culture with MCF-7 cell with depletion of TFF3 in serum-free conditions. MCF-7 cells with 
siRNA control vector were used as control. Total tubule length (A) and tubule number (B) 
were assessed after 12 hours incubation. C and D, HUVEC tubule formation in vitro on 
Matrigel after 12 hours co-culture with T47D cells with depletion of TFF3 in serum-free 
conditions. T47D cells with siRNA control vector were used as control. Total tubule length 
(C) and tubule number (D) were assessed after 12 hours incubation using ImageJ analysis 
software. E and F, representative light microscopy images of HUVEC tubule formation in 
vitro on Matrigel after 12 hours co-culture with MCF-7 and T47D cells with depletion of 
TFF3. The light microscopy images were taken at ×40 magnification. **, P < 0.01; scale bar, 
200 µm.  
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3.2.9 Forced expression of TFF3 in mammary carcinoma cells increased IL-8 
expression 
 According to the previously published microarray data set (Gene Expression 
Omnibus accession number GSE3494) (Miller et al., 2005) as well as the gene expression 
profiling of MCF-7 with forced expression of TFF3 (Kannan et al., 2010), several angiogenic 
markers associated with tumor angiogenesis were selected for further validation using real-
time qPCR analysis. The qPCR analysis showed that forced expression of TFF3 in MCF-7 
cells significantly increased the gene expression of VEGF-A (1.8-fold increase), IL-8 (5.5-
fold increase) and transforming growth factor-beta (TGFB) (11.4-fold increase) as compared 
with the control MCF7-Vec (Figure 34). High level of TGF-beta is observed at the edges of 
breast tumor spread and is correlated with lymph node metastases (Dalal et al., 1993). TGF-
beta exhibits dual roles in promoting and suppression of tumor formation (Lebrun, 2012). It 
has previously reported that the motogenic activity of TFF3 for epithelial cells was not 
associated with alteration in the concentrations of TGF-beta protein and not affected by the 
presence of anti-TGF beta antibody (Dignass et al., 1994). Hence, IL-8 was selected for 
further investigation the role of IL-8 in mammary carcinoma angiogenesis stimulated by 
TFF3. The expression of VEGF-A and IL-8 in mammary carcinoma cells with forced 
expression of TFF3 was analyzed by semi-quantitative RT-PCR and Western blot or ELISA 
analysis. The qPCR analysis showed that the VEGF-A gene expression was slightly up-
regulated by TFF3, but the expression of VEGF-A mRNA in MCF-7 cells with forced 
expression of TFF3 appeared to be not markedly different from the control MCF7-Vec 
(Figure 35A). This discrepancy probably due to the semi-quantitative RT-PCR was not able 
to detect the relative differences. The protein expression of VEGF-A in MCF-7 cells with 
forced expression of TFF3 was relatively similar to the control MCF7-Vec (Figure 35B). This 
result indicated that the expression of VEGF-A was probably not regulated by TFF3. 
Mammary carcinoma cells endogenously expressed relatively low level of IL-8 mRNA 
(Figure 35C), but forced expression of TFF3 in MCF-7 and T47D cells increased IL-8 mRNA 
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level (Figure 35D-E) and increased IL-8 protein secreted to the medium (Figure 35F-G) as 
compared with the respective control cells. These data suggested that TFF3 stimulated the 
expression of IL-8 in mammary carcinoma cells.  
The functional receptors for IL-8, CXCR1 and CXCR2, are present in different cells 
including tumors and endothelial cells, and have been demonstrated to involve in tumor 
angiogenesis (Richards et al., 1997, Kitadai et al., 1998, Miller et al., 1998). Besides over-
expression of IL-8, the differential expression of IL-8 receptors in benign and malignant 
breast tissues has been reported (Miller et al., 1998). The expression of CXCR1 and CXCR2 






























































Figure 34: Real-time qPCR analysis of the gene expression of angiogenic markers 
modulated by TFF3. Fold expression indicated gene expression of angiogenic markers in 
MCF-7 cells with forced expression of TFF3 relative to control MCF7-Vec. Fold expression 
≥ 2 indicated the gene expression of angiogenic markers was up-regulated by TFF3. *, P < 
0.05; ***, P < 0.001. Pro-angiogenic markers included IL-8, interleukin 8; TGFB, 
Transforming growth factor beta; ANGPT1, Angiopoietin 1; VEGF-A, Vascular endothelial 
growth factor; TNF; Tumor necrosis factor and anti-angiogenic markers included COL18A1, 







































Figure 35: Forced expression of TFF3 in mammary carcinoma cells increased IL-8 
expression. A, semi-quantitative RT-PCR analysis of VEGF-A mRNA level in MCF-7 cells 
with forced expression of TFF3. MCF-7 cells with empty vector were used as control. B, 
Western blot analysis of VEGF-A protein in MCF-7 cells with forced expression of TFF3. C, 
semi-quantitative RT-PCR analysis of endogenous expression of IL-8 mRNA in MCF-7 and 
T47D cells. D, semi-quantitative RT-PCR analysis of the expression of IL-8 mRNA in MCF-
7 with forced expression of TFF3. E, semi-quantitative RT-PCR analysis of the expression of 
IL-8 mRNA in T47D cells with forced expression of TFF3. T47D cells with empty vector 
were used as control. F, ELISA analysis of IL-8 protein secreted to the medium by MCF-7 
cells with forced expression of TFF3. G, ELISA analysis of IL-8 protein secreted to the 
medium by T47D cells with forced expression of TFF3. β-ACTIN was used as a loading 
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Figure 36: Expression of CXCR1 and CXCR2 mRNA in mammary carcinoma cells with 
forced expression of TFF3. A, semi-quantitative RT-PCR analysis of the expression of 
CXCR1 and CXCR2 mRNA in MCF-7 cells with forced expression of TFF3. MCF-7 cells 
with empty vector were used as control. B, semi-quantitative RT-PCR analysis of the 
expression of CXCR1 and CXCR2 mRNA in T47D cells with forced expression of TFF3. 
T47D cells with empty vector were used as control. β-ACTIN was used as a loading control 
in semi-quantitative RT-PCR. 
 
3.2.10 Forced expression of TFF3 in mammary carcinoma cells increased IL-8 
promoter activity   
 IL-8 protein is secreted in normal tissue to maintain homeostasis, but its expression is 
rapidly increased in response to pro-inflammatory cytokines or growth factors. The 
production of IL-8 is regulated by the combinatorial activation of transcription factors and 
their interaction with the IL-8 promoter gene (Lakshminarayanan et al., 1998, Roebuck et al., 
1999). It is known that the proximal region of IL-8 promoter contains functional binding sites 
for the transcription factors namely NF-IL-6 (-94 to -81 bp), AP-1 (-126 to -120 bp) and NF-
κB (-80 to -70 bp) (Mukaida et al., 1994). Besides these binding sites, additional potential 
binding sites for STAT3 (-245 to -237 bp) have also been identified (Oka et al., 2010). Firstly, 
I determined if TFF3 stimulates IL-8 promoter activity, MCF-7 and T47D cells with forced 
expression of TFF3 were transiently transfected with a full length of IL-8 promoter reporter 
vector (full length, -4800 to + 104 bp) and a pRL-CMV control reporter vector. MCF-7 and 
T47D cells with forced expression of TFF3 significantly increased IL-8 promoter activity by 
4.5-fold and 2.2-fold respectively when compared with the respective control cells (Figure 
B    RT-PCR 
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37A-B), indicating that TFF3 stimulated IL-8 promoter activity in mammary carcinoma cells. 
The cooperative actions of NF-κB, AP-1, and NF-IL-6 transcription factors increase the 
expression of IL-8 protein (Mukaida et al., 1990, Mukaida et al., 1994, Roebuck, 1999). 
Secondly, I determined if these transcription factors are involved in enhancing IL-8 promoter 
activity in mammary carcinoma cells stimulated by TFF3, MCF-7 and T47D with forced 
expression of TFF3 were transiently transfected with a shorter IL-8 promoter, pGL-IL8-152 
reporter vector (-152 to +44 bp) containing transcription factors namely NF-κB, AP-1, and 
NF-IL-6 , and a pRL-CMV control reporter vector. MCF-7 and T47D cells with forced 
expression of TFF3 increased IL-8 promoter activity when compared with the respective 
control MCF7-Vec and T47D-Vec transiently transfected with pGL-IL8-152 reporter vector 
(Figure 37C-D). The binding sites for AP-1, NF-IL-6 and NF-κB, present at the proximal 
region of IL-8 promoter, were also involved in enhancing IL-8 promoter activity stimulated 
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Figure 37: Forced expression of TFF3 in mammary carcinoma cells increased IL-8 
promoter activity. A, IL-8 promoter activity (full length, -4800 to + 104 bp) in MCF-7 cells 
with forced expression of TFF3. MCF-7 cells with empty vector were used as control.  B, IL-
8 promoter activity in T47D cells with forced expression of TFF3. T47D cells with empty 
vector were used as control. C, IL-8 promoter activity in MCF7-Vec and MCF7-TFF3 
transiently transfected with pGL-IL8-152 reporter (-152 to +44 bp). D, IL-8 promoter activity 
in T47D-Vec and T47D-TFF3 transiently transfected pGL-IL8-152 reporter. Reporter 
constructs consist of 5' flanking regions of the IL-8 gene were subcloned upstream of a 
luciferase reporter gene in the pGL3 basic vector. pGL-IL8-152 reporter construct 
encompassing nucleotides -152 to +44 of the IL-8 promoter, which was consist of NF-IL6,  
AP-1, NFκB binding sites. The TATA box, and the NF-IL6, NFκB and AP-1 binding sites are 
located at -13, -70, -80 and -120, respectively. Fold stimulation was measured by the ratio 
firefly luciferase of IL-8 reporter in MCF7-TFF3 and T47D-TFF3 to firefly luciferase of IL-8 








3.2.11 Depletion of TFF3 in mammary carcinoma cells decreased IL-8 promoter 
activity  
To determine if depletion of TFF3 by siRNA in mammary carcinoma cells decreased 
IL-8 expression, mammary carcinoma cells with depletion of TFF3 were transiently 
transfected with an IL-8 reporter vectors including IL-8 promoter (-1480 to +104 bp) or pGL-
IL8-152 reporter vector, together with a pRL-CMV control reporter vector. MCF-7 and T47D 
cells with depletion of TFF3 and transiently transfected with a full length of IL-8 promoter (-
1480 to +104 bp) exhibited significantly decreased IL-8 promoter activity by 3.4-fold or 1.7-
fold respectively when compared with the respective control cells (Figure 38A-B). 
Additionally, MCF-7 and T47D cells with depletion of TFF3 and transiently transfected with 
a shorter IL-8 promoter, pGL-IL8-152 reporter vector, exhibited significantly decreased IL-8 
promoter activity when compared with the respective control cells (Figure 38C-D). These 
data indicated that depletion of TFF3 in mammary carcinoma cells by siRNA abrogated IL-8 
promoter activity and the transcription factors namely AP-1, NF-IL-6 and NF-κB were 
necessary for TFF3-stimulated IL-8 promoter activity. Subsequently, depletion of TFF3 in 
MCF-7 and T47D cells decreased IL-8 mRNA (Figure 39A-B) and IL-8 protein secreted to 
the medium (Figure 39C-D) when compared with the respective control cells. Depletion of 
TFF3 by siRNA reduced IL-8 promoter activity and subsequently decreased the expression of 
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Figure 38: Depletion of TFF3 in mammary carcinoma cells decreased IL-8 promoter 
activity. A, IL-8 promoter reporter activity (full length, -4800 to + 104 bp) in MCF-7 cells 
with depletion of TFF3. MCF-7 cells with empty vector were used as control.  B, IL-8 
promoter reporter activity (full length, -4800 to + 104 bp) in T47D cells with depletion of 
TFF3. T47D cells with empty vector were used as control. C, IL-8 promoter activity in 
MCF7-Vec and MCF7-TFF3 transiently transfected with a shorter IL-8 promoter namely 
pGL-IL8-152 reporter. D, IL-8 promoter activity in T47D-Vec and T47D-TFF3 transiently 














































Figure 39: Depletion of TFF3 in mammary carcinoma cells decreased IL-8 expression. A, 
semi-quantitative RT-PCR analysis of IL-8 mRNA in MCF-7 cells with depletion of TFF3. 
MCF-7 cells with siRNA control vector were used as control. B, semi-quantitative RT-PCR 
analysis of IL-8 mRNA in T47D cells depletion of TFF3. T47D cells with siRNA control 
vector were used as control. C, ELISA analysis of IL-8 protein secreted to the medium by 
MCF-7 cells with depletion of TFF3. D, ELISA analysis of IL-8 protein secreted to the 
medium by T47D cells with depletion of TFF3. β-ACTIN was used as a loading control in 
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3.2.12 Depletion of IL-8 by siRNA abrogated the stimulatory effect of TFF3 on 
HUVEC migration, invasion, and tubule formation in vitro 
 To determine if IL-8 mediated the stimulatory effect of TFF3 on the angiogenic 
behaviors of HUVEC, an IL-8 siRNA was employed to deplete the expression of IL-8 in 
MCF-7 cells with forced expression of TFF3. Hence, MCF-7 cells with forced expression of 
TFF3 were transiently transfected with an IL-8 siRNA (designated as siIL-8) or a scrambled 
control siRNA (designated as siControl). MCF-7 cells with forced expression of TFF3 and 
transiently transfected with IL-8 siRNA appeared to relatively decrease the expression of IL-8 
mRNA (after 24 hours transfection) (Figure 40A).  Semi-quantitative RT-PCR was not 
sensitive enough to detect the relative discrepancy of the IL-8 mRNA expression between 
MCF-7 cells with forced expression of TFF3 transiently transfected with IL-8 siRNA and 
those transiently transfected with scrambled control siRNA. Therefore, ELISA was used to 
quantify the concentration of IL-8 protein secreted to the medium.  MCF-7 cells with forced 
expression of TFF3 and transiently transfected with IL-8 siRNA decreased IL-8 protein 
secreted to the medium (after 48 hours and 72 hours transfection) (Figure 40B-C) when 
compared with the respective siControl cells. IL-8 siRNA selectively depleted the expression 
of IL-8 in MCF-7 cells with forced expression of TFF3 and vector control cells. Subsequently, 
HUVEC were co-cultured with MCF7-Vec or MCF7-TFF3 with depletion of IL-8. Depletion 
of IL-8 in MCF7-Vec significantly decreased HUVEC migration by 42% (Figure 41A) and 
invasion by 42% (Figure 41B) when compared with the MCF7-Vec transiently transfected 
with control siRNA. Depletion of IL-8 in MCF7-TFF3 significantly decreased HUVEC 
migration by 74% (Figure 41A) and invasion by 65% (Figure 41B) when compared with 
MCF7-TFF3 transiently transfected with control siRNA, indicating that the depletion of IL-8 
by siRNA abrogated the stimulatory effect of TFF3 on HUVEC migration and invasion. 
Furthermore, MCF7-Vec with depletion of IL-8 by siRNA significantly decreased tubule 
length by 43% (Figure 41C) and tubule number by 37% (Figure 41D) when compared with 
MCF7-Vec transiently transfected with control siRNA, indicating that depletion of IL-8 by 
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siRNA inhibited angiogenic effect of IL-8 on HUVEC tubule formation in vitro. Depletion of 
IL-8 in MCF7-TFF3 significantly decreased tubule length by 61% (Figure 41C) and tubule 
number by 58% (Figure 41D) when compared with MCF7-TFF3 transiently transfected with 
control siRNA, indicating that depletion of IL-8 by siRNA abrogated the stimulatory effects 
of TFF3 on HUVEC tubule formation in vitro. Depletion of IL-8 by siRNA in MCF-7 cells 
with forced expression of TFF3 significantly decreased tubules formed by the HUVEC in the 
Matrigel when compared with the control cells (Figure 41E). These data indicated that 
depletion of IL-8 by siRNA decreased the stimulatory effects of TFF3 on HUVEC tubule 
formation in vitro. Depletion of IL-8 in MCF-7 cells by siRNA abrogated the ability of TFF3 








































Figure 40: Depletion of IL-8 in mammary carcinoma cells with forced expression of 
TFF3 by siRNA decreased IL-8 expression. A, semi-quantitative RT-PCR of the expression 
of IL-8 mRNA in MCF-7 cells with forced expression of TFF3 transiently transfected with 
control siRNA or IL-8 siRNA after 24 hours transfection. Scrambled control siRNA was used 
as control. MCF7-Vec transiently transfected with scrambled control siRNA was used as 
baseline. B, ELISA analysis of IL-8 protein secreted to the medium by MCF-7 cells with 
forced expression of TFF3 transiently transfected with control siRNA or IL-8 siRNA after 48 
hours transfection. C, ELISA analysis of IL-8 protein secreted to the medium by MCF-7 with 
forced expression of TFF3 transiently transfected with control siRNA or IL-8 siRNA after 72 
hours transfection. β- ACTIN was used as a loading control in semi-quantitative RT-PCR. 
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Figure 41: Depletion of IL-8 in mammary carcinoma cells by siRNA abrogated 
stimulatory effect of TFF3 on HUVEC migration, invasion, and tubule formation in 
vitro. A, HUVEC migration after 24 hours co-culture with MCF-7 cells with forced 
expression of TFF3 transiently transfected with control siRNA or IL-8 siRNA in serum-free 
conditions. Scrambled control siRNA was used as control. MCF7-Vec transiently transfected 
with scrambled control siRNA was used as baseline. B, HUVEC invasion after 24 hours co-
culture with MCF-7 cells with forced expression of TFF3 transiently transfected with control 
siRNA or IL-8 siRNA in serum-free conditions. C and D, HUVEC tubule formation in vitro 
on Matrigel after 12 hours co-culture with MCF-7 cells with forced expression of TFF3 
transiently transfected with control siRNA or IL-8 siRNA in serum-free conditions for 12 
hours incubation. Total tubule length (C) and tubule number (D) was assessed using ImageJ 
analysis software. E, representative light microscopy images of HUVEC tubule formation in 
vitro in the Matrigel after 12 hours co-culture of with MCF7-Vec and MCF7-TFF3 transiently 
transfected with control siRNA or IL-8 siRNA. The light microscopy images were taken at 
×40 magnification. **, P < 0.01 as compared with MCF7-Vec and MCF7-TFF3 transiently 
transfected with control siRNA; scale bar, 200 µm.   
 
3.2.13 Blocking IL-8 in mammary carcinoma cells by anti-IL-8 monoclonal antibody 
inhibited the stimulatory effect of TFF3 on HUVEC tubule formation in vitro 
 The development of humanized monoclonal antibodies against IL-8 has been 
exploited to inhibit the tumor-promoting effect of IL-8 in melanoma and bladder xenograft 
models (Huang et al., 2002, Mian et al., 2003). Humanized anti-IL-8 monoclonal antibodies 
(e.g., ABX-IL8) bind to IL-8 and prevent it from binding to its receptors (Yang et al., 1999, 
Huang et al., 2002, Mian et al., 2003). Administration of anti-IL-8 antibodies suppress IL-8 
signaling on tumor progression and development (Huang et al., 2002). Accordingly, an anti-
IL-8 monoclonal antibody was utilized for blocking IL-8 in MCF-7 cells with forced 
expression of TFF3 and vector control cells. To initially determine the effect of blocking IL-8 
in control MCF7-Vec on the IL-8-mediated HUVEC tubule formation in vitro, HUVEC were 
co-cultured with MCF7-Vec treated with different concentration of anti-IL-8 monoclonal 
antibody (2.5, 5.0, 10.0, 20.0, 50.0 µg/mL) or IgG control (50.0 µg/mL) . Blocking IL-8 in 
MCF7-Vec by different concentration of anti-IL-8 monoclonal antibody decreased tubule 
length in a concentration-dependent manner, with 57% reduction of HUVEC tubule formation 
in vitro at 50 µg/mL anti-IL-8 monoclonal antibody (Figure 42A). These data indicated that 
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blocking of IL-8 in control MCF7-Vec by anti-IL-8 monoclonal antibody decreased HUVEC 
tubule formation in vitro.  
 To determine if blocking of IL-8 by anti-IL-8 monoclonal antibody inhibited the 
stimulatory effect of TFF3 on HUVEC tubule formation in vitro, HUVEC were co-cultured 
with MCF7-Vec and MCF7-TFF3 treated with 50 µg/mL of anti-IL-8 monoclonal antibody or 
IgG control. Blocking of IL-8 in MCF7-Vec by anti-IL-8 monoclonal antibody significantly 
decreased tubule length by 39% (Figure 42B) and tubule number by 40% (Figure 42C) when 
compared with MCF7-Vec treated with IgG control, indicating that inhibition of IL-8 in 
MCF7-Vec by anti-IL-8 monoclonal antibody attenuated IL-8-mediated angiogenesis in vitro. 
Blocking of IL-8 in MCF7-TFF3 by anti-IL-8 monoclonal antibody significantly decreased 
tubule length by 52% (Figure 42B) and tubule number by 49% (Figure 42C) when compared 
with MCF7-TFF3 treated with IgG control, indicating that blocking of IL-8 in MCF7-TFF3 
cells by anti-IL-8 monoclonal antibody inhibited the stimulatory effect of TFF3 in 
angiogenesis in vitro. Blocking of IL-8 in MCF7-Vec or MCF7-TFF3 by anti-IL-8 
monoclonal antibody significantly decreased tubules formed by HUVEC in the Matrigel when 
compared with the respective cells treated with IgG control (Figure 42D). Depletion of IL-8 
in MCF-7 cells by anti-IL-8 monoclonal antibody inhibited the ability of TFF3 to stimulate 
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Figure 42: Blocking IL-8 in mammary carcinoma cells by anti-IL-8 monoclonal 
antibody inhibited the ability of TFF3 on stimulation of HUVEC tubule formation in 
vitro. A, HUVEC tubule formation in vitro in the Matrigel after 12 hours co-culture with 
MCF7-Vec treated with different concentration of anti-IL-8 monoclonal antibody (2.5, 5.0, 
10.0, 20.0, 50 µg/mL) or IgG control in serum-free conditions. IgG was used as control. Total 
tubule length was assessed after 12 hours incubation. B and C, HUVEC tubule formation in 
vitro on Matrigel after 12 hours co-culture with control vector cells or MCF-7 cells with 
forced expression of TFF3 treated with IgG control and 50 µg/mL of anti-IL-8 monoclonal 
antibody in serum-free conditions. Total tubule length (B) and tubule number (C) was 
assessed using ImageJ analysis software. D, representative light microscopy images of 
HUVEC tubule formation in vitro in the Matrigel after 12 hours co-culture with MCF7-Vec 
or MCF7-TFF3 treated with IgG control rand 50 µg/mL anti IL-8 monoclonal antibody. IgG 
control was used as control. MCF7-Vec treated with IgG control was used as baseline. The 
light microscopy images were taken at x40 magnification. *, P < 0.05; **, P < 0.01 as 
compared to MCF7-Vec and MCF7-TFF3 treated with IgG control; scale bar, 200 µm.  
 
3.2.14 Blocking CXCR2 in HUVEC inhibited IL-8 mediated stimulatory effect of TFF3 
on HUVEC tubule formation in vitro 
IL-8 receptors CXCR1 and CXCR2 are highly expressed in cancer and endothelial 
cells to mediate the angiogenic function of IL-8 in tumor angiogenesis (Holmes et al., 1991, 
Cerretti et al., 1993). Neutralizing antibody to IL-8, CXCR1 or CXCR2 has been reported to 
inhibit endothelial cell proliferation and capillary tube formation (Li et al., 2005). To 
determine whether blocking CXCR2 in HUVEC inhibited tubule formation in vitro, parental 
HUVEC were treated with different concentration of anti-CXCR2 monoclonal antibody. 
HUVEC tubule formation in vitro was inhibited by anti-CXCR2 monoclonal antibody in a 
concentration-dependent manner, with 44% reduction of tubule length at 20 µg/mL anti-
CXCR2 monoclonal antibody (Figure 43A). These data indicated that anti-CXCR2 
monoclonal antibody inhibited HUVEC tubule formation in vitro in a concentration-
dependent manner.  
To determine whether the effect of TFF3 on stimulation of HUVEC tubule formation 
in vitro was mediated by IL-8 through CXCR1 or CXCR2 receptor, MCF7-Vec and MCF7-
TFF3 co-cultured with HUVEC were treated with 20 µg/mL anti-CXCR2 or anti-CXCR1 
monoclonal antibody respectively. Co-culturing MCF7-Vec and MCF7-TFF3 with HUVEC 
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treated with anti-CXCR1 monoclonal antibody exhibited similar or slight changes in tubule 
length and tubule number when compared with the respective cells co-cultured with HUVEC 
treated with IgG control (Figure 44A-C). Anti-CXCR1 monoclonal antibody presumably was 
not able to affect the ability of TFF3 on stimulation of HUVEC tubule formation in vitro. 
However, co-culturing MCF7-Vec with HUVEC treated with anti-CXCR2 monoclonal 
antibody decreased tubule length by 41% (Figure 43B) and tubule number by 47% (Figure 
43C) when compared with HUVEC treated with IgG control. Co-culturing MCF7-TFF3 with 
HUVEC treated with anti-CXCR2 monoclonal antibody significantly decreased tubule length 
by 66% (Figure 43B) and tubule number by 58% (Figure 43C) when compared with HUVEC 
treated with IgG control. Co-culturing MCF7-Vec and MCF7-TFF3 with HUVEC treated 
with anti-CXCR2 monoclonal antibody decreased tubules in the Matrigel when compared 
with MCF7-Vec and MCF7-TFF3 co-cultured with HUVEC treated with IgG control (Figure 
43D). These observations indicated that blocking of CXCR2 in HUVEC by anti-CXCR2 
monoclonal antibody inhibited the effect of TFF3 on the stimulation of angiogenic behaviors 
of HUVEC mediated by IL-8 through CXCR2 receptor. It is also possible that the anti-
CXCR2 monoclonal antibody is disrupting IL-8-independent events because CXCR2 binds to 
































Figure 43: Blocking of CXCR2 in HUVEC by anti-CXCR2 monoclonal antibody 
inhibited IL-8 mediated stimulatory effect of TFF3 on HUVEC tubule formation in vitro. 
A, HUVEC tubule formation in vitro, in which HUVEC treated with different concentration 
of anti-CXCR2 monoclonal antibody (1.25, 2.5, 5.0, 10.0, 20 µg/mL) or IgG control. IgG was 
used as control. MCF7-Vec co-cultured with HUVEC treated with IgG control was used as 
baseline. Total tubule length was assessed after 12 hours incubation. B and C, HUVEC tubule 
formation in vitro, in which control vector cells or MCF-7 cells with forced expression of 
TFF3 co-cultured with HUVEC treated with IgG control and 20 µg/mL of anti-CXCR2 
monoclonal antibody. Total tubule length (B) and tubule number (C) was assessed by ImageJ 
analysis software. D, representative light microscopy images of HUVEC tubule formation in 
vitro, in which MCF7-Vec and MCF7-TFF3 co-cultured with HUVEC treated with IgG 
control and 20 µg/mL of anti-CXCR2 monoclonal antibody. IgG  was used as control. MCF7-
Vec co-cultured with HUVEC treated with IgG control was used as baseline. The light 
microscopy images were taken at ×40 magnification. **, P < 0.01 as compared to HUVEC 
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Figure 44: Blocking of CXCR1 in HUVEC by anti-CXCR1 monoclonal antibody did not 
affect IL-8 mediated stimulatory effect of TFF3 on HUVEC tubule formation in vitro. A 
and B, HUVEC tubule formation in vitro,  in which control vector cells or MCF-7 cell with 
forced expression of TFF3 co-cultured with HUVEC treated with IgG control and 20 µg/mL 
anti-CXCR1 monoclonal antibody. Total tubule length (A) and tubule number (B) was 
assessed by ImageJ analysis software. C, representative light microscopy images of HUVEC 
tubule formation in vitro, in which MCF7-Vec and MCF7-TFF3 co-cultured with HUVEC 
treated with IgG control or 20 µg/mL of anti-CXCR1 monoclonal antibody. IgG was used as 
control. MCF7-Vec co-cultured with HUVEC treated with IgG control was used as baseline. 
The light microscopy images were taken at ×40 magnification. n.s indicated not significant, as 








IgG control           +         +               -           -










































IgG control            +          +               -           -





























B Tubule numberA Tubule length
C Tubule formation









3.2.15 Forced expression of TFF3 in mammary carcinoma cells promoted activation of 
STAT3 and subsequently partially increased IL-8 expression   
 In addition to the three main transcription factors NF-κB, NF-IL-6, and AP-1, TFF3 
may be stimulated other transcription factors for regulation of IL-8 expression. STAT3 
regulated IL-8 expression presumably through direct binding to its consensus binding site at 
the IL-8 promoter region (Oka et al., 2010). To determine if TFF3 stimulated activation of 
STAT3 (tyrosine 705 phosphorylation) in MCF-7 cells, the expression of total STAT3 and 
Y705 phosphorylated STAT3 protein (STAT3α and STAT3β isoforms) in MCF-7 cells with 
forced expression of TFF3 were analyzed by Western blot analysis. When compared with 
control MCF7-Vec, forced expression of TFF3 in MCF-7 cells increased Y705 
phosphorylated STAT3 proteins (STAT3α and STAT3β isoforms) and exhibited relatively 
similar level of total STAT3 protein (Figure 45A), indicating that TFF3 increased Y705 
phosphorylated STAT3 protein and presumably not affected the total STAT3 protein 
expression. 
 To determine if TFF3 stimulated activation of STAT3 in MCF-7 cells and involved in 
the regulate IL-8 expression, STAT3 siRNA was employed to deplete STAT3 and therefore 
decreased STAT3 activity in mammary carcinoma cells. MCF-7 cells with forced expression 
of TFF3 were transiently transfected with a pcDNA containing STAT3 siRNA (siSTAT3) or 
pcDNA vector containing control siRNA (siControl). The expressions of total STAT3 and 
Y705 phosphorylated STAT3 in MCF7-Vec and MCF7-TFF3 with depletion of STAT3 were 
analyzed by Western blot analysis. Depletion of STAT3 in MCF-7 cells with forced 
expression of TFF3 decreased total STAT3 protein and Y705 phosphorylated STAT3 protein 
(Figure 45B) when compared with the respective cells transiently transfected with control 
siRNA. Subsequently, MCF7-Vec and MCF7-TFF3 with depletion of STAT3 were 
transiently transfected with a full length of IL-8 promoter reporter vector (-1480 to + 104 bp) 
and a pRL-CMV control reporter vector. Depletion of STAT3 by siRNA in MCF7-Vec and 
MCF7-TFF3 resulted in a small but consistently decreased of IL-8 promoter activity when 
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compared with the respective siControl cells (Figure 45C), indicating that STAT3 siRNA 
partially inhibited the effect of TFF3 on stimulation of IL-8 promoter activity. Additionally, 
depletion of STAT3 by siRNA partially abrogated the ability of TFF3 to regulate the 
expression of IL-8 and resulted in a small but consistently decreased expression of IL-8 
mRNA (Figure 45D) and IL-8 protein secreted to the medium (Figure 45E) when compared 
with the respective siControl cells. These observations indicated that depletion of STAT3 by 
siRNA in MCF-7 cells partially reduced IL-8 promoter activity and subsequently led to a 












































Figure 45: Forced expression of TFF3 in mammary carcinoma cells promoted the 
activation of STAT3 and subsequently partially increased IL-8 expression. A, Western 
blot analysis of total STAT3 protein and Y705 phosphorylated STAT3 (pSTAT3) in MCF-7 
cells with forced expression of TFF3. B, Western blot analysis of total STAT3 and Y705 
phosphorylated STAT3 protein in MCF7-Vec and MCF7-TFF3 transiently transfected with 
pcDNA vector containing STAT3 siRNA or control siRNA. C, IL-8 promoter activity in 
MCF7-Vec and MCF7-TFF3 with depletion of STAT3 transiently transfected with an IL-8 
promoter reporter vector and a pRL-CMV control reporter vector. Scrambled control siRNA 
was used as control. MCF7-Vec transiently transfected with scrambled control siRNA was 
used as baseline. D, semi-quantitative analysis of IL-8 mRNA expression in MCF-7 cells with 
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forced expression of TFF3 transiently transfected with pcDNA vector containing STAT3 
siRNA or control siRNA. E, ELISA analysis of IL-8 protein secreted to the medium by 
MCF7-Vec and MCF7-TFF3 transiently transfected with pcDNA vector containing STAT3 
siRNA or control siRNA. β-ACTIN was used as a loading control in semi-quantitative RT-
PCR and Western blot analysis.  **, P < 0.01 as compared MCF7-Vec or MCF7-TFF3 
transiently transfected with control siRNA. 
 
3.2.16 Depletion of STAT3 by siRNA partially abrogated stimulatory effect of TFF3 on 
HUVEC migration, invasion, and tubule formation in vitro 
 To determine if STAT3 mediated TFF3 enhancement of angiogenic behaviors of 
endothelial cells, HUVEC were co-culture with MCF7-Vec and MCF7-TFF3 with depletion 
of STAT3. Depletion of STAT3 by siRNA in MCF7-Vec partially decreased HUVEC 
migration by 36% (Figure 46A) and invasion by 31% (Figure 46B) when compared with 
MCF7-Vec transiently transfected with control siRNA. Depleted expression of STAT3 in 
MCF7-TFF3 partially decreased HUVEC migration by 47% (Figure 46A) and invasion by 
58% (Figure 46B) when compared with MCF7-TFF3 transiently transfected with control 
siRNA. These observations indicated that depletion of STAT3 by siRNA partially abrogated 
the ability of TFF3 to stimulate HUVEC migration and invasion.  
 Furthermore, depletion of STAT3 in MCF7-Vec significantly decreased tubule length 
by 32% (Figure 46C) and tubule number by 31% (Figure 46D) when compared with MCF7-
Vec transiently transfected with control siRNA. Depletion of STAT3 in MCF7-TFF3 
significantly decreased tubule length by 46% (Figure 46C) and tubule number by 58% (Figure 
46D) when compared with MCF7-TFF3 transiently transfected with control siRNA. Depleted 
expression of STAT3 by siRNA in MCF7-Vec and MCF-TFF3 significantly decreased 
tubules formed by the HUVEC when compared with the respective siControl cells (Figure 
46E). These observations indicated that depletion of STAT3 by siRNA partially abrogated the 


































Figure 46: Depletion of STAT3 in mammary carcinoma cells by siRNA partially 
abrogated stimulatory effect of TFF3 on HUVEC migration, invasion, and tubule 
formation in vitro. A, HUVEC migration after 24 hours co-culture with MCF-7 cells with 
forced expression of TFF3 transiently transfected with STAT3 siRNA. Scrambled control 
siRNA was used as control. MCF7-Vec transiently transfected with scrambled control siRNA 
was used as baseline. B, HUVEC invasion after 24 hours co-culture with MCF-7 cells with 
forced expression of TFF3 transiently transfected with control siRNA or STAT3 siRNA. C 
and D, HUVEC tubule formation in vitro in the Matrigel after 12 hours co-culture with MCF-
7 cells with forced expression of TFF3 transiently transfected with control siRNA or STAT3 
siRNA in serum-free conditions. Total tubule length (C) and tubule number (D) was assessed. 
E, representative light microscopy images of HUVEC tubule formation in vitro in the 
Matrigel after 12 hours co-culture of with MCF7-Vec and MCF7-TFF3 transiently transfected 
with control siRNA or STAT3 siRNA. The light microscopy images were taken at ×40 
magnification. **, P < 0.01 as compared to MCF7-Vec or MCF7-TFF3 transiently transfected 
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3.3.1 Forced expression of TFF3 in mammary carcinoma cells promoted de novo 
angiogenesis  
 TFF3 has been reported increased its expression in mammary carcinoma and the 
expression of TFF3 is positively associated with metastasis and poor survival outcome of 
patients with ER+ mammary carcinoma (Smid et al., 2006, Kannan et al., 2010, Pandey et al., 
2014). Increased TFF3 expression in mammary carcinoma cells promotes tumor growth and 
metastatic progression by promoting cell survival and invasion (Kannan et al., 2010, Ahmed 
et al., 2012, Pandey et al., 2014). It is known that TFF3 is an estrogen-responsive gene and its 
expression is associated with the ER status in human mammary carcinoma (May and Westley, 
1997a, Gruvberger et al., 2001). However,  there is a subset of ER- mammary carcinoma cells 
that express high levels of TFF3 (Doane et al., 2006). Herein, I have demonstrated that ER+ 
mammary carcinoma cells endogenously expressed TFF3 protein.  Both MCF-7 and T47D 
cells expressed moderate levels of TFF3 and were utilized as mammary adenocarcinoma cell 
models. HUVEC was used as an in vitro model to investigate the stimulatory effect of TFF3 
secreted from mammary carcinoma cells on the angiogenic behaviors of endothelial cells. 
TFF3 secreted from mammary carcinoma cells promoted HUVEC monolayer proliferation, 
cell cycle progression, survival, migration, invasion and tubule formation in vitro. Depletion 
of TFF3 in mammary carcinoma cells by siRNA diminished angiogenic behaviors of HUVEC. 
 During neovascularization, endothelial cells invade to avascular environments to 
generate vasculature in the tumor (Hanahan and Folkman, 1996). The survival of endothelial 
cells is one of the major factors for maintaining the stability of vascularity in the growing 
tumor (Nor et al., 1999). It has been reported that TFF3 decreased apoptotic cell death of 
MCF-7 cells by approximately 10% in serum free conditions (Kannan et al., 2010). I have 
demonstrated that TFF3 secreted from MCF7 cells decreased HUVEC apoptotic cell death by 
61% in 10%FBS condition and 52% in serum free conditions. Similarly, Artemin secreted 
from mammary carcinoma cells decreased apoptotic cell death of endothelial cells in serum 
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deprived condition by 20% (Banerjee et al., 2012). It is possible that the survival of 
endothelial cells was not affected by the supplemental function of serum but is dependent on 
the pro-survival effect of TFF3. I have demonstrated that TFF3 secreted by mammary 
carcinoma cells with forced expression of TFF3 promoted HUVEC proliferation and survival. 
TFF3 may also a pro-survival factor for endothelial cells. It has previously been reported that 
TFF3 is a pro-survival factor for cancer cells (Chen et al., 2000, Taupin et al., 2000b, Regalo 
et al., 2005, Kannan et al., 2010) and induced resistance to serum deprivation and drug-
induced apoptosis in colon carcinoma cells (Emami et al., 2004). Forced expression of TFF3 
increased Bcl-2 (Kannan et al., 2010), which is an anti-apoptotic protein (Yip and Reed, 2008) 
and decreased Bax, which is a pro-apoptotic Bcl-2-family proteins (Yip and Reed, 2008, 
Czabotar et al., 2009). Increased the expression of Bcl-2 mediated TFF3-stimulated resistance 
to serum deprivation and doxorubicin-induced apoptosis in mammary carcinoma cells 
(Kannan et al., 2010). TFF3 appears to be linked with multiple survival pathways including 
mitogen-activated protein kinase (MAPK) (Taupin et al., 1999), phosphatidylinositol-3-
kinase-Akt (PI3K-Akt) (Kinoshita et al., 2000b, Taupin et al., 2000b), STAT3 (Rivat et al., 
2005) and nuclear factor kappa B (NF-κB) (Chen et al., 2000). Enhanced Bcl2 expression is 
probably a consequence of activation of survival pathways, resulting from increased TFF3 
expression (Kannan et al., 2010). Additionally, I have demonstrated that forced expression of 
TFF3 in mammary carcinoma cells promoted HUVEC migration and invasion. TFF peptides 
induced cellular invasion of kidney and colonic carcinoma cells through autocrine loops 
(Emami et al., 2001). TFF3 also promoted colon carcinoma cell migration through repression 
of E-cadherin-catenin complex formation and loss of cell adhesion (Emami et al., 2004).  
 De novo angiogenesis is a fundamental requirement for tumor growth and metastasis 
of mammary carcinoma. High microvessel density has been associated with metastasis and 
poor survival in node-negative mammary carcinoma (Schneider and Miller, 2005, Fox et al., 
2007, Ran et al., 2010). TFF3 has been implicated in tumor progression by promoting cell 
scattering and cellular invasion (Rodrigues et al., 2003b). Increased the expression of TFF3 
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was positively correlated with microvessel density as evaluated by CD31 and  CD34 of 
endothelial markers in gastric carcinoma (Dhar et al., 2005) and mammary carcinoma 
(Ahmed et al., 2012). Concordantly, I have demonstrated that TFF3 secreted from mammary 
carcinoma cells promoted HUVEC tubule formation in vitro. Hence, TFF3 secreted from 
mammary carcinoma cells stimulated angiogenic behaviors of HUVEC to promote in vitro 
angiogenesis. In xenograft models, TFF3 enhanced microvessel density (increased areas of 
CD31 and CD34 labeled cells) in the tumors produced by MCF-7 cells and suggesting that 
TFF3 promoted in vivo angiogenesis. These observations further supported that TFF3 
promotes de novo angiogenesis in mammary carcinoma and therefore TFF3 is as a promoter 
of angiogenesis.  
 
3.3.2 The mechanism by which TFF3 promoted de novo angiogenesis in mammary 
carcinoma cells 
(i) IL-8 mediated angiogenic behaviors of endothelial cells stimulated by TFF3 
 Herein, I have demonstrated that TFF3 may not enhance VEGF-A expression in 
mammary carcinoma cells, suggesting that VEGF-A probably may not involve in modulation 
of TFF3 to stimulate angiogenic behaviors of HUVEC. TFF3 promoted de novo angiogenesis 
in mammary carcinoma is probably independent of VEGF-A signaling. These observations 
were unexpected because several reports have suggested that the angiogenic responses of 
VEGF-A are mediated by VEGFR2 receptor and it also stimulated activation of COX-2 or 
EGF-R tyrosine kinase to exert its angiogenic functions controlled by TFF peptides 
(Rodrigues et al., 2003). It is well-known that VEGF-A plays a dominant role in tumor 
angiogenesis and is a potent angiogenic cytokine. VEGF-A promotes proliferation, migration, 
and survival of endothelial cells (Ferrara et al., 2003, Ferrara, 2005). Increased VEGF-A 
expression is associated with tumor angiogenesis and poor prognosis of patient with breast 
cancer (Schneider and Miller, 2005). TFF peptides are not acting through VEGF-A/VEGFR 
signaling pathway because VEGFR2 tyrosine kinase inhibitor was not effectively attenuated 
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invasion of colon cancer cells stimulated by TFF3 (Rivat et al., 2005). Conversely, depletion 
of STAT3 by siRNA abrogated cellular invasion promoted by TFF3 and VEGF-A, suggesting 
that the autocrine self-activation of TFF3 and VEGF-A in colon cancer cells are dependent on 
STAT3 signal transduction pathway (Rivat et al., 2005). Concordantly, TFF3 stimulated 
phosphorylation of c-Src and subsequently increased STAT3 activity which led to down-
regulation of E-cadherin for promoting invasion and metastasis of mammary carcinoma 
(Pandey et al., 2014).  
 Herein, I have demonstrated that forced expression of TFF3 in mammary carcinoma 
cells increased IL-8 promoter activity and subsequently enhanced IL-8 expression. In 
xenograft model, mammary carcinoma cells with forced expression of TFF3 produced tumor 
with increased IL-8 protein expression. Forced expression of TFF3 in mammary carcinoma 
cells increased IL-8 expression, which in turn mediated the stimulatory effect of TFF3 in 
promoting de novo angiogenesis of mammary carcinoma. It has been reported that chemokine 
and its cognate receptors play an important role in facilitating invasion, angiogenesis, and 
metastasis of cancer cells (Richmond et al., 2009, Singh et al., 2010). IL-8 directly promoted 
angiogenesis via stimulation of endothelial cell proliferation, migration, survival and tubule 
formation (Koch et al., 1992, Hu et al., 1993, Heidemann et al., 2003, Snyder et al., 2004, 
Ning et al., 2010). Increased IL-8 expression is associated with enhancing invasion and 
angiogenesis in mammary carcinoma (Lin et al., 2004). Furthermore, IL-8 has been suggested 
as a metastatic factor in mammary carcinoma to regulate angiogenesis, tumor growth, and 
dissemination of cancer cells (Murdoch et al., 1999, Salcedo et al., 2000b). An in vivo study 
showed that the basal level of IL-8 expression is substantially higher in the estrogen-
independent mammary carcinoma cell lines (e.g. MDA-MB-231) when compared with the 
estrogen-dependent mammary carcinoma cell lines (e.g. MCF-7), demonstrating a positive 
correlation between IL-8 expression and the metastatic capacity of mammary carcinoma cell 
lines (De Larco et al., 2001, Lin et al., 2004). In a tumor xenograft model, IL-8 expressing 
cells formed larger tumors than the control cells with enhanced microvessel density and 
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increased IL-8 expression was associated with the tumor growth and angiogenesis of breast 
cancer (Lin et al., 2004, Zhou et al., 2006).  
 In addition to metastatic potential of IL-8, the expression of TFF3 in mammary 
carcinoma is an predictive biomarker for metastasis (Ahmed et al., 2012). TFF3 has also been 
identified as a promoter of metastatic dissemination of mammary carcinoma cells (Pandey et 
al., 2014). The expression of TFF3 is positively associated with the metastatic phenotype in 
mammary carcinoma cells. Increased expression of TFF3 is associated with invasion of 
muscle, the nipple, neural sheath, and the lymphovasculature (Ahmed et al., 2012). Increased 
TFF3 expression stimulated mammary carcinoma cells to metastasize away from the primary 
tumor and penetrated into the lymphovasculature followed by forming of micrometastatic 
breast cancer (Ahmed et al., 2012). 
 I have observed that mammary carcinoma cells with forced expression of TFF3 
expressed CXCR1 and CXCR2 mRNAs. Numerous of studies have demonstrated that the 
differential expression of IL-8 receptors between benign and malignant breast cancer tissues. 
A clinical study by Miller et al. (1998) reported that all breast cancer cells expressed IL-8 
receptors, CXCR1 and CXCR2. In contrast, Freund et al. (2003) observed that CXCR1 
expression is extremely low in mammary carcinoma cell lines, but most of the cells expressed 
CXCR2, without any correlation with ER status (Freund et al., 2003). Notably, IL-8 receptors 
expressed in many human cancer cells with no apparent correlation with the grade of the 
tumor (Miller et al., 1998, Muller et al., 2001). 
 The tumor promoting effects of IL-8 in modulating the survival, angiogenesis, and 
metastasis of cancer cells were attenuated by humanized anti-IL-8 monoclonal antibodies 
(Fujisawa et al., 2000, Li et al., 2003a). Depletion of IL-8 in human melanoma cell lines by 
anti-sense RNA has revealed that IL-8 may function as a growth modulator (Schadendorf et 
al., 1993). Administration of humanized monoclonal antibodies against IL-8 (e.g., ABX-IL-8) 
attenuated the growth of bladder cancer (Mian et al., 2003) and decreased tumorigenic and 
metastatic potential of melanoma in xenograft models (Huang et al., 2002). IL-8 gene 
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silencing by siRNA has been exploited to deplete IL-8 expression in ovarian tumor xenograft 
models, resulting in growth retardation and reduced microvessel density (Merritt et al., 2008). 
Concordantly, I have demonstrated that depletion of IL-8 in mammary carcinoma cells by 
siRNA or inhibition of IL-8 with anti-IL-8 monoclonal antibody abrogated the ability of TFF3 
to stimulate angiogenic behaviors of HUVEC. Additionally, inhibition of IL-8 in mammary 
carcinoma cells by anti-IL-8 monoclonal antibody attenuated the effect of TFF3 on the 
stimulation of HUVEC tubule formation in vitro mediated by IL-8. Both IL-8 siRNA and 
anti-IL-8 monoclonal antibody were able to inhibit the ability of TFF3 to stimulate angiogenic 
behaviors of HUVEC for promoting de novo angiogenesis in mammary carcinoma. 
IL-8 receptors in the endothelial cells have been shown to be involved in tumor 
angiogenesis (Singh et al., 2010). IL-8 binds to its cognate receptors either CXCR1 or 
CXCR2 and subsequently promotes endothelial cell proliferation and tumor angiogenesis. 
Administration of neutralizing antibodies against to CXCR1 and CXCR2 in endothelial cells 
abrogated tubule formation stimulated by IL-8, indicating that these two receptors are critical 
for activation of angiogenic responses of IL-8 (Salcedo et al., 2000a, Li et al., 2005). Other 
studies have also supported the importance of CXCR1 and CXCR2 in tumor angiogenesis 
(Varney et al., 2006, Singh et al., 2009). Of these two high affinity receptors, CXCR2 
receptor in the endothelial cells is more prone to implicate in tumor angiogenesis stimulated 
by IL-8 (Addison et al., 2000, Strieter et al., 2004). I have observed that blocking of CXCR1 
in the HUVEC by anti-CXCR1 monoclonal antibody was probably not able to inhibit the 
effect of TFF3 on the stimulation of HUVEC tubule formation in vitro. However, blocking of 
CXCR2 in the HUVEC by anti-CXCR2 monoclonal antibody abrogated the ability of TFF3 to 
stimulate HUVEC tubule formation in vitro mediated by IL-8 through CXCR2. It is known 
that CXCR2 has other chemokine ligands such as IL-1, IL-2 and IL-6 (Addison et al., 2000). 
It is possible that anti-CXCR2 is disrupting IL-8-independent events. These observations 
were concordant with Heidemann et al. (2003) that IL-8 promoted angiogenesis in the human 
intestinal microvascular endothelial cells is dependent on CXCR2, a receptor targeted by 
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multiple angiogenic CXC chemokines. Other studies have also reported that the migration of 
endothelial cells can be suppressed by neutralizing antibody to CXCR2 (Schraufstatter et al., 
2001, Li et al., 2005) and delayed vascularization in CXCR2 knockout mice (Devalaraja et al., 
2000). Therefore, I suggested that TFF3 stimulates angiogenic behaviors of HUVEC for 
promoting de novo angiogenesis in mammary carcinoma mediated by IL-8 through CXCR2 
axis. 
(ii) STAT3 partially mediated angiogenic behaviors of endothelial cells stimulated 
by TFF3 
 IL-8 promoter activity is regulated by the differential binding of the transcription 
factors namely NF-IL-6, NF-κB, and AP-1 (Mukaida et al., 1990, Roebuck, 1999) and several 
other nuclear factors such as hepatocyte nuclear factor-1 and glucocorticoid-responsive 
element (Mukaida et al., 1989). The regulatory elements in the proximal region of IL-8 gene 
are important for activation of IL-8 promoter activity (Kashima et al., 2009). The 5'-flanking 
region of the IL-8 contains DNA response elements for transcription factors NF-IL-6 (-94 to -
81 bp), AP-1 (-126 to 120 bp) and NF-κB (-80 to -70 bp) (Mukaida et al., 1994). These three 
transcription factors binding sites are the major elements involved in the regulation of the IL-
8 and their physical proximity may facilitate cooperative activation of these elements 
(Roebuck, 1999). Concordantly, I have demonstrated that TFF3 stimulated IL-8 promoter 
activity and subsequently increased IL-8 expression. Additionally, the transcription factors 
namely NF-IL-6, AP-1 and NF-κB, present at the proximal region of IL-8 promoter, were 
involved in enhancing TFF3-stimulated IL-8 promoter activity. Apparently, multiple 
transcription factors are involved in the regulation of IL-8 stimulated by TFF3. 
 The production of IL-8 is modulated by activation of IL-8 promoter via cooperation 
of multiple transcription factors (Le et al., 2000). It has been reported that increased IL-8 
expression was predominantly stimulated by NF-κB (Karashima et al., 2003). Constitutive 
IL-8 expression required both NF-κB and STAT3, over-expression of activated STAT3 
resulted in a drastically increase of IL-8 protein expression (Scholz et al., 2003). The 
160 
 
Src/STAT3 pathways may promote IL-8 production independent of NF-κB (Trevino et al., 
2006). Gharavi et al. (2007) suggested that either STAT3 alone is adequate or a different co-
activator such as NF-κB is required to cooperate with STAT3 for stimulation of IL-8 
expression in cancer cells (Gharavi et al., 2007). STAT3 is an important regulatory element 
involved in the regulation of IL-8 and STAT3 presumably direct interaction with its 
consensus binding site at the IL-8 promoter region (Oka et al., 2010). Concordantly, Seidel et 
al. (1995) has reported that a putative STAT3 binding site was predicted in the 5'-flanking 
region of IL-8 gene (Seidel et al., 1995).  
 Herein, I have demonstrated that forced expression of TFF3 in mammary carcinoma 
cells increased tyrosine phosphorylation of STAT3 protein (Y705 pSTAT3). This observation 
was consistent with a recent study shown that TFF3 promoted STAT3 activity in mammary 
carcinoma cells through activation of c-Scr protein (Pandey et al., 2014). Depletion of STAT3 
by siRNA partially abrogated the ability of TFF3 to stimulate IL-8 promoter activity and 
resulted in a small decreased of IL-8 expression. Additionally, depletion of STAT3 in 
mammary carcinoma cells by siRNA partially abrogated the ability of TFF3 to stimulate 
angiogenic behaviors of HUVEC mediated by STAT3. Furthermore, TFF3 was shown to 
promote a mesenchymal and invasive (EMT) phenotype to enhance the metastatic capability 
of  mammary carcinoma cells through c-Src/STAT3 signaling pathway by activation of EMT 
markers (Pandey et al., 2014). Thereby, forced expression of TFF3 down-regulated the 
expression of E-cadherin and concomitantly increased expression of vimentin to promote 
metastatic dissemination of mammary carcinoma cells (Pandey et al., 2014). 
 A number of reports have shown that STAT3 plays a pivotal role in tumor 
angiogenesis by enhancing VEGF protein expression (Niu et al., 2002, Osugi et al., 2002, 
Schaefer et al., 2002). STAT3 activity is regulated by post-translational modifications 
involving phosphorylation of specific conserved tyrosine residues (e.g., tyrosine 705) and 
active nuclear translocation followed by DNA binding and transcriptional activation of the 
target genes (Jove, 2000). The constitutively active STAT3 directly acts on VEGF-A gene to 
161 
 
stimulate VEGF-A promoter activity and subsequently up-regulates VEGF-A expression to 
stimulate neovascularization in the tumors (Niu et al., 2002). Similarly, STAT3 may be able 
to directly act on the IL-8 promoter to regulate IL-8 expression. Several studies have 
suggested that IL-8 promoter may be containing a putative consensus binding site for STAT3, 
which is involved in the regulation of IL-8 (Seidel et al., 1995, Oka et al., 2010). Presumably, 
TFF3 secreted from mammary carcinoma cells stimulated tyrosine phosphorylation of STAT3, 
the activated STAT3 dimerizes, translocates into the nucleus, and directly binds to the IL-8 
promoter for regulation of IL-8 gene transcription (Bromberg et al., 1999, Garcia et al., 2001, 
Niu et al., 2002, Rivat et al., 2005). Mechanistically, I suggested that forced expression of 
TFF3 in mammary carcinoma cells elevated IL-8 expression and increased the 
phosphorylated STAT3 activity. Subsequently, TFF3 stimulated angiogenic behaviors of 
endothelial cells for promoting de novo angiogenesis in mammary carcinoma through IL-
8/CXCR2 axis. Hence, TFF3 is a promoter of angiogenesis, which may also co-coordinate 
with the growth promoting and metastatic actions of TFF3 in mammary carcinoma to enhance 
tumor progression. 















Exogenous Human Recombinant TFF3 and TFF3 Secreted from 
HUVEC Promoted Angiogenesis  
4.1 Introduction  
 Angiogenesis is a complex and sequential process in which the existing blood vessel 
generates new vasculature. Following stimulation of endothelial cells by angiogenic factors, 
the endothelium is destabilized, producing a decrease in endothelial cell adhesion and a 
concomitant increase in vascular permeability (Petreaca et al., 2007). The basal lamina of 
blood vessel is then degraded by matrix metalloproteinases to allow the endothelial cells to 
proliferate and migrate into surrounding connective tissues. The endothelial cells then sprout 
from adjacent vessel and fuse to produce a labyrinth of new blood vessels (Petreaca et al., 
2007). The nascent vessel recruits periendothelial and smooth muscle-like cells to stabilize 
the endothelium by promotion of the depositions of basal lamina and intercellular adhesion 
(Daniel and Abrahamson, 2000, Conway et al., 2001). Angiogenesis is critical for different 
physiological and pathophysiological processes, including embryonic development, wound 
healing and chronic inflammation, and cancer progression (Folkman, 1995).   
 Under normal physiological conditions, angiogenesis is a tightly regulated process in 
which quiescent endothelial cells are induced to divide, leading to the spread of the vascular 
network, which supplies oxygen and nutrients to the growing tissues. Normal angiogenesis 
occurs during embryogenesis where it establishes the primary vasculature and generates 
adequate blood vessels for development of organs (Folkman, 1995). De novo angiogenesis is 
important in normal physiological repair mechanisms such as wound healing (Klagsbrun and 
D'Amore, 1991). The angiogenic switch in cancer is coordinated  by the combinatorial 
balance between pro- and anti-angiogenic factors, produced either by cancer cells or by 
stromal cells in the surrounding interstitium (Baeriswyl and Christofori, 2009).  
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 It is already known that angiogenic factors derived from a tumor are implicated in de 
novo angiogenesis, but there is evidence showed that angiogenic factors and the endothelial 
cells are pivotal origins of signals to non-vascular tissue cells during development of organs 
(Crivellato, 2011). Endothelial cells produce a number of secreted angiogenic proteins that 
enhance migration, survival and function of neighboring cells (e.g. mature endothelial cells), 
thereby promoting neovascularization. Furthermore, endothelial cells are crucial participants 
in tumor angiogenesis (Harvey et al., 2002).  
 The expression of the TFF family of protein has been observed  in  tissues containing 
mucus-secreting cells as exemplified by the gastrointestinal tract, and colon, suggesting that 
their physiological functions may be related to that of mucin (Kraljevic Pavelic et al., 2011). 
Importantly, these peptides are involved in the protection of the gastrointestinal tract against 
mucosal damage and in mucosal restitution (Taupin and Podolsky, 2003). In addition, TFF 
peptides are expressed in other organs including lymphoid tissue (Cook et al., 1999), brain 
(Probst et al., 1996, Jagla et al., 2000), liver and gall bladder (Sasaki et al., 2007). Thus, the 
functions of TFF peptides are cell-type specific. TFF peptides are secreted from diverse 
organs and exert different functional effects, yet their biological significance for most part is 
still elusive (Kjellev, 2009). In vitro experimental data have shown that exogenous 
recombinant human TFF3 (rhTFF3) stimulated migration of intestinal, respiratory and corneal 
epithelial cells in wound healing assays (Chinery and Playford, 1995, Playford et al., 1995, 
Göke et al., 2001, Oertel et al., 2001, Graness et al., 2002). Extracellular administration of 
rhTFF3 provides protection against ethanol-induced gastric mucosal damage and drug-
induced intestinal mucosal injury (Kindon et al., 1995, Playford et al., 1996, McKenzie et al., 
2000, Babyatsky et al., 2009). Furthermore, functional studies of TFF3 on epithelial mucosal 
damage have shown that rhTFF3 potently stimulated the migration of intestinal epithelial 
cells, promoted wound healing, and altered E-cadherin expression to enhance the migration of 
epithelial cells (Dignass et al., 1994, Playford et al., 1995). 
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 A study by Rodrigues et al. (2003b) demonstrated that exogenous rhTFF3 promoted 
capillary vessel formation in a CAM assay, suggesting that TFF3 may function as pro-
angiogenic factor. Moreover, the angiogenic activity of TFF1 in HUVEC tubule formation in 
vitro was comparable to that stimulated by VEGF-A. TFF1 promoted angiogenesis in vitro 
which mediated by both cyclooxgenase-2 (COX-2) and epidermal growth factor receptor 
(EGF-R) (Rodrigues et al., 2003b). Given that TFF3 is analogous to TFF1, TFF3 may possess 
similar pro-angiogenic characteristic as TFF1, suggesting that TFF3 may also be involved in 
angiogenesis in vivo, although further studies are required to determine whether TFF3 can 
directly act on endothelial cells to stimulate its angiogenic behaviors. 
 HUVEC are preferable to use as a cell-based model for study of angiogenesis in vitro 
as they retain the traits or functional characteristics of normal human endothelial cells (Ades 
et al., 1992, Bouis et al., 2001). HUVEC possesses the ability to form tubule in the basement 
membrane extract Matrigel resembles to the ECM, thus mimicking angiogenesis in vitro 
(Donovan et al., 2001, Auerbach et al., 2003, Bagley et al., 2003). HUVEC tubule formation 
in vitro is a simple, feasible and reproducible assay and commonly used to determine the 
angiogenic potential an angiogenic factor (Okamura et al., 1992, Ito et al., 1995). HUVEC are 
grown in the Matrigel in the presence of a tested angiogenic protein and subsequently lead to 
either promotion or inhibition of tubule formation, indicating that the angiogenic protein can 
directly stimulate or inhibit angiogenic behaviors of HUVEC (Aranda and Owen, 2009). The 
angiogenic potential of an angiogenic protein can be quantified by measuring tubule length 
and/or tubule number (Jones et al., 1998).  
 In this study, the immortalized human umbilical vein endothelial cells (HUVEC) 
were utilized as an in vitro endothelial model. HUVEC with forced expression of TFF3 were 
generated by transient transfection with a pIRESneo3 (Invitrogen, Carlsbad, CA) expression 
vector containing human TFF3 cDNA (NM_003226) (designated as HUVEC-TFF3), or the 
pIRESneo3 empty vector (designated as HUVEC-Vec). HUVEC with depletion of TFF3 were 
generated by transient transfection of HUVEC with a pSilencer 2.1-U6 hygro (Ambion, 
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Austin, TX) expression vector containing TFF3 siRNA (designated as HUVEC-siTFF3), or 
with control siRNA encoding a siRNA that has no significant sequence similarity to human 
gene sequences (designated as HUVEC-siVec).  
 I therefore postulate that exogenous rhTFF3 directly acts on HUVEC to promote 
angiogenic behavior of HUVEC and TFF3 secreted from HUVEC may also exert similar 
functional effects as exogenous rhTFF3 in promoting of angiogenesis.  
 
4.2 Results 
4.2.1 Exogenous rhTFF3 increased HUVEC monolayer proliferation 
 Recombinant human TFF3 (rhTFF3) was expressed from pGEX-4T1-TFF3 plasmid 
in E coli and purified using glutathione-S-transferase tag affinity chromatography under non-
reducing condition as previously described (Amiry et al., 2009). The specificity and purity of 
this protein has been determined by Western blot analysis, whereby a single band was 
detected as a monomer at 7 kDa or dimer at 14 kDa under reducing and non-reducing 
conditions, respectively (Amiry et al., 2009).  
 Different concentrations of rhTFF3 (0.1, 1.0, 2.5, 5.0, and 10.0 ng/mL) were used to 
examine the effect of exogenous rhTFF3 stimulation on HUVEC monolayer proliferation. 
The effect of exogenous rhTFF3 on HUVEC monolayer proliferation (total cell number) after 
48 hours with different concentration of rhTFF3 in 0.2% FBS (serum deprived) and 10% FBS 
(serum replete) conditions were determined. Exogenous rhTFF3 stimulation significantly 
increased HUVEC monolayer proliferation from 35% at 2.5 ng/mL rhTFF3 to 100% at 10.0 
ng/mL rhTFF3 in 10% FBS conditions when compared with HUVEC treated with BSA 
control protein (Figure 47A). Lower concentration of exogenous rhTFF3 may not able to 
stimulate HUVEC monolayer proliferation in serum deprived conditions (0.2% FBS), but 
slightly increased HUVEC monolayer proliferation by 18% at a higher concentration of 
rhTFF3 (10 ng/mL) (Figure 47B), indicating that exogenous rhTFF3 promoted HUVEC 
monolayer proliferation in a concentration-dependent manner.  
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A Monolayer proliferation in 10% FBS B Monolayer proliferation in 0.2% FBS
Figure 47: Exogenous rhTFF3 stimulation increased monolayer proliferation of HUVEC. 
A, HUVEC monolayer proliferation at different concentrations of rhTFF3 (0.1, 1.0, 2.5, 5.0, 5, 
10 ng/mL of rhTFF3) in 10% FBS condition. B, HUVEC monolayer proliferation at different 
concentrations of rhTFF3 (0.1, 1.0, 2.5, 5.0, 5, 10 ng/mL of rhTFF3) in 0.2% FBS condition. 
Different concentrations of rhTFF3 in 0.2% FBS or 10% FBS EBM media was added to the 
HUVEC and incubated at 37
o
C for 48 hours. BSA was used as control. HUVEC treated with 
10 ng/mL BSA was used as baseline. *, P < 0.05; **, P < 0.01 as compared with BSA control. 
 
 
4.2.2 Exogenous rhTFF3 stimulation increased HUVEC migration, invasion, and 
tubule formation in vitro 
 To determine whether the exogenous rhTFF3 stimulation acted as a chemoattractant 
or stimulant, a transwell migration assay was performed to examine the effect of exogenous 
rhTFF3 stimulation on HUVEC migration. The untreated HUVEC plated in the membrane of 
the transwell insert incubated with 5.0 ng/mL rhTFF3 in the bottom well of the companion 
plate increased HUVEC migration as compared to the HUVEC incubated with BSA control 
and therefore rhTFF3 acted as a chemoattractant (Figure 48A). Alternatively, HUVEC treated 
with 5 ng/mL rhTFF3 plated in the membrane of transwell insert and  incubated with 10% 
FBS EBM medium in the bottom well of the companion plate also increased HUVEC 
migration as compared to the HUVEC incubated with BSA control and therefore rhTFF3 
acted as stimulant of migration (Figure 48A). Exogenous rhTFF3 acted as both a 
chemoattractant and stimulant to induce migratory behavior of HUVEC and to promote 
HUVEC migration. Notably, the chemoattractant effect of rhTFF3 on the HUVEC migration 
is more significant than the stimulant effect of rhTFF3. Subsequently, the effect of different 
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concentrations of rhTFF3 (0.1, 1.0, 2.5, 5.0, 10.0 ng/mL of rhTFF3) on HUVEC migration 
and invasion was determined. HUVEC were plated in the membrane of the transwell insert 
and incubated with different concentrations of rhTFF3 or BSA control in the bottom well of 
the companion plate. As compared to HUVEC incubated with BSA control, exogenous 
rhTFF3 significantly increased HUVEC migration from 45% to 104% at varying 
concentrations of rhTFF3 (2.5, 5.0, 10.0 ng/mL of rhTFF3), with the maximal HUVEC 
migration observed at 5.0 ng/mL of rhTFF3 (Figure 48B). Additionally, exogenous rhTFF3 
stimulation significantly increased HUVEC invasion from 47% to 52% at varying 
concentrations of rhTFF3 (2.5, 5.0, 10.0 ng/mL of rhTFF3), with maximal HUVEC invasion 
at 5.0 ng/mL of rhTFF3 as compared with HUVEC incubated with BSA control (Figure 48C). 
These observations indicated that exogenous rhTFF3 promoted HUVEC migration and 
invasion in a concentration-dependent manner, with maximal stimulation at 5.0 ng/mL 
rhTFF3. 
 To determine the effect of exogenous rhTFF3 stimulation on HUVEC tubule 
formation in vitro, HUVEC plated in the Matrigel were treated with different concentrations 
of rhTFF3 (0.1, 1.0, 2.5, 5.0, 10.0 ng/mL of rhTFF3). Exogenous rhTFF3 stimulation 
significantly increased tubule length formed by HUVEC from 48% to 69% at varying 
concentration of rhTFF3 (1.0, 2.5, 5.0 ng/mL of rhTFF3), with maximal HUVEC tubule 
formation in vitro at 5.0 ng/mL (Figure 48D-E). Higher concentration of rhTFF3 (10.0 ng/mL) 
exhibited a slight increase of tubule length formed by HUVEC (22%) when compared with 
HUVEC treated with control BSA. These observations suggested that exogenous rhTFF3 
stimulation significantly increased HUVEC tubule formation in vitro with maximal 
stimulation at 5.0 ng/mL of rhTFF3 and exhibited lesser stimulatory effect on HUVEC tubule 






































































































































































A Migration B Migration
C Invasion D Tubule length
E Tubule formation
200 μm 200 μm 
200 μm 200 μm 200 μm BSA control 0.1 ng/mL rhTFF3 1.0 ng/mL rhTFF3 
2.5 ng/mL rhTFF3 5.0 ng/mL rhTFF3 10.0 ng/mL rhTFF3 200 μm 
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Figure 48: Exogenous rhTFF3 stimulation increased HUVEC migration, invasion, and 
tubule formation in vitro. A, Exogenous rhTFF3 acted as chemoattractant and stimulant on 
HUVEC migration. For rhTFF3 to act as a chemoattractant, HUVEC were plated on the 
membrane of a transwell insert and incubated with either exogenous rhTFF3 (5 ng/mL) or 
BSA used as a control (5 ng/mL) in the bottom well of companion plate for 24 hour. For 
rhTFF3 to act as a stimulant, 5 ng/mL rhTFF3 or BSA control was added to the HUVEC were 
plated on the membrane of a transwell insert and incubated with 10% FBS EBM medium in 
bottom well of companion plate of for 24 hour. B, Migration of HUVEC after 24 hour 
incubation with different concentration of exogenous rhTFF3 (0.1, 1.0, 2.5, 5, 10 ng/mL of 
rhTFF3) or BSA control (10 ng/mL).  C, Invasion of HUVEC after 24 hours incubation with 
different concentration of exogenous rhTFF3 (0.1, 1.0, 2.5, 5, 10 ng/mL of rhTFF3) or BSA 
control (10 ng/mL). D, Exogenous rhTFF3 stimulation in the HUVEC tubule formation in 
vitro. HUVEC plated in the Matrigel were treated with different concentration of exogenous 
rhTFF3 (0.1, 1.0, 2.5, 5, 10 ng/mL of rhTFF3) or BSA control (10 ng/mL).  Total tubule 
length was assessed after 12 hour using ImageJ analysis software. E, representative light 
microscopy images of HUVEC tubule formation in vitro in which HUVEC treated with 
different concentrations of rhTFF3 or BSA control. BSA was used as control. HUVEC treated 
with BSA control was used as baseline. The light microscopy images were taken at ×40. *, P 
< 0.05; **, P < 0.01; ***, P < 0.001 as compared with BSA control; scale bar, 200 µm. 
 
 
4.2.3 Forced expression of TFF3 in HUVEC increased TFF3 expression 
 I have demonstrated that exogenous rhTFF3 stimulation directly acted on HUVEC to 
promote angiogenic behaviors in vitro. I then determined whether TFF3 secreted from 
HUVEC exerted similar functional activity as exogenous rhTFF3 to promote the angiogenic 
behaviors of endothelial cells. HUVEC were transiently transfected with an expression vector 
containing TFF3 cDNA (designated as HUVEC-TFF3) or pIRESneo3 empty vector 
(designated as HUVEC-Vec). Forced expression of TFF3 in HUVEC increased TFF3 mRNA 
as compared with control HUVEC-Vec after 24 hours transfection and the expression of 
TFF3 mRNA in HUVEC, though slightly decreased as compared to the 24 hour of post-
trnasfection, was maintained until 72 hours of post-transfection (Figure 49A). Nevertheless, 
HUVEC with forced expression of TFF3 exhibited higher TFF3 mRNA than the control 
HUVEC-Vec from 24 hours to 72 hours post-transfection. Parental HUVEC endogenously 
expressed undetectable or very low level of TFF3 mRNA (Figure 49B) and protein (Figure 
49C) as compared to the control (MCF-7 cells). HUVEC endogenously secreted TFF3 protein 
to the medium and was detected by rabbit anti-TFF3 polyclonal antibody in Western blot 
analysis (Figure 49D). Furthermore, forced expression of TFF3 in HUVEC increased TFF3 
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mRNA (Figure 49E) as compared with control HUVEC-Vec. Concordantly, forced 
expression of TFF3 in HUVEC also increased TFF3 protein in cell lysate and secreted to the 
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Figure 49: Forced expression of TFF3 in HUVEC increased TFF3 expression. A, Semi-
quantitative RT-PCR analysis of TFF3 mRNA in HUVEC with forced expression of TFF3 
after 24, 48, and 72 hours transfection. HUVEC with empty vector was used as control. B, 
Semi-quantitative RT-PCR analysis of TFF3 mRNA in parental HUVEC and control (MCF-7 
cells). C, Western blot analysis of TFF3 protein in the cell lysate of HUVEC and control 
(MCF-7 cells). D, Western blot analysis of TFF3 protein in the medium of HUVEC which 
contained 10, 20 μg of total protein. E, semi-quantitative RT-PCR analysis of TFF3 mRNA in 
HUVEC with forced expression of TFF3. F, Western blot analysis of TFF3 protein in the cell 
lysate and conditioned medium of HUVEC with forced expression of TFF3. β-ACTIN was 
used as a loading control in both semi-quantitative RT-PCR and Western blot analysis. 
 
4.2.4 Forced expression of TFF3 in HUVEC increased monolayer cell proliferation, 
cell cycle progression, survival 
 The effect of TFF3 secreted from HUVEC with forced expression of TFF3 on 
monolayer cell proliferation in both 10% FBS conditions (serum replete) for 72 hours and 
0.2% FBS conditions (serum deprived) for 48 hours were determined. TFF3 secreted from 
HUVEC significantly increased monolayer cell proliferation in both 10% FBS and 0.2 % FBS 
conditions when compared with the control HUVEC-Vec (Figure 50A-B). When compared 
with control HUVEC-Vec, TFF3 secreted from HUVEC significantly increased monolayer 
cell proliferation by 29% in 10% FBS condition after 72 hours (Figure 50A) and by 30% in 
serum deprived conditions (0.2% FBS) after 48 hours (Figure 50B). These data indicated that 
TFF3 secreted from HUVEC promoted HUVEC monolayer cell proliferation in both 10% 
FBS and 0.2% FBS conditions. Furthermore, TFF3 secreted from HUVEC increased cell 
cycle progression, as indicated by BrdU incorporation, in both serum-free conditions and 10% 
FBS conditions by 30% and 43%, respectively, when compared with control HUVEC-Vec 
(Figure 50C). TFF3 secreted from HUVEC also decreased apoptotic cell death, as indicated 
by fluorescent microscopic nuclear staining,  in both serum-free and 10% FBS conditions by 
37% and 39%, respectively when compared with control HUVEC-Vec (Figure 50D). These 

























































































































A Monolayer proliferation in 10% FBS B Monolayer proliferation in 0.2% FBS
C BrdU incorperation D Apoptotic cell death
Figure 50: Forced expression of TFF3 in HUVEC increased monolayer cell 
proliferation, cell cycle progression, and survival. A, HUVEC monolayer cell proliferation 
after co-culture with HUVEC with forced expression of TFF3 in 10% FBS conditions. 
HUVEC with empty vector was used as control. B, HUVEC monolayer cell proliferation after 
co-culture with HUVEC with forced expression of TFF3 in 0.2% FBS condition. C, HUVEC 
cell cycle progression after 24 hours co-culture with HUVEC with forced expression of TFF3 
in serum-free (SF) and 10% FBS conditions. D, HUVEC apoptotic cell death after 24 hours 
co-culture with HUVEC with forced expression of TFF3 in serum-free (SF) and 10% FBS 
conditions. *, P < 0.05; **, P < 0.01. 
 
 
4.2.5 Forced expression of TFF3 in HUVEC increased migration, invasion, and tubule 
formation in vitro 
 To determine the effect of TFF3 secreted from HUVEC on the migratory and 
invasive behavior of endothelial cells, transwell migration and invasion assays were 
conducted. Forced expression of TFF3 in HUVEC consistently increased migration by 21% 
(Figure 51A) and invasion by 11% (Figure 51B) when compared with control HUVEC-Vec, 
suggesting that TFF3 secreted from HUVEC slightly promoted cell migration and invasion. 
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 To determine whether TFF3 secreted from HUVEC stimulates angiogenesis in vitro, 
a tubule formation assay was conducted whereby HUVEC with forced expression of TFF3 
were seeded in the Matrigel. TFF3 secreted from HUVEC significantly increased tubule 
length by 125% (Figure 51C) and tubule number by 56% (Figure 51D) when compared with 
control HUVEC-Vec. TFF3 secreted from HUVEC increased tubules formed by endothelial 
cells when compared with control HUVEC-Vec (Figure 51E), suggesting that TFF3 secreted 





























































Figure 51: Forced expression of TFF3 in HUVEC increased cell migration, invasion, and 
tubule formation in vitro. A, HUVEC migration after 24 hours co-culture with HUVEC with 
forced expression of TFF3 in serum-free conditions. HUVEC with empty vector was used as 
control. B, HUVEC invasion after 24 hours co-culture with HUVEC with forced expression 
of TFF3 in serum-free conditions. C and D, tubule formation in vitro after 12 hours co-culture 
HUVEC with forced expression of TFF3 in the Matrigel. Total tubule length (C) and tubule 
number (D) were assessed using ImageJ analysis software. E, representative light microscopy 
images of tubule formation in vitro after 12 hours co-culture with HUVEC with forced 
expression of TFF3 in the Matrigel. The light microscopy images were taken at ×40 
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4.2.6 Depletion of TFF3 in HUVEC by siRNA decreased TFF3 expression 
 To determine the effect of depletion of TFF3 on the angiogenic behaviors of 
endothelial cells, the endogenous expression of TFF3 in HUVEC was depleted by siRNA to 
TFF3. HUVEC were transiently transfected with an expression vector containing TFF3 
siRNA (designated as HUVEC-siTFF3) or pSilencer 2.1-U6 hygro empty vector (designated 
as HUVEC-siVec). Depletion of TFF3 in HUVEC decreased TFF3 mRNA and protein when 









Figure 52: Depletion of TFF3 in HUVEC by siRNA decreased TFF3 expression. A, RT-
PCR analysis of TFF3 mRNA in HUVEC with depletion of TFF3. HUVEC with control 
siRNA was used as control. B, Western blot analysis of TFF3 protein in HUVEC with 
depletion of TFF3. β-ACTIN was used as a loading control in both semi-quantitative RT-PCR 
and Western blot analysis.  
 
4.2.7 Depletion of TFF3 in HUVEC decreased monolayer cell proliferation, cell cycle 
progression, and survival 
 The effect of TFF3 secreted from HUVEC with depletion of TFF3 by siRNA on 
monolayer cell proliferation in both 10% FBS conditions for 72 hours and 0.2% FBS 
conditions for 48 hours were determined. Depletion of TFF3 in HUVEC significantly 
decreased monolayer cell proliferation in both 10% FBS and 0.2% FBS conditions when 
compared with the control HUVEC-Vec (Figure 53A-B).  When compared with the control 
HUVEC-siVec, depletion of TFF3 in HUVEC significantly decreased monolayer cell 
proliferation by 65% in 10% FBS condition (Figure 53A) and by 20% in serum deprived 
conditions after 48 hours (Figure 53B). Furthermore, depletion of HUVEC decreased cell 
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cycle progression in both serum-free conditions and 10% FBS conditions by 38% and 30%, 
respectively when compared with control HUVEC-Vec (Figure 53C). Depletion of TFF3 in 
HUVEC also increased apoptotic cell death in both serum-free conditions and 10% FBS 
conditions by 32% and 37%, respectively when compared with control HUVEC-Vec (Figure 
53D). Depletion of TFF3 by siRNA in HUVEC decreased cell proliferation and survival. 
 
















































































































A Monolayer proliferation in 10% FBS B Monolayer proliferation in 0.2% FBS
C BrdU incorporation D Apoptotic cell death
Figure 53: Depletion of TFF3 in HUVEC decreased monolayer cell proliferation, cell 
cycle progression, and survival. A, HUVEC monolayer cell proliferation after co-culture 
with HUVEC with depletion of TFF3 in 10% FBS conditions. HUVEC with control siRNA 
was used as control. B, HUVEC monolayer cell proliferation after co-culture with HUVEC 
with depletion of TFF3 in 0.2% FBS conditions. C, HUVEC cell cycle progression after co-
culture with HUVEC with depletion of TFF3 in both serum-free (SF) and 10% FBS 
conditions. D, HUVEC apoptotic cell death after 24 hours co-culture with HUVEC with 




4.2.8 Depletion of TFF3 in HUVEC decreased migration, invasion, and tubule 
formation in vitro 
 The effect of depletion of TFF3 by siRNA on the angiogenic behaviors of HUVEC 
was determined. Depletion of TFF3 in HUVEC significantly decreased HUVEC migration by 
37% (Figure 54A) and invasion by 28% (Figure 54B) when compared with control HUVEC-
siVec. Furthermore, depletion of TFF3 by siRNA in HUVEC significantly decreased tubule 
length by 37% and tubule number by 38% when compared with control HUVEC-siVec 
(Figure 54C-D). Depletion of TFF3 in HUVEC decreased tubules formed by endothelial cells 
when compared with the control HUVEC-siVec (Figure 54E). Therefore, depletion of TFF3 








































Figure 54: Depletion of TFF3 in HUVEC decreased migration, invasion, and tubule 
formation in vitro. A, cell migration after 24 hours co-culture with HUVEC with depletion of 
TFF3 in serum-free conditions. HUVEC with control siRNA was used as control B, cell 
invasion after 24 hours co-culture with HUVEC with depletion of TFF3 in serum-free 
conditions. C and D, tubule formation in vitro on Matrigel after 12 hours co-culture with 
HUVEC with depletion of TFF3 in serum-free conditions. Total tubule length (C) and tubule 
number (D) were assessed after 12 hours incubation using ImageJ analysis software. E, 
representative light microscopy images of tubule formation in vitro in the Matrigel after 12 
hours co-culture with HUVEC with depletion of TFF3. The light microscopy images were 
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4.2.9 Forced expression of TFF3 in HUVEC increased IL-8 promoter activity 
 To determine if TFF3 secreted from HUVEC regulated IL-8 promoter activity, 
HUVEC with forced expression of TFF3 were transiently transfected with an full length IL-8 
promoter reporter vector (-4800 to +104 bp) and a pRL-CMV control reporter. Forced 
expression of TFF3 in HUVEC significantly increased IL-8 promoter activity (1.5-fold 
increase) as compared to the control HUVEC-Vec, indicating that TFF3 secreted from 
HUVEC stimulated IL-8 promoter activity, albeit slightly (Figure 55A). Additionally, 
HUVEC with forced expression of TFF3 transiently transfected with a shorter promoter, 
pGL-IL8-152 reporter vector (-152 to + 44 bp), significantly increased IL-8 promoter activity 








































































A IL-8 promoter activity B IL-8 promoter activity
 
Figure 55: Forced expression of TFF3 in HUVEC increased IL-8 promoter activity. A, 
IL-8 promoter activity in HUVEC with forced expression of TFF3 transiently transfected with 
IL-8 promoter (full length, -4800 to + 104 bp). HUVEC with empty vector was used as 
control. B, IL-8 promoter activity in HUVEC with forced expression of TFF3 transiently 
transfected with pGL-IL8-152 reporter (-152 to +44 bp). Fragment containing 5' flanking 
regions of the IL-8 gene were subcloned upstream of a luciferase reporter gene in the pGL3-
basic vector. pGL-IL8-152 reporter vector encompassing nucleotides -152 to +44 of the IL-8 
promoter, which contain the transcriptional factors, AP-1, NF-IL6 and NF-κB response site. 
The TATA box, and the NF-IL6, NF-κB and AP-1 binding sites are located at -13, -70, -80 
and -120, respectively. HUVEC with forced expression of TFF3 were transiently transfected 
with a reporter and a pRL-CMV control reporter. IL-8 promoter activity measured by firefly 
luciferase activity that normalized by Renilla luciferase activity. **, P < 0.01. 
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4.2.10 Forced expression of TFF3 in HUVEC increased IL-8 expression 
 Forced expression of TFF3 in HUVEC stimulated angiogenic behaviors of HUVEC 
to promote angiogenesis in vitro. Presumably, TFF3 modulated the expression of one or more 
specific angiogenic factors that can mediate the angiogenic action of TFF3, in addition to the 
direct action of TFF3 on the HUVEC as previously demonstrated by exogenous rhTFF3 
stimulation. Forced expression of TFF3 in HUVEC exhibited relatively similar expression 
levels of VEGF-A (VEGF-A121 and VEGF-A165 mRNAs) and its tyrosine kinase receptors 
(VEGFR1 and VEGFR2 mRNAs) when compared with the control HUVEC-Vec. Forced 
expression of TFF3 in HUVEC regulated neither the expression of VEGF-A121 and VEGF-
A165 nor its tyrosine kinase receptors VEGFR1 and VEGFR2 (Figure 56A). The mRNA 
expressions of VEGF-A and VEGFR1/2 were observed in HUVEC. Nevertheless, forced 
expression of TFF3 in HUVEC increased IL-8 mRNA (Figure 56B) and protein (Figure 56C) 
when compared with the control HUVEC-Vec. Forced expression of TFF3 in HUVEC 
slightly increased IL-8 protein secreted to medium as compared with the control HUVEC-Vec 
(Figure 56D).  
 The angiogenic function of IL-8 is activated through the binding of IL-8 to its 
cognate receptors, termed as CXCR1 and CXCR2, which belong to the G protein–coupled 
receptor family (Holmes et al., 1991). HUVEC with forced expression of TFF3 expressed 
both CXCR1 and CXCR2 mRNAs (Figure 56E). Forced expression of TFF3 in HUVEC 
slightly increased IL-8 protein secreted to the medium (Figure 56D). Parental HUVEC 
endogenously expressed IL-8 protein in cell lysate and also secreted to the medium (Figure 
57A). Additionally, exogenous rhTFF3 (at the lower concentration of rhTFF3 e.g., 0.1 and 1.0 
ng/mL rhTFF3) marginally increased the expression of IL-8 mRNA (Figure 57B) and protein 
(Figure 57C) in parental HUVEC, suggesting that the lower concentration of exogenous 











       









       
 



















Figure 56: Forced expression of TFF3 in HUVEC increased IL-8 expression. A, semi-
quantitative RT-PCR analysis of the expression of VEGF-A, VEGFR1, and VEGFR2 mRNA 
in HUVEC with forced expression of TFF3. HUVEC with empty vector was used as control 
B, semi-quantitative RT-PCR analysis of IL-8 mRNA in HUVEC with forced expression of 
TFF3. C, Western blot analysis of IL-8 protein in HUVEC with forced expression of TFF3. D, 
ELISA analysis of IL-8 protein secreted to the medium by HUVEC with forced expression of 
TFF3. E, semi-quantitative RT-PCR analysis of the expression of IL-8 receptors, CXCR1 and 
CXCR2 mRNA in HUVEC with forced expression of TFF3. β-ACTIN was used as a loading 
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Figure 57: Exogenous rhTFF3 stimulation induced IL-8 expression in parental HUVEC. 
A, Western blot analysis of IL-8 protein in cell lysate and conditioned medium of Parental 
HUVEC. B, semi-quantitative RT-PCR analysis the expression of IL-8 mRNA in parental 
HUVEC treated with exogenous rhTFF3 (0.1, 1.0 ng/mL of rhTFF3) and BSA control. C, 
Western blot analysis of the expression of IL-8 protein in parental HUVEC treated with 
exogenous rhTFF3 (0.1, 1.0 ng/mL of rhTFF3) and BSA control. Parental HUVEC treated 
with BSA control was used as baseline. β-ACTIN was used as a loading control in semi-
quantitative RT-PCR and Western blot analysis.  
 
4.2.11 Depletion of TFF3 in HUVEC decreased IL-8 promoter activity and 
subsequently decreased IL-8 expression 
 I then determined if depletion of TFF3 in HUVEC decreased IL-8 promoter activity 
and subsequently its expression. Firstly, HUVEC with depletion of TFF3 was transiently 
transfected with full length of IL-8 promoter (-4800 to +104 bp). Depletion of TFF3 in 
HUVEC significantly lessened IL-8 promoter activity (2.3-fold decrease) when compared 
with the control HUVEC-siVec (Figure 58A). Secondly, HUVEC with depletion of TFF3 was 
transiently transfected with shorter IL-8 promoter, pGL-IL8-152 (-152 to + 44 bp). HUVEC 
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with depletion of TFF3 also lessened IL-8 promoter activity (1.9-fold decrease) when 
compared with the control HUVEC-siVec (Figure 58B). The transcription factors namely NF-
IL-6, NF-κB, and AP-1 present at the proximal region of IL-8 promoter are required for 
promoting of TFF3-stimulated IL-8 promoter activity in HUVEC. Furthermore, depletion of 
TFF3 in HUVEC by siRNA decreased IL-8 mRNA (Figure 58C) and IL-8 protein secreted to 
medium (Figure 58D) when compared with the control HUVEC-siVec. Hence, depletion of 
TFF3 by siRNA in HUVEC lessened the IL-8 promoter activity and subsequently decreased 




















































































A IL-8 promoter activity B IL-8 promoter activity
C RT-PCR D ELISA
 
Figure 58: Depletion of TFF3 in HUVEC decreased IL-8 promoter activity and 
subsequently decreased IL-8 expression. A, IL-8 promoter activity in HUVEC with 
depletion of TFF3 transiently transfected with IL-8 promoter (full length, -4800 to + 104 bp). 
HUVEC with control siRNA was used as control. B, IL-8 promoter activity in HUVEC with 
depletion of TFF3 transiently transfected with pGL-IL8-152 reporter (-152 to +44 bp). 
HUVEC was transiently transfected with a reporter and a pRL-CMV control reporter. C, 
semi-quantitative RT-PCR analysis of IL-8 mRNA in HUVEC with depletion of TFF3. D, 
ELISA analysis of IL-8 protein secreted to the medium by HUVEC with depletion of TFF3. 












4.3.1 Exogenous rhTFF3 stimulation promoted angiogenic activity of HUVEC  
 Herein, I have demonstrated that exogenous rhTFF3 promoted HUVEC monolayer 
proliferation, migration, invasion, tubule formation in vitro in a concentration-dependent 
manner. Exogenous rhTFF3 directly acted on HUVEC to stimulate angiogenesis in vitro. 
Exogenous rhTFF3 stimulation increased HUVEC monolayer proliferation in 10% FBS 
conditions and induced a small increase of HUVEC monolayer proliferation in serum 
deprived conditions (0.2% FBS). Hence, exogenous rhTFF3 was able to stimulate HUVEC 
monolayer proliferation in both 10% FBS and serum deprived conditions. These results are 
supported by Kindon et al. (1995) who previously demonstrated that recombinant TFF3 
protects human colon cancer cell monolayer from external insults. Protection of colon cancer 
cell from injury or damage was enhanced by the addition of both recombinant TFF3 and 
human colonic mucin (Kindon et al., 1995). We have identified that TFF3 acted as mitogenic 
and cytoprotective factor. 
 All TFF peptides have been demonstrated to be motogenic and are involved in wound 
healing process by promotion of cell migration and resistance to anoikis.  TFF3 and TFF1 are 
potent motogens in both normal and cancer cells. These peptides are able to promote 
migration of epithelial cells, TFF3 is the only family member that has been reported to be a 
crucial factor implicated in mucosa restitution (Mashimo et al., 1996, Poulsom, 1996). Earlier 
studies have reported that exogenous rhTFF3 stimulated migration of intestinal epithelial cells 
in vitro (Dignass et al., 1994, Chinery and Playford, 1995). Additionally, Taupin et al. (1999) 
showed that the migration rate of epidermal cells was significantly increased after rhTFF3 
treatment. Furthermore, Li et al. (2011) recently demonstrated that rhTFF3 slightly increased 
the expression of EGF, enhanced the restitution of the damaged mucosa and increased 
migration of the epithelial cells, thus promoting the healing of injured mucosa in colitis (Li et 
al., 2011). Concordantly, I have demonstrated that exogenous rhTFF3 may function as both 
chemoattractant and stimulant to promote migration of endothelial cells but more remarkable 
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as a chemoattractant. I suggested that TFF3 is a potent chemotactic factor for endothelial cells 
and stimulates directional movement of endothelial cells towards increasing concentration of 
rhTFF3. I have also shown that exogenous rhTFF3 promoted HUVEC migration and invasion 
in a concentration-dependent manner with maximal stimulation at 5.0 ng/mL rhTFF3. 
Exogenous rhTFF3 is able to stimulate HUVEC migration and invasion. Notably, the effect of 
exogenous rhTFF3 on HUVEC migration was more prominent than invasion. Similarly, 
exogenous rhTFF1 stimulates migration and proliferation of mammary carcinoma cells (May 
and Westley, 1997a, Prest et al., 2002). Prest et al. (2002) has suggested that rhTFF1 may 
stimulate cell migration by interacting with cell surface receptors. After mucosal injury, a 
functional EGF receptor is required for activation of TFF gene transcription through the 
Ras/MEK/MAP kinase signaling pathway (Taupin et al., 1999). Since activation of MAP 
kinase enhanced cell migration, the effects of trefoil peptides on epithelial restitution may 
occur through MAP kinase signaling pathway (Taupin et al., 1999). TFF peptides indirectly 
activated EGF-R to stimulate the TFF-mediated signaling events (McKenzie et al., 1997, 
Taupin et al., 1999). TFF peptides and EGF have been reported to exert synergistic effects in 
promotion of cell migration (Poulsom, 1996). However, TFF3 stimulates cell invasion 
through an EGFR-independent signaling pathway (Rodrigues et al., 2003b). TFF3 induced 
intestinal epithelial cells resistance to apoptosis via activation of nuclear factor-κB (NF-κB), a 
pivotal regulator implicated in survival pathway of intestinal epithelial cells. Hence, intestinal 
epithelial cells treated with recombinant TFF3 were resistant to anoikis (Chen et al., 2000). 
The anti-apoptotic function of TFF3 in colon cancer was regulated via an alternative signaling 
cascade such as PI3K, protein kinase B (PKB), and NF-κB. Blocking of EGF signaling 
abrogated TFF3-stimulated cell survival and partially inhibited Erk/MAPK-dependent 
transcriptional signaling following TFF3 stimulation (Taupin et al., 1999). These observations 
suggested that TFF peptides stimulated activation of Erk/MAPK through alternative pathways. 
 Addition of exogenous recombinant human TFF1 and TFF3 has been reported to 
promote formation of capillary vessel in a CAM assay. Exogenous rhTFF1 stimulated 
186 
 
HUVEC to form tubules in the Matrigel and the angiogenic activity of rhTFF1 is comparable 
to that stimulated by VEGF-A and TGF-α (Rodrigues et al., 2003b). Since TFF3 is analogous 
with TFF1, TFF3 may also function as pro-angiogenic factor to promote angiogenesis in vivo. 
Concordant with these observations, I have demonstrated that exogenous rhTFF3 directly 
acted on endothelial cells and promoted tubule formation in vitro in a concentration-
dependent manner with the maximal stimulation at 5.0 ng/mL rhTFF3. Notably, higher 
concentrations of exogenous rhTFF3 (10 ng/mL rhTFF3) exerted lesser stimulatory effect on 
HUVEC tubule formation in vitro. Previous reports have demonstrated that 100 nM of 
recombinant TFF1 and TFF3 were needed to stimulate capillary vessel formation in CAM 
assay or tubule formation in vitro (Rodrigues et al., 2003b). Additionally, migration of MCF-
7 cell lines was stimulated by 10 μg/mL of recombinant TFF1 (Prest et al., 2002). In relation 
to this observation, Prest et al., (2002) proposed that TFF1 and possibly TFF3, at the higher 
concentrations may inhibit dimerization of the putative TFF receptor and subsequently lead to 
attenuation of receptor activation for signal transduction. Angiogenesis in vitro induced by 
TFF peptides was demonstrated to be dependent on both cyclooxegenase (COX-2) and the 
EGF-R tyrosine kinase to mediate pro-angiogenic activity of TFF3 (Rodrigues et al., 2001). 
Increased expression of COX-2 promotes resistance to apoptosis and tumor angiogenesis as 
well as enhances invasion and metastasis (Labayle et al., 1991, Jacoby et al., 1996, Tsujii et 
al., 1998). Furthermore, nitric oxide plays an important role in tumor angiogenesis, and TFF3 
has been demonstrated to enhance nitric oxide (NO) formation through the inducible nitric 
oxide synthase (iNOS/NOS2) (Tan et al., 1999). 
 Although TFF1 and TFF3 peptides only contain a single trefoil domain, they are 
capable of forming homodimers via utilization of an unpaired cysteine residue located near 
the C-terminus (May et al., 2003). TFF1 dimer is more potent in stimulating migration of 
mammary carcinoma cells via a bivalent dimeric receptor (Marchbank et al., 1998, Prest et al., 
2002). Additionally, TFF1 dimer is more biologically active than TFF1 monomer in 
preventing drug-induced gastric damage and promoting cell migration. It has been postulated 
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that dimerization may enhance the interaction of TFF1 with its receptor (Marchbank et al., 
1998). The relative biological activity of dimeric and monomeric recombinant TFF3 has been 
compared in a mice model of ischaemic necrotising enterocolitis. TFF3 dimer was shown to 
possess a similar potency as the TFF3 monomer and  both forms of  recombinant TFF3 
promoted healing of intestinal injury induced by ischemia (Carrasco et al., 2004). It has been 
suggested that TFF3 dimer is necessary for activation of signal transduction pathways in 
intestinal epithelial cells, for instance PI3K and NF-κB survival pathways (Taupin et al., 
1999).  
 The combined functions of TFF peptides and mucin may cooperatively protect the 
mucosa from injury and increase mucus viscosity (Kindon et al., 1995). The interaction 
between TFF peptide and mucin has also been demonstrated to enhance cell migration and 
nitric oxide production (Dignass et al., 1994, Tan et al., 1999). TFF1 is co-localized with 
MUC5AC and TFF3 is co-localized with MUC2 in the gastrointestinal tract, indicating that 
specific TFF peptides may have specific mucin partner (Longman et al., 2000). Moreover, 
Chinery and Cox (1995) have suggested that TFF3 binds to a phosphorylated tyrosine-
containing peptide of 28 kDa. Recent evidence has reported that mutation in the brichos 
domain of SP-C promoted annexin V association and subsequent apoptosis by activating 
caspase 3 (Mulugeta et al., 2005), suggesting that there was a putative binding between trefoil 
factors and the brichos domain, which can abrogate anti-apoptotic activity of TFF3 (Mulugeta 
et al., 2005). Many reports pertaining to the functions of trefoil factors are suggestive of a 
receptor-mediated mode of action such as activation of tyrosine kinase or tyrosine 
phosphatase, and signaling via transduction pathways such as RAS/MEK/MAPK (Kanai et al., 
1998, Taupin et al., 1999). However, there is still no trefoil factors binding molecule with the 
canonical characteristics of a receptor that has yet been identified (Otto and Thim, 2005). A 
recent study suggested TFF3 receptor is present in the intestinal epithelial cells and the 
binding between this receptor and TFF3 is as if specific receptor-ligand interaction. The 
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identity of this specific TFF3 receptor is yet to be identified and required for further 
investigation (Yong et al., 2013). 
 In summary, exogenous rhTFF3 can directly stimulate angiogenic behaviors of 
endothelial cells, although HUVEC endogenously expressed relatively low level of TFF3. 
Hence, exogenous rhTFF3 is able to stimulate angiogenesis in vitro. 
 
4.3.2 Forced expression of TFF3 in HUVEC promoted angiogenesis  
 I have demonstrated that forced expression of TFF3 in HUVEC promoted 
angiogenic behavior of endothelial cells through an autocrine loop. Additionally, TFF3 
secreted from HUVEC may exhibit similar functions as exogenous rhTFF3 stimulation and 
thus stimulated angiogenic behaviors of endothelial cells. The effect of forced expression of 
TFF3 in HUVEC was generally not very drastic because the function of TFF3 in endothelial 
cells is more predisposed in maintaining the angiogenic activity and normal cellular processes 
(Kinoshita et al., 2000a, Podolsky, 2000, Taupin et al., 2000a). The ability of TFF3 to 
stimulate angiogenic behaviors of endothelial cells was consistent with others secreted protein 
such as Artemin secreted from mammary carcinoma cells that exhibited its stimulatory effect 
on HMEC-1 around 20 - 30% (Banerjee et al., 2011). Endothelial cells expressed 
undetectable or very low level of TFF3 (Dhar et al., 2005, Kjellev, 2009). Concordantly, 
HUVEC utilized in this study also expressed undetectable or very low level of TFF3 protein. 
Forced expression of TFF3 in HUVEC promoted monolayer cell proliferation, cell cycle 
progression, survival, migration, invasion, and tubule formation in vitro. Depletion of TFF3 
by siRNA in HUVEC decreased angiogenic behaviors of endothelial cells. In general, 
increased TFF3 expression in HUVEC exhibited lesser effect in cellular processes than 
exogenous rhTFF3 stimulation. 
 The mitogenic role of TFF3 in normal and cancer cells are controversial. Over-
expression of TFF3 has been reported to decrease cell proliferation of human gastrointestinal 
cells (Uchino et al., 2000, Bossenmeyer-Pourie et al., 2002). In contrast, increased TFF3 
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expression in mammary carcinoma cells promoted cell proliferation (Xu et al., 2005, Kannan 
et al., 2010). I have demonstrated that TFF3 secreted from HUVEC promoted monolayer cell 
proliferation by increased cell cycle progression and decreased apoptotic cell death, 
suggesting that TFF3 secreted from HUVEC may act as pro-mitogenic and pro-survival factor. 
Concordantly, TFF3 was shown to protect intestinal epithelial cells from apoptosis after 
mucosal damage is dependent on PI3K and EGF-R signaling pathways. Additionally, TFF3 
also promotes serine phosphorylation of Akt kinase, which is associated with cell survival 
(Kinoshita et al., 2000b, Podolsky, 2000, Taupin et al., 2000b). 
 It is well established that TFF3 promotes intestinal epithelial cell migration and 
resistance to apoptosis in the process of mucosa restitution (Dignass et al., 1994, Playford et 
al., 1995). The pro-migratory function of TFF3 has furthermore been observed in epithelial 
cells not from the gastrointestinal tract, suggesting that TFF peptides are normally expressed 
in any type of epithelial cells and its functions are cell-type specific (Kjellev, 2009). TFF3 is 
an anti-apoptotic protein secreted by goblet cells to protect intestinal epithelial cells from 
anoikis (Regalo et al., 2005). It has been shown that TFF3 stimulated intestinal epithelial cell 
resistance to anoikis via activation of NF-κB signaling pathway (Chen et al., 2000). Another 
study has reported that TFF3 exerted anti-anoikis effects on the intestinal cells through 
activation of EGF-R signaling pathway (Kinoshita et al., 2000a). Consistent with these 
previous reports, I have demonstrated that TFF3 secreted from HUVEC promoted cell 
migration, invasion and tubule formation in vitro, supporting that TFF3 enhanced angiogenic 
behaviors of HUVEC to promote angiogenesis in vitro. Similarly, TFF3 secreted from 
mammary carcinoma cells also was able to stimulate angiogenic behaviors of HUVEC and 
promoted de novo angiogenesis in mammary carcinoma via STAT3/IL-8 dependent signaling 
pathway. 
 Cancer cells often lose cadherin function in the transition to an invasive and 
metastatic phenotype (Perl et al., 1998, Cavallaro et al., 2002). Experimental evidence has 
suggested that TFF3 promoted cell migration requires modulation of E-cadherin function and 
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tyrosine phosphorylation of β-catenins (Liu et al., 1997, Efstathiou et al., 1998, Efstathiou et 
al., 1999). TFF3 stimulated migration and invasion of rat fibroblastic cells that correlated 
with down-regulated E-cadherin and tissue inhibitor of metalloproteinase-1 (TIMP-1) as well 
as increased β-catenin and metalloproteinase-9 (MMP-9) (Chan et al., 2005b). TFF3 has also 
been shown to promote colon cancer cell migration through repression of E-cadherin-catenin 
complex formation (Emami et al., 2004). Additionally, TFF3 promoted migration of both 
normal and oncogenically transformed bronchial epithelial cells through activation of MAPK 
pathway (Graness et al., 2002). Collectively, TFF3 may also promote cell migration of 
endothelial and mammary carcinoma cells through the same signaling pathways. 
 In the past decades, numerous of angiogenic factors have been reported that can 
promote both differentiation and proliferation of endothelial cells. Of these angiogenic factors, 
VEGF-A and IL-8 are the most potent regulators of tumor angiogenesis (Koch et al., 1992, 
Nor et al., 1999). VEGF-A is also known as an endothelial-cell-specific mitogen and vascular 
permeability factor that promotes de novo angiogenesis (Nor et al., 1999). Nevertheless, I 
have observed that TFF3 secreted from HUVEC may not able to stimulate the expression of 
VEGF-A and its receptors, indicating that VEGF-A was probably not involved in TFF3-
stimulated tumor angiogenesis. Another potent angiogenic factor, IL-8 is synthesized in 
multiple different cell types including cancer and endothelial cells (Polverini, 1995, Strieter et 
al., 1995b). IL-8 binds to its cognate receptors to mediate endothelial proliferation, survival 
and tumor angiogenesis (Rollins, 1997, Addison et al., 2000). It has been reported that that 
CXCR1 and CXCR2 are expressed in endothelial cells and thus IL-8 interacts with 
endothelial cells through these receptors and induces tumor angiogenesis (Murdoch et al., 
1999, Addison et al., 2000, Salcedo et al., 2000b). Consistent with these reports, I have 
demonstrated that TFF3 secreted from HUVEC slightly increased IL-8 expression. Parental 
HUVEC endogenously expressed IL-8 but its expression was also marginally increased in 
response to exogenous TFF3 stimulation. Both CXCR1 and CXCR2 mRNAs were present in 
HUVEC with forced expression of TFF3. 
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 Increased the expression of IL-8 has been characterized in cancer cells and 
endothelial cells. IL-8 has the capacity to exert oncogenic effects in the tumor 
microenvironment. For example, secretion of IL-8 can activate endothelial cells in the tumor 
vasculature to promote angiogenesis (Oude Nijhuis et al., 2003, Ramjeesingh et al., 2003, 
Vadeboncoeur et al., 2003). Previous reports have highlighted that IL-8 promoter activity 
appears to be regulated by the combinatorial activation and binding of NF-κB, NF-IL-6, and 
AP-1 families of transcription factors (Mukaida et al., 1990, Roebuck, 1999). I have observed 
that TFF3 secreted from HUVEC stimulated IL-8 promoter activity and subsequently lead to 
a slight increase of IL-8 expression. Additionally, the transcription factors namely NF-κB, 
NF-IL-6, and AP-1 are required for promoting TFF3-stimulated IL-8 promoter activity in 
HUVEC. 
 In summary, TFF3 secreted from endothelial cells promoted monolayer proliferation, 
cell cycle progression, survival, migration, invasion and tubule formation in vitro. Depletion 
of TFF3 in HUVEC diminished the ability of TFF3 on stimulation of angiogenic behaviors of 
endothelial cells. TFF3 secreted from HUVEC stimulated angiogenic behaviors of endothelial 
















General Conclusion and Future Direction 
5.1 General conclusion 
5.1.1 TFF3 promoted de novo angiogenesis in mammary carcinoma  
 The main focus of this study was to investigate the role of TFF3 in promoting de 
novo angiogenesis in mammary carcinoma and delineate the underlying mechanism by which 
TFF3 may exert this effect. Herein, I have demonstrated that TFF3 secreted either from 
mammary carcinoma cells or HUVEC stimulated angiogenic behaviors of endothelial cells 
and thus promote de novo angiogenesis. TFF3 secreted from mammary carcinoma cells 
exhibited more compelling effect on stimulation of angiogenic behaviors of endothelial cells 
when compared with the autonomous effect of TFF3 in HUVEC. TFF3 has been shown to 
promote survival, invasion, and metastatic expansion of mammary carcinoma (Kannan et al., 
2010, Ahmed et al., 2012, Pandey et al., 2014). In addition to other growth factors produced 
by mammary carcinoma cells (Perry et al., 2008), TFF3 was able to stimulate angiogenic 
behaviors of endothelial cells. In contrast, the autonomous effect of TFF3 in HUVEC was 
generally not very drastic because the role of TFF3 in endothelial cells is more predisposed in 
maintaining angiogenic activity and normal cellular processes (Kinoshita et al., 2000a, 
Podolsky, 2000, Taupin et al., 2000a). It is known that the functions of TFF3 are cell-type 
specific, for instance, TFF3 normally expressed in gastric mucosa and is involved in 
protection of GI tract against mucosal damage (Taupin and Podolsky, 2003, Hoffmann, 2006), 
however increased TFF3 expression promotes tumorigenesis of mammary carcinoma 
(Kannan et al., 2010, Ahmed et al., 2012, Pandey et al., 2014).  
 I have demonstrated that TFF3 secreted from mammary carcinoma cells stimulated 
HUVEC monolayer proliferation, cell cycle progression, survival, migration, invasion, and 
tubule formation in vitro. Depletion of TFF3 in mammary carcinoma cells by siRNA 
diminished HUVEC monolayer proliferation, cell cycle progression, survival, migration, 
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invasion and tubule formation in vitro. In  a xenograft model, forced expression of TFF3 in 
MCF-7 cells produced tumors with increased IL-8 protein expression and enhanced 
microvessel density (as indicated by increased area of both CD31- and CD34-labeled cells) 
when compared with tumors produced by control MCF7-Vec cells. These observations 
further confirmed that TFF3 promotes tumor angiogenesis in vivo.  
 Tumor angiogenesis is modulated by a large number of secreted angiogenic proteins 
(Sudhakar, 2009). I therefore examined a range of angiogenic factors implicated in 
angiogenesis and observed that TFF3 regulated the gene expression of IL-8.  Increased TFF3 
expression in mammary carcinoma cells promoted IL-8 expression. The functional roles of 
IL-8 in promotion of invasion, survival and chemotherapeutic drug resistance of prostate 
cancer cell lines could be effectively inhibited by IL-8 siRNA (Singh and Lokeshwar, 2009). 
Hence, I employed the same IL-8 siRNA to selectively deplete IL-8 expression in MCF-7 
cells with forced expression of TFF3. TFF3 secreted from mammary carcinoma cells 
stimulated IL-8 promoter activity and subsequently increased the expression of IL-8. 
Depletion of IL-8 by siRNA in mammary carcinoma cells with forced expression of TFF3 
decreased IL-8 protein expression. Depletion of IL-8 by siRNA in mammary carcinoma cells 
significantly abrogated the stimulatory effect of TFF3 on HUVEC migration, invasion and 
tubule formation in vitro. It has been reported that neutralizing antibodies to IL-8, CXCR1 or 
CXCR2 abrogated endothelial cell proliferation, survival, migration, and angiogenesis as 
compared to control antibody (Li et al., 2005). Therefore, I utilized the same clone of anti-IL-
8 monoclonal antibody inhibitory to TFF3 on stimulation of angiogenic behaviors of 
endothelial cells mediated by IL-8. Blocking of IL-8 in mammary carcinoma cells by anti-IL-
8 monoclonal antibody inhibited the ability of TFF3 on stimulation of HUVEC tubule 
formation in vitro. These results suggested that depletion of IL-8 in mammary carcinoma cells 
by siRNA or inhibition of IL-8 with anti-IL-8 monoclonal antibody abrogated the ability of 
TFF3 to stimulate the angiogenic behaviors of endothelial cells. Additionally, blocking of 
CXCR1 in HUVEC by anti-CXCR1 monoclonal antibody may not be able to inhibit the 
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stimulatory effect of TFF3 on HUVEC tubule formation in vitro. However, blocking of 
CXCR2 in HUVEC by use of anti-CXCR2 monoclonal antibody inhibited the stimulatory 
effect of TFF3 on HUVEC tubule formation in vitro mediated by IL-8. It is known that 
CXCR2 receptor has other ligands such as IL-1, IL-2 and IL-6 (Addison et al., 2000). It is 
possible that anti-CXCR2 is disrupting IL-8 independent events. Hence, the ability of TFF3 to 
stimulate angiogenic behaviors of endothelial cells was mediated by IL-8/CXCR2 axis. 
 IL-8 is synthesized in different cells in response to inflammatory stimuli such as that 
provided by IL-1 and TNF-α (Brasier et al., 1998). Up-regulation of IL-8 gene expression is 
achieved through activation of NF-κB in concert with other transcription factors and also 
dependent on cell type and stimuli (Mukaida et al., 1994). IL-8 promoter contains response 
elements for a number of different transcription factors and has been reported to constitute 
with pro-inflammatory responsive elements important for IL-8 gene expression (Mukaida et 
al., 1989, Mukaida et al., 1994). Several studies have suggested that production of IL-8 
protein is regulated by STAT3 through direct binding to consensus binding site at the 
proximal region of IL-8 promoter gene (Seidel et al., 1995, Oka et al., 2010).  
 Herein, I have demonstrated that the transcription factors namely AP-1, NF-IL-6, and 
NF-κB at the proximal region of IL-8 promoter were necessary for enhancing IL-8 promoter 
activity stimulated by TFF3. In fact, the expression of IL-8 is regulated by multiple 
transcription factors. Besides these transcription factors, TFF3 secreted from mammary 
carcinoma cells activated and increased tyrosine phosphorylation of STAT3. Depletion of 
STAT3 by siRNA partially abrogated the effect of TFF3 on IL-8 promoter activity and 
resulted in a small decrease of IL-8 expression. Hence, I postulate that STAT3 is one of a 
number of factors involved in the regulation of IL-8 expression stimulated by TFF3. 
Presumably, STAT3 is a transcription factor for IL-8 and cooperate with other transcription 
factors in the regulation of IL-8. TFF3 secreted from mammary carcinoma cells stimulated 
tyrosine phosphorylation of STAT3, the activated STAT3 dimerizes, and translocates into the 
nucleus to activate IL-8 gene expression (Bromberg et al., 1999, Niu et al., 2002, Rivat et al., 
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2005). It has been reported that IL-6 induced STAT3 phosphorylation and increased the 
expression of TFF3 to promote cell migration and wound healing in biliary epithelial cells, 
which is through the activation of STAT3 and subsequent up-regulation of TFF3 expression 
(Jiang et al., 2010). Additionally, TFF3 and VEGF-A function as promoters of colon cancer 
cell invasion, survival, and angiogenesis through STAT3-dependent signaling pathway (Rivat 
et al., 2005). Earlier studies reported that VEGF-A activates STAT3, which in turn increased 
VEGF-A gene expression (Niu et al., 1999, Niu et al., 2002). It has been reported that TFF3 
activated STAT3 activity to promote TFF3 gene transcription via autocrine loop (Rivat et al., 
2005). TFF3 and VEGFA have been demonstrated to activate STAT3 through tyrosine (Y705) 
phosphorylation of STAT3-α and STAT3-β isoforms (Bromberg et al., 1999). TFF3 and 
VEGFA promoted cellular invasion and migration of colon cancer cells (Rivat et al., 2005). 
Notably, TFF1 does not promote activation of STAT3, yet TFF1 was still capable to promote 
cellular invasion (Rivat et al., 2005). Recently, TFF3 has been shown to promote invasion 
and metastasis of mammary carcinoma cells in Src-STAT3 dependent manner (Pandey et al., 
2014).  
 The constitutively active STAT3 increases VEGF-A expression and induces tumor 
angiogenesis in human pancreatic cancer cells. However, inhibition of STAT3 signaling with 
dominant-negative STAT3 inhibits VEGF-A expression, angiogenesis, and tumor growth 
(Wei et al., 2003a). IL-6 stimulated VEGF-A protein expression in cervical cancer cells 
through activation of STAT3 phosphorylation. However, abrogation of the STAT3 pathway 
with a dominant-negative STAT3 protein reduced IL-6 stimulated tumor angiogenesis and the 
growth of cervical cancer cells (Wei et al., 2003b). In accordance with these evidences, I have 
shown that STAT3 partially mediated the action of TFF3 on the stimulation of angiogenic 
behaviors of endothelial cells. Depletion of STAT3 by siRNA in mammary carcinoma cells 
with forced expression of TFF3 partially abrogated the effect of TFF3 on HUVEC migration, 
invasion and tubule formation in vitro. Mechanistically, TFF3 increased IL-8 expression and 
STAT3 phosphorylation that can partially elevated the expression of IL-8, which in turn 
196 
 
mediated the ability of TFF3 on the stimulation of angiogenic behaviors of endothelial cells 
via IL-8/CXCR2 axis. Therefore, TFF3 is a promoter of angiogenesis, which may also co-
coordinate with the growth promoting and metastatic actions of TFF3 in mammary carcinoma 




Figure 59: TFF3 is a promoter of angiogenesis in mammary carcinoma. TFF3 promoted 
IL-8 expression and increased tyrosine phosphorylation of STAT3 that is partially involved in 
the regulation of IL-8. The ability of TFF3 to stimulate angiogenic behaviors of HUVEC was 
mediated by IL-8 through CXCR2 axis. Furthermore, exogenous rhTFF3 directly acted on 
HUVEC to promote angiogenic behaviors of HUVEC. Additionally, TFF3 secreted from 
HUVEC promoted angiogenesis in vitro mediated by IL-8. Therefore, TFF3 is a promoter of 
angiogenesis, which may also co-coordinate with the growth promoting and metastatic 
actions of TFF3 in mammary carcinoma to enhance tumor progression. 
 
 In summary, I have demonstrated that depletion of TFF3 by siRNA in mammary 
carcinoma cells diminished the angiogenic behaviors of HUVEC. A previous study has 
reported that neutralization of TFF3 by anti-TFF3 polyclonal antibody reduced cell viability 
of mammary carcinoma cells and inhibited tumor growth in xenograft models (Kannan et al., 
2010). Collectively, inhibition of TFF3 by siRNA or anti-TFF3 antibody can be an effective 
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strategy to suppress tumor angiogenesis and metastasis in mammary carcinoma. Depletion of 
IL-8 by siRNA and inhibition IL-8 with anti-IL-8 monoclonal antibody abrogated the ability 
of TFF3 to stimulate angiogenic behaviors of HUVEC mediated by IL-8. Consistently, human 
anti-IL-8 antibody (e.g., ABX-IL8) has been reported to inhibit tumor angiogenesis, growth, 
and metastasis in bladder cancer and melanoma (Yang et al., 1999, Huang et al., 2002, Mian 
et al., 2003). In addition, preclinical evaluation of the effectiveness of repertaxin (inhibitor of 
CXCR1/2) on animal models showed that mice treated with repertaxin developed fewer 
metastases than the mice treated with chemotherapy alone (Ginestier et al., 2010). Therefore, 
the functional antagonism of TFF3 and/or IL-8 in mammary carcinoma cells could be a 
promising therapeutic strategy for suppression of the growth of TFF3-stumulated carcinomas.  
 
5.5.2  Exogenous rhTFF3 stimulation and TFF3 secreted from HUVEC promoted 
angiogenesis  
 Herein, I have demonstrated that exogenous rhTFF3 stimulated HUVEC monolayer 
proliferation, migration, invasion, and tubule formation in vitro in concentration-dependent 
manner. Exogenous rhTFF3 directly acted on HUVEC to promote angiogenesis in vitro. 
Exogenous rhTFF3 may serve as both chemoattractant and stimulant to promote HUVEC 
migration and invasion. I suggested that TFF3 is a pro-angiogenic factor to promote 
angiogenic behaviors of endothelial cells through an autocrine loop. The angiogenic 
responsiveness of endothelial cells to the stimulation of TFF3 reflects the functional roles of 
TFF3 are unique, cell-type specific and implicated in different tissue of origin. 
 TFF3 secreted from HUVEC promoted monolayer cell proliferation, cell cycle 
progression, survival, migration, invasion, tubule formation in vitro. Depletion of TFF3 by 
siRNA in HUVEC decreased angiogenic behaviors of endothelial cells. TFF3 secreted from 
HUVEC exhibited similar functional effects as exogenous rhTFF3 stimulation. The protein 
expression of IL-8 in HUVEC was marginally increased by exogenous rhTFF3 stimulation. 
Additionally, TFF3 secreted from HUVEC was able to stimulate IL-8 promoter activity and 
198 
 
subsequently increased IL-8 expression, which in turn mediated the action of TFF3 to 
promote angiogenesis in vitro (Figure 59). 
 Considering therapeutic implications, both TFF3 siRNA and anti-sense TFF3 
suppressed the growth and tumorigencity of mammary carcinoma (Kannan et al., 2010). The 
anti-tumorigenic effect is mediated through induction of apoptosis and restored tamoxifen 
sensitivity in tamoxifen-resistance mammary carcinoma cells (Kannan et al., 2010). TFF3 
protein expression in tamoxifen-resistance mammary carcinoma cells was substantially 
increased and further induced by tamoxifen. Functional antagonism of TFF3 by antibody 
inhibited cell growth and improved tamoxifen sensitivity of tamoxifen-resistance mammary 
carcinoma cells (Kannan et al., 2010). Over-expression of IL-8 is associated with a drug 
resistance phenotype (Duan et al., 1999). Hence, neutralizing antibody IL-8 reversed the 
drug-resistance of MCF-7 cells to a taxol and doxorubicin. Inhibition of endogenous IL-8 by 
siRNA significantly enhanced the drug sensitivity of the drug resistant MCF-7 cells (Shi et al., 
2012). Additionally, depletion of IL-8 in prostate cancer increased the cytotoxic potency of a 
number of chemotherapeutic drugs (Singh and Lokeshwar, 2009). Therefore, anti-IL-8 
antibody not only inhibit endothelial cell proliferation and capillary tube formation, but this 
neutralizing antibody also can restore the drug sensitivity of the doxorubicin resistant MCF-7 
cells (Li et al., 2005, Shi et al., 2012).  Hence, the functional antagonism of TFF3 and IL-8 
would be an effective therapeutic approach to abolish the ability of TFF3 on the stimulation 









5.2 Future direction 
 TFF3 is a small secreted protein and amenable to inhibition by antibody, inhibitor, 
and RNAi molecule. Several studies have attempted to delineate the potential of TFF 
antagonism as a cancer therapeutic. One study has recently employed anti-TFF3 polyclonal 
antibody to neutralize the secreted TFF3 from mammary carcinoma cells. Neutralization of 
TFF3 by anti-TFF3 polyclonal antibody reduced cell viability of mammary carcinoma cells 
and inhibited xenograft growth (Kannan et al., 2010). The anti-TFF3 polyclonal antibody 
exhibited no potential adverse effects on the vital organs including liver, lung, intestine, 
kidney, and stomach in mice treated with anti-TFF3 polyclonal antibody when compared with 
mice treated with Ig-G control. Additionally, it has been reported that anti-sense TFF3 
molecule inhibits the growth of gastric cancer cells, increases adriamycin-induced apoptosis, 
and enhances the response to chemotherapy (Chan et al., 2005a). The anti-TFF3 polyclonal 
antibody and anti-sense TFF3 molecule can be utilized for studying the functional antagonism 
of TFF3 for suppression of de novo angiogenesis in mammary carcinoma. Alternatively, it is 
worth to develop inhibitor of TFF3 or neutralizing agent comprises RNAi molecule that can 
specifically target to TFF3 functional domain. 
 The effect of inhibition of TFF3 in mammary carcinoma cells by anti-TFF3 
polyclonal antibody or inhibitor of TFF3 on the angiogenic activity of endothelial cells is 
required for further investigation. The in vitro functional antagonism study may define the 
effectiveness of anti-TFF3 polyclonal antibody to abrogate the effect of TFF3 in de novo 
angiogenesis in mammary carcinoma. The xenograft study may provide in vivo evidence to 
support that the functional antagonism of TFF3 by anti-TFF3 polyclonal antibody is capable 
to suppress tumor angiogenesis and metastasis of mammary carcinoma. This approach may be 
a novel therapeutic strategy for treatment of tumor angiogenesis stimulated by TFF3 in 
mammary carcinoma and it may also applicable for other neoplastic disorders. The efficacy, 
safety, and route of administration of TFF3 neutralizing agent or inhibitor of TFF3 are 
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required for further investigation and this agent may be of value in pharmacological 
intervention (Kjellev, 2009).  
 I have also demonstrated that TFF3 stimulated activation of STAT3 phosphorylation 
in mammary carcinoma cells. STAT3 partially increased the expression of IL-8 and partially 
mediated the effect of TFF3 on stimulation of angiogenic behaviors of endothelial cells. 
STAT3 is one of a number of transcription factors involved in the regulation of IL-8 
expression. The mechanism by which TFF3 stimulated the activation of STAT3 in the 
regulation of IL-8 expression remains unclear. A study has reported that STAT3 may directly 
bind to the IL-8 promoter gene in the region from -272 to -133 bp (Oka et al., 2010). A 
potential STAT3-binding sequence TTCACCAAA, consistent with the reported consensus 
sequences TT(N4/N5)AA, was identified from -245 to -237 bp in the 5′-flanking region of the  
IL-8 gene (Seidel et al., 1995). Thereby, I propose that TFF3 stimulates activation of STAT3 
and mediates direct binding of STAT3 to its consensus sites in IL-8 promoter. The potential 
STAT3-binding sites in IL-8 promoter would be validated by searching the 5'-flanking region 
of IL-8 gene for consensus STAT3-binding sites, TT(N4)AA and TT(N5)AA (Seidel et al., 
1995) using DNAStar sequence analysis software. The putative STAT3-binding site from -
245 to -237 bp in the 5′-flanking region of human IL-8 gene cloned into the luciferase 
reporter plasmid pGL3-Basic and designated as wild-type construct. The mutation of 
individual base pairs in plasmid DNA (from 5'-TTCCCAAA-3' to 5'-GCGTCAAA-3') can be 
constructed according to site-specific mutagenesis procedure (Deng and Nickoloff, 1992) or 
using Site-Directed Mutagenesis Kit. The STAT3 mutant can be confirmed by sequencing. 
IL-8 promoter activity for STAT3 mutant will be assayed to determine if STAT3 is involved 
in the regulation of IL-8 expression stimulated by TFF3 and if STAT3 is one of the 
transcription factors required for activation of IL-8 expression. Furthermore, chromatin 
immunoprecipitation (ChIP) assays will be performed to determine if STAT3 directly bind to 
the STAT3-binding site in the IL-8 promoter in vivo. ChIP assay is commonly used for the 
identification of particular genomic DNA sequences that associated with a specific 
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transcription factor (Wells et al., 2000). Thereby, the ChIP assay will validate if STAT3 
directly bind to its consensus-binding site at the IL-8 promoter mediated by TFF3, IL-8 is the 
target gene of STAT3, and STAT3 is a transcription factor for IL-8. The other transcription 
factors for example, interferon regulatory factor-1 in the IL-8 promoter gene may be involved 
in the regulation of IL-8 mediated by TFF3 and these factors can be examined by the same 
approach.  
 The major challenge of future work is to identify the receptor(s) for TFF3 to mediate 
its functional effects in promoting of tumor growth and metastasis of cancers. Although a few 
of TFF3-binding proteins have recently been characterized, the receptor that mediates TFF3 
signaling has not yet been identified (Otto and Thim, 2005). Many studies suggested that the 
existence of a TFF receptor, is localized at the basolateral cell membrane in epithelial cells, 
and is exposed only after injuries in the mucosal (Taupin and Podolsky, 2003, Hoffmann, 
2009). However, the identity of this receptor is unknown. One study reported that the low-
affinity chemokine receptor CXCR4 was identified to be a potential receptor for TFF2 
(Dubeykovskaya et al., 2009). As TFF3 are relatively similar to TFF2, it is rational that TFF3 
should also be considered as potential ligand for that receptor as well (Hoffmann, 2009). The 
interaction between TFF3 and a TFF receptor on the membrane of epithelial cells is specific 
and as a typical binding of ligand-receptor (Yong et al., 2013). The signaling pathways 
activated by the postulated receptors for TFF on the cell surface to the cytoplasm and/or 
nucleus remains to be determined. Several studies have proposed that the possible 
contribution of APC/E-cadherin/β-catenins, EGF receptors and MAPK as downstream 
signaling pathways activated by TFF peptides, leading to decreased cell-cell contact and cell-
substratum adhesion (Liu et al., 1997, Efstathiou et al., 1998). It has been reported that 
signaling pathways including Src/RhoA, PI3K/Akt, and phospholipase C/PKC are mediated 
by TFF peptides to promote cellular invasion and survival of colon carcinoma cells (Emami et 
al., 2001). Many bioinformatics software are available and can be used to integrate 
microarray data and in vitro experimental data of the functionality of a targeted gene. For 
202 
 
example, DAVID bioinformatics resources is a feasible screening tool for highlighting the 
functional domain and motif of TFF3 protein, predicting interacting protein to the trefoil 
domain of TFF3, and integrating the functionality of TFF3 with the downstream signaling 
pathways. KEGG pathway maps can display the interconnection between TFF3 and the 
signaling proteins implicated in promoting or inhibiting of tumor growth and progression. The 
information generated from these tools is required for further validation by in vitro and in vivo 
experimental studies. Collaboration researchers from different discipline (bioinformatics and 
cancer biology) will build up a multi-discipline platform to identify TFF3 interacting proteins 
on the surface of mammary carcinoma cell lines (Lei et al., 2012). Identification of TFF3 
receptor(s) can provide a better understanding of TFF3 biology and develop a novel drug 
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5g NaCl, 1L Milli-Q H2O, autoclaved and 
stored at room temperature 
LB plate 
15g agarose was added to 1L liquid LB medium 
and sterilized by autoclaving. After the medium 
was cooled down to 50ºC, ampicillin was added 
at the concentration of 100 µg/mL. After gently 
mixing, the medium was poured into the sterile 
plates. Upon the medium was solidified, the 




10.39g/L RPMI powder, 2g/L NaHCO4; 
Dissolve it by adding autoclaved H20, adjust the 
pH to 7.2 by adding HCl or NaOH, adjust 
volume to 1L with additional autoclaved H20 
and filter sterilize. 
Advanced DMEM-
F12 
Advanced DMEM-F12 media supplemented 
with 10 mM L-Glutamine, 




450 mL RPMI medium, 50ml heat-inactivated 
fetal bovine serum, 5mL glutamine, 5mL 
penicillin/streptomycin 
10x PBS 
80g NaCl, 2g KCl, 14.4g Na2HPO4, 2.4g 
KH2PO4, 1L Milli-Q H2O. Adjust pH to 7.4 
10x trypsin/EDTA 
solution (0.25%) 
2.5g Trypsin, 0.372g EDTA, 0.35g NaHCO3, 
1L autoclaved H2O. Adjust pH to 7.2. 
HEPES buffer 
0.8766 g NaCl, 0.47688 g HEPES, 100 mL 
MilliQ H2O. Adjust pH value to 7.4 and sterilize 
by 0.2 µm filter 
HBSS 
0.4g/L Potassium Chloride; 0.06 g/L Potassium 
Phosphate Monobasic (anhydrous); 8 g/L 
Sodium Chloride; 0.04788 g/L Sodium 
Phosphate Dibasic (anhydrous); 1g/L D-
Glucose 
Freezing medium 
1 mL DMSO, 20  mL heat inactivated fetal 
bovine serum 
0.4% trypan blue 0.4g Trypan blue, 100 mL 1x PBS. 
RNA extraction DEPC water 1 mL DEPC, 1L Milli-Q H2O. Solution was 
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made in the fume hood and stirred overnight at 
room temperature before being autoclaved. 
DNA 
electrophoresis 
50x TAE buffer 
242g Tris, 37.2g Na2EDTA.2H2O, 57.2 mL 
glacial acetic acid, 1L Milli-Q H2O 
10x TBE buffer 
108g Tris, 55g boric acid, 7.44g EDTA (pH 8.0), 
1 L  H2O 
1-2% agarose gel 




0.2g ethidium bromide, 20 mL Milli-Q H2O 
DNA loading dye 6x 
250 mg bromophenol, 30ml glycerol, 70 mL 
H2O 
Protein extraction Lysis buffer 
10 mL (final concentration): 500 µL (1 M Tris-
HCl pH 7.4 (121.1 g/mol)); 1 mL (10% Nonidet 
P-40); 300 µL (5 M NaCl (58.44 g/mol)); 50 µL 
(0.2 M EDTA (452.24 g/mol)); 1mM NaF; 
1mM  PMSF; 100 µL (100 mM Na3VO4); 1.43 
mL(7x protease inhibitor stock); 6.62 mL H20 
SDS-PAGE 4% Stacking gel 
500µl 40% acrylamide, 1.26 mL 0.5M Tris-HCl 
pH 6.8, 50 µL 10% SDS, 3.18 mL Milli-Q H20, 
5 µL TEMED, 25 µL 10% APS 
 
12% Separating gel 
3 mL 40% acrylamide, 2.5 mL 1.5 M Tris-HCl 
pH 8.8, 100 µL 10% SDS, 4.35 mL Milli-Q 
H20, 5 µL TEMED, 50 µL 10% APS 
 
6x SDS loading dye 
6 mL glycerol, 3 mL 1M Tris-HCl, pH 6.8, 1.2g 
SDS and 5mg bromophenol blue 
 
1x SDS 3.03g Tris, 14.41g glycine, 10ml 10% SDS, 1L 
Milli-Q H20 running buffer 
 
1x Transfer buffer 
3.03g Tris, 14.41g glycine, 200 mL MeOH, 800 
mL Milli-Q H20 
Western blot 
0.1% Tween-20 PBS 
100 mL 10x PBS, 900 mL MilliQ H20, 1 mL 
Tween-20 
Blocking buffer 




2g Commassie Blue; 500 mL MeOH; 70 mL 
Acetic acid, in 1L H20 
Commassie destain 
95 mL MeOH; 75mL Glacial acetic acid; Made 
up to 1L with MilliQ H20 
Precast gel Western 
blot 
1x running buffer 
1x MOPS SDS buffer (20x) in 600 mL MilliQ 
H20 
1X transfer buffer 
1x transfer buffer (20x); 10%/20% MeOH; in 
500ml MilliQ H20 





Anti-BrdU antibody (1:100) in 10 mL PBS with 
2% horse serum 
Secondary Antibody 
Solution 
Secondary Antibody (1:200) in 10 mL PBS with 
0.2% Triton (2µL ) and 2% horse serum 
Tertiary Antibody 
solution 
1 drop Reagent A; 1 drop reagent B; 10 mL 1x 
PBS 
Substrate solution 1 DAB tablet; 1 H202 tablet; 1 mL MilliQ H20 
Others 
1.5 M Tris-HCl 
27.3g Tris; 80 mL MilliQ H20 ; Adjust pH value 
to 8.8 with 2N HCl and make up to 150 mL 
with MilliQ H20 
0.5M Tris HCL 
9.1 g Tris; 80 mL MilliQ H20 ; Adjust pH value 
to 6.8 with 2N HCl and make up to 150 mL 
with MilliQ H20 
TE buffer 10mM Tris-HCl ; 1mM EDTA pH 8.0 
4x Electrophoresis 
stock buffer 
57.4g Glycine; 7g Tris; 4g SDS; make up to 1L 
with MilliQ H20 
Anesthetic for in vivo 
10 mL:  1 mL of 100 mg/mL ketamine, 0.5 mL 
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